
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="68F7E0628095406300E0620038A45175.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="mcomm">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="MedComm">
<meta name="citation_title" content="Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine">
<meta name="citation_author" content="Ting Zhao">
<meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China">
<meta name="citation_author" content="Xiaowei Zhang">
<meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China">
<meta name="citation_author" content="Xin Liu">
<meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China">
<meta name="citation_author" content="Qifeng Wang">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China">
<meta name="citation_author_institution" content="Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China">
<meta name="citation_author" content="Xichun Hu">
<meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China">
<meta name="citation_author" content="Zhiguo Luo">
<meta name="citation_author_institution" content="Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China">
<meta name="citation_author_institution" content="Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China">
<meta name="citation_publication_date" content="2025 Apr 16">
<meta name="citation_volume" content="6">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="e70161">
<meta name="citation_doi" content="10.1002/mco2.70161">
<meta name="citation_pmid" content="40242159">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/pdf/MCO2-6-e70161.pdf">
<meta name="description" content="Cancer of unknown primary (CUP), a set of histologically confirmed metastases that cannot be identified or traced back to its primary despite comprehensive investigations, accounts for 2–5% of all malignancies. CUP is the fourth leading cause of ...">
<meta name="og:title" content="Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Cancer of unknown primary (CUP), a set of histologically confirmed metastases that cannot be identified or traced back to its primary despite comprehensive investigations, accounts for 2–5% of all malignancies. CUP is the fourth leading cause of ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12000684">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1002/mco2.70161"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/MCO2-6-e70161.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12000684%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12000684/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12000684/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-mcomm.jpg" alt="MedComm logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to MedComm" title="Link to MedComm" shape="default" href="https://onlinelibrary.wiley.com/journal/26882663" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">MedComm (2020)</button></div>. 2025 Apr 16;6(5):e70161. doi: <a href="https://doi.org/10.1002/mco2.70161" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1002/mco2.70161</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22MedComm%20(2020)%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22MedComm%20(2020)%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22MedComm%20(2020)%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22MedComm%20(2020)%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Ting Zhao</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Ting Zhao</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhao%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Ting Zhao</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Xiaowei Zhang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Xiaowei Zhang</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaowei Zhang</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Xin Liu</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Xin Liu</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Liu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xin Liu</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Q%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Qifeng Wang</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Qifeng Wang</span></h3>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div class="p">
<sup>
<sup>3</sup>
</sup>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wang%20Q%22%5BAuthor%5D" class="usa-link"><span class="name western">Qifeng Wang</span></a>
</div>
</div>
<sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Xichun Hu</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Xichun Hu</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xichun Hu</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Luo%20Z%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Zhiguo Luo</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Zhiguo Luo</span></h3>
<div class="p">
<sup>
<sup>1</sup>
</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="p">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Luo%20Z%22%5BAuthor%5D" class="usa-link"><span class="name western">Zhiguo Luo</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="mco270161-aff-0001">
<sup>
<sup>1</sup>
</sup>Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div id="mco270161-aff-0002">
<sup>
<sup>2</sup>
</sup>Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China</div>
<div id="mco270161-aff-0003">
<sup>
<sup>3</sup>
</sup>Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China</div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Revised 2025 Mar 7; Received 2024 Oct 15; Accepted 2025 Mar 12; Collection date 2025 May.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 The Author(s). <em>MedComm</em> published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</div>
<p>This is an open access article under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12000684  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40242159/" class="usa-link">40242159</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>ABSTRACT</h2>
<p>Cancer of unknown primary (CUP), a set of histologically confirmed metastases that cannot be identified or traced back to its primary despite comprehensive investigations, accounts for 2–5% of all malignancies. CUP is the fourth leading cause of cancer‐related deaths worldwide, with a median overall survival (OS) of 3–16 months. CUP has long been challenging to diagnose principally due to the occult properties of primary site. In the current era of molecular diagnostics, advancements in methodologies based on cytology, histology, gene expression profiling (GEP), and genomic and epigenomic analysis have greatly improved the diagnostic accuracy of CUP, surpassing 90%. Our center conducted the world's first phase III trial and demonstrated improved progression‐free survival and favorable OS by GEP‐guided site‐specific treatment of CUP, setting the foundation of site‐specific treatment in first‐line management for CUP. In this review, we detailed the epidemiology, etiology, pathogenesis, as well as the histologic, genetic, and clinical characteristics of CUP. We also provided an overview of the advancements in the diagnostics and therapeutics of CUP over the past 50 years. Moving forward, we propose optimizing diagnostic modalities and exploring further‐line treatment regimens as two focus areas for future studies on CUP.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> cancer of unknown primary, molecular diagnostics, empirical chemotherapy, site‐specific therapy, molecularly guided therapy</p></section></section><section class="abstract" id="mco270161-abs-0001"><hr class="headless">
<p>In clinical practice, routine examinations for patients with CUP include taking a medical history, conducting a physical examination, and detecting serum tumor markers. In addition, IHC or MTP‐based methodologies were suggested to assist in identifying the tissue origin of CUP and guiding site‐specific therapy for CUP.
</p>
<section class="bt xbox font-sm" id="boxed-text1"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9adc/12000684/ac15e825fc41/MCO2-6-e70161-g001.jpg" loading="lazy" id="jats-graphic-1" height="148" width="180" alt="graphic file with name MCO2-6-e70161-g001.jpg"></p></section></section><section id="mco270161-sec-0010"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Cancer of unknown primary (CUP) refers to a group of histologically confirmed metastatic malignancies that cannot be identified or traced back to its primary site despite comprehensive examination, which accounts for 2–5% of all tumors [<a href="#mco270161-bib-0001" class="usa-link" aria-describedby="mco270161-bib-0001">1</a>, <a href="#mco270161-bib-0002" class="usa-link" aria-describedby="mco270161-bib-0002">2</a>, <a href="#mco270161-bib-0003" class="usa-link" aria-describedby="mco270161-bib-0003">3</a>, <a href="#mco270161-bib-0004" class="usa-link" aria-describedby="mco270161-bib-0004">4</a>, <a href="#mco270161-bib-0005" class="usa-link" aria-describedby="mco270161-bib-0005">5</a>, <a href="#mco270161-bib-0006" class="usa-link" aria-describedby="mco270161-bib-0006">6</a>, <a href="#mco270161-bib-0007" class="usa-link" aria-describedby="mco270161-bib-0007">7</a>]. CUP ranks as the seventh to eighth most common type of malignancy and is the fourth leading cause of cancer‐related deaths worldwide [<a href="#mco270161-bib-0006" class="usa-link" aria-describedby="mco270161-bib-0006">6</a>, <a href="#mco270161-bib-0008" class="usa-link" aria-describedby="mco270161-bib-0008">8</a>]. Despite recent therapeutic advancements, patients with CUP still face a bleak prognosis, with a median overall survival (OS) of 3–16 months [<a href="#mco270161-bib-0006" class="usa-link" aria-describedby="mco270161-bib-0006">6</a>, <a href="#mco270161-bib-0009" class="usa-link" aria-describedby="mco270161-bib-0009">9</a>, <a href="#mco270161-bib-0010" class="usa-link" aria-describedby="mco270161-bib-0010">10</a>], which is primarily attributed to the diagnostic challenges for CUP. Actually, patients with CUP are categorized into favorable (15–20%) and unfavorable (80–85%) subgroups with distinct prognosis, according to their clinical and pathological characteristics [<a href="#mco270161-bib-0001" class="usa-link" aria-describedby="mco270161-bib-0001">1</a>]. Recently, new favorable subsets of CUP seem to emerge, including colorectal, lung, and renal CUP [<a href="#mco270161-bib-0011" class="usa-link" aria-describedby="mco270161-bib-0011">11</a>]. In fact, fewer than 30% of cases of CUP have specified lesions identified prior to systemic therapy before 2000.</p>
<p>CUP is characterized by high heterogeneity, early dissemination, strong invasiveness, and unpredictable metastasis patterns. Incidence of CUP varies across countries due to the absence of a precise definition and differences at the health facility level. On the whole, CUP typically occurs around the age of 60 years, with rare cases observed in individuals under 40 years of age and a peak incidence in patients over 80 years of age. Males consistently have a slightly higher incidence compared with females [<a href="#mco270161-bib-0002" class="usa-link" aria-describedby="mco270161-bib-0002">2</a>]. In addition to age and sex, other potential risk factors include long‐term smoking, alcohol abuse, autoimmune disorders, diabetes mellitus, and a family history of cancer [<a href="#mco270161-bib-0012" class="usa-link" aria-describedby="mco270161-bib-0012">12</a>, <a href="#mco270161-bib-0013" class="usa-link" aria-describedby="mco270161-bib-0013">13</a>, <a href="#mco270161-bib-0014" class="usa-link" aria-describedby="mco270161-bib-0014">14</a>, <a href="#mco270161-bib-0015" class="usa-link" aria-describedby="mco270161-bib-0015">15</a>, <a href="#mco270161-bib-0016" class="usa-link" aria-describedby="mco270161-bib-0016">16</a>, <a href="#mco270161-bib-0017" class="usa-link" aria-describedby="mco270161-bib-0017">17</a>]. However, there is still a lack of sufficient epidemiological evidence to determine a distinct risk factor profile for CUP.</p>
<p>Identifying the primary site for CUP remains challenging due to several reasons, principally including incomplete examination, insufficient pathological sampling, unique tumor metastatic patterns, occult primary sites, spontaneous regression of the primary tumor, and absence of primary lesions. Over the past 50 years, significant efforts have been dedicated to identifying the tissue origin of CUP in order to optimize therapeutic strategies. In addition to comprehensive history taking and full physical examination, a variety of diagnostic techniques, such as imaging and pathological examination, gene expression profiling (GEP), as well as genomic and epigenomic analysis, have been applied to diagnose CUP [<a href="#mco270161-bib-0008" class="usa-link" aria-describedby="mco270161-bib-0008">8</a>, <a href="#mco270161-bib-0018" class="usa-link" aria-describedby="mco270161-bib-0018">18</a>, <a href="#mco270161-bib-0019" class="usa-link" aria-describedby="mco270161-bib-0019">19</a>]. Histopathological analysis, including morphological analysis and immunohistochemistry (IHC) on specimens, was the most commonly used methodology for diagnosing CUP in early‐stage [<a href="#mco270161-bib-0020" class="usa-link" aria-describedby="mco270161-bib-0020">20</a>, <a href="#mco270161-bib-0021" class="usa-link" aria-describedby="mco270161-bib-0021">21</a>, <a href="#mco270161-bib-0022" class="usa-link" aria-describedby="mco270161-bib-0022">22</a>, <a href="#mco270161-bib-0023" class="usa-link" aria-describedby="mco270161-bib-0023">23</a>]. Currently, a step‐by‐step IHC staining with lineage‐ and organ‐specific markers is adopted to assist in identifying the tissue origin of CUP [<a href="#mco270161-bib-0023" class="usa-link" aria-describedby="mco270161-bib-0023">23</a>, <a href="#mco270161-bib-0024" class="usa-link" aria-describedby="mco270161-bib-0024">24</a>], which enables the development of individualized therapeutic options tailored to the specific organ or histological type. We have to admit, however, the IHC staining also has many limitations, particularly in poorly differentiated and undifferentiated tumors. In this case, the diagnostic accuracy of IHC may be compromised, which poses challenges in accurately determining the tumor tissue origin [<a href="#mco270161-bib-0010" class="usa-link" aria-describedby="mco270161-bib-0010">10</a>]. Published studies revealed that the overall diagnostic accuracy of IHC alone for CUP is approximately 77% [<a href="#mco270161-bib-0025" class="usa-link" aria-describedby="mco270161-bib-0025">25</a>]. Over the past two decades, there have been significant advancements in molecular diagnostics, making the widespread adoption and recognition of GEP and next‐generation sequencing (NGS) as two effective methodologies for the diagnosis of CUP [<a href="#mco270161-bib-0026" class="usa-link" aria-describedby="mco270161-bib-0026">26</a>, <a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0028" class="usa-link" aria-describedby="mco270161-bib-0028">28</a>]. These methodologies have demonstrated superiority over IHC, with an accuracy of 83–94% [<a href="#mco270161-bib-0029" class="usa-link" aria-describedby="mco270161-bib-0029">29</a>, <a href="#mco270161-bib-0030" class="usa-link" aria-describedby="mco270161-bib-0030">30</a>, <a href="#mco270161-bib-0031" class="usa-link" aria-describedby="mco270161-bib-0031">31</a>]. However, the molecular tumor profiling (MTP) is not always performed and still lacks clinical penetration in resource‐poor settings. With the advancements of artificial intelligence (AI) in clinical diagnosis of certain tumor types, machine learning and deep learning algorithms based on cytology, histology, GEP, and NGS‐based genomic and epigenomic analysis have been extensively validated to improve the diagnostic accuracy of CUP [<a href="#mco270161-bib-0032" class="usa-link" aria-describedby="mco270161-bib-0032">32</a>, <a href="#mco270161-bib-0033" class="usa-link" aria-describedby="mco270161-bib-0033">33</a>, <a href="#mco270161-bib-0034" class="usa-link" aria-describedby="mco270161-bib-0034">34</a>, <a href="#mco270161-bib-0035" class="usa-link" aria-describedby="mco270161-bib-0035">35</a>, <a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036">36</a>], which opens a fresh chapter in the diagnosis and management for patients with CUP.</p>
<p>Challenges in diagnosis present significant obstacles to clinical therapy for CUP, further contributing to a worse prognosis for CUP. In the past five decades, empirical chemotherapy has been widely acknowledged as the cornerstone for the treatment of CUP. Organ‐specific therapy, tailored to the identified tumor tissue origin, has been proven to be effective. However, in subsets of CUP with undefined tumor tissue origin, empirical treatment using combination regimens of taxane or platinum is employed, leading to less optimal patient outcomes [<a href="#mco270161-bib-0010" class="usa-link" aria-describedby="mco270161-bib-0010">10</a>]. To further improve the prognosis of patients with CUP, several clinical trials have been conducted to explore the benefits of MTP‐directed site‐specific first‐line therapy over empirical chemotherapy [<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>, <a href="#mco270161-bib-0038" class="usa-link" aria-describedby="mco270161-bib-0038">38</a>, <a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>, <a href="#mco270161-bib-0040" class="usa-link" aria-describedby="mco270161-bib-0040">40</a>, <a href="#mco270161-bib-0041" class="usa-link" aria-describedby="mco270161-bib-0041">41</a>, <a href="#mco270161-bib-0042" class="usa-link" aria-describedby="mco270161-bib-0042">42</a>]. In 2013, the Sarah Cannon Research Institute conducted the first prospective trial worldwide to indicate that patients with CUP who received GEP‐directed first‐line site‐specific treatment exhibited improved OS compared with those who received empirical therapy [<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>]. However, another phase II clinical trial performed by Kindai University Faculty of Medicine reported that GEP‐directed site‐specific treatment did not yield a significant improvement in OS and progression‐free survival (PFS) compared with empirical chemotherapy [<a href="#mco270161-bib-0038" class="usa-link" aria-describedby="mco270161-bib-0038">38</a>]. Furthermore, a recent study from Moffitt Cancer Center demonstrated that patients who underwent NGS‐directed site‐specific therapy had a longer OS compared with those treated with standard options, although this comparison did not reach statistical significance [<a href="#mco270161-bib-0040" class="usa-link" aria-describedby="mco270161-bib-0040">40</a>]. However, neither of these studies has confirmed the superiority of site‐specific therapy over empirical chemotherapy, which may be attributed to the significant deficiencies present in the currently available studies. These limitations include patient recruitment (oversampling treatment‐resistant tumor types and long recruitment), study design limitations (retrospective and observational trials), heterogeneity among the classifiers (different omic approaches with variable performance), as well as incomparable treatment regimens [<a href="#mco270161-bib-0043" class="usa-link" aria-describedby="mco270161-bib-0043">43</a>]. In light of this, our center conducted the world's first phase III clinical trial and demonstrated improved PFS and favorable OS with GEP‐guided site‐specific therapy for patients with CUP [<a href="#mco270161-bib-0041" class="usa-link" aria-describedby="mco270161-bib-0041">41</a>, <a href="#mco270161-bib-0042" class="usa-link" aria-describedby="mco270161-bib-0042">42</a>], which provides new strategies for the treatment and clinical management for CUP in the future.</p>
<p>In this review, we have detailed the epidemiology, etiology, pathogenesis, and histologic, genetic, and clinical features of CUP, as well as provide an overview of the advancements in the clinical diagnosis and treatment of CUP. We have proposed and established the status of site‐specific first‐line therapy in improving patient outcomes of CUP through the world's first phase III clinical trial. Meanwhile, we are now working on exploring effective second‐line therapy regimen for previously treated or progressed CUP, and the data will be made public in the near future. Furthermore, we construct a hierarchical management system for the diagnosis, treatment and follow‐up of CUP. Looking ahead, we believe that the optimization of diagnostic approaches and the exploration of second‐line regimens are two crucial areas in future studies for CUP, which still have a long way to go.</p></section><section id="mco270161-sec-0020"><h2 class="pmc_sec_title">2. Epidemiology of Cup</h2>
<p>Over the past few decades, the incidence rate of CUP has varied between developed and developing countries, with an overall global incidence ranging from 2 to 5% from a holistic perspective [<a href="#mco270161-bib-0044" class="usa-link" aria-describedby="mco270161-bib-0044">44</a>]. Overall, geographic differences in the morbidity of CUP were attributed to the absence of a unified criterion for defining and diagnosing CUP. Between 1961 and 2010, the age‐standardized incidence rate (ASIR) of CUP was about 5–18 per 100,000 in Scotland, reaching a peak in the early to middle 1990s followed by a steeper decrease, accounting for 3.9% of all registrations of tumors [<a href="#mco270161-bib-0045" class="usa-link" aria-describedby="mco270161-bib-0045">45</a>]. Meanwhile, from 1960 to 2008 in Sweden, the ASIR of patients with CUP was approximately four to eight per 100,000, exhibiting a peak in rates in the late 1990s followed by a significant decrease, and accounted for 3.9% of all diagnosed cancers [<a href="#mco270161-bib-0046" class="usa-link" aria-describedby="mco270161-bib-0046">46</a>]. In Switzerland, the ASIR of CUP increased from 10.3 to 17.6 per 100,000 between 1981 and 1997, and then decreased to 5.8 in 2014, representing approximately 0.9–2.6% of newly diagnosed cancers [<a href="#mco270161-bib-0004" class="usa-link" aria-describedby="mco270161-bib-0004">4</a>]. Based on epidemiological statistics from Europe, we observed a consistent trend of peak of ASIR in the 1990s followed by an obvious decline, which may primarily result from constantly improved diagnostic methods to identify the primary sites and decreased autopsy rates. Compared with data from Europe, the USA experienced earlier decreases in ASIR since the early 1980s. Between 2000 and 2010 in the USA, the average ASIR of CUP was 4.1 per 100,000 [<a href="#mco270161-bib-0047" class="usa-link" aria-describedby="mco270161-bib-0047">47</a>]. Until now, however, there has been no detailed epidemiological report of the incidence rate of CUP in the Asian population. According to the latest statistics from Fudan University Shanghai Cancer Center, which analyzed 1420 pathologically confirmed CUP between 2019 and 2020, CUP accounted for approximately 0.82% of all cancer diagnoses [<a href="#mco270161-bib-0048" class="usa-link" aria-describedby="mco270161-bib-0048">48</a>]. Actually, the observed relatively low and significant decrease of incidence rate in CUP may primarily be due to consistent advancements in diagnostic techniques [<a href="#mco270161-bib-0005" class="usa-link" aria-describedby="mco270161-bib-0005">5</a>].</p></section><section id="mco270161-sec-0030"><h2 class="pmc_sec_title">3. Etiology and Pathogenesis of Cup</h2>
<p>In terms of etiology, previous studies have indicated that human papillomavirus is a definite causative factor in squamous cell carcinomas arise in the head and neck, abdomen, pelvis, and retroperitoneum with unknown primary tumor sites [<a href="#mco270161-bib-0049" class="usa-link" aria-describedby="mco270161-bib-0049">49</a>, <a href="#mco270161-bib-0050" class="usa-link" aria-describedby="mco270161-bib-0050">50</a>, <a href="#mco270161-bib-0051" class="usa-link" aria-describedby="mco270161-bib-0051">51</a>]. Furthermore, long‐term smoking, alcohol abuse, diabetes mellitus, obesity, autoimmune disorders, and a family history of cancer have been suggested as potential risk factors for CUP [<a href="#mco270161-bib-0013" class="usa-link" aria-describedby="mco270161-bib-0013">13</a>, <a href="#mco270161-bib-0014" class="usa-link" aria-describedby="mco270161-bib-0014">14</a>, <a href="#mco270161-bib-0016" class="usa-link" aria-describedby="mco270161-bib-0016">16</a>, <a href="#mco270161-bib-0052" class="usa-link" aria-describedby="mco270161-bib-0052">52</a>, <a href="#mco270161-bib-0053" class="usa-link" aria-describedby="mco270161-bib-0053">53</a>]. In addition, age and gender were another two established risk factors for CUP. Patients with CUP typically experience a peak incidence at the age of 80 years, with the average onset of the disease occurring around the age of 60 years. Further, the incidence of CUP progressively increases with advancing age [<a href="#mco270161-bib-0054" class="usa-link" aria-describedby="mco270161-bib-0054">54</a>]. Male gender is also considered as a potential risk factor for patients with CUP [<a href="#mco270161-bib-0002" class="usa-link" aria-describedby="mco270161-bib-0002">2</a>]. In addition, black ethnic background and low socioeconomic status may be considered as other possible risk factors for CUP [<a href="#mco270161-bib-0052" class="usa-link" aria-describedby="mco270161-bib-0052">52</a>, <a href="#mco270161-bib-0055" class="usa-link" aria-describedby="mco270161-bib-0055">55</a>]. However, no significant correlation has been observed between dietary habits, lifestyle, and physical activity levels and onset of CUP [<a href="#mco270161-bib-0013" class="usa-link" aria-describedby="mco270161-bib-0013">13</a>, <a href="#mco270161-bib-0056" class="usa-link" aria-describedby="mco270161-bib-0056">56</a>, <a href="#mco270161-bib-0057" class="usa-link" aria-describedby="mco270161-bib-0057">57</a>]. Overall, no specific causative factors or risk factors have been confirmed for CUP that differ significantly from those associated with other types of metastases with known primaries.</p>
<p>Since the occult of primary site and the heterogeneity of metastases, there is no define consensus on the pathogenesis of CUP. Currently, there have been two main theories regarding the pathogenesis of CUP. In the first scenario, deregulated, premalignant, or cancerous stem cells migrate to a distant site and initiate a cancer, without forming a tumor at the primary site [<a href="#mco270161-bib-0058" class="usa-link" aria-describedby="mco270161-bib-0058">58</a>]. Alternatively, the primary lesions disappear before they develop into detectable lesions [<a href="#mco270161-bib-0059" class="usa-link" aria-describedby="mco270161-bib-0059">59</a>, <a href="#mco270161-bib-0060" class="usa-link" aria-describedby="mco270161-bib-0060">60</a>]. In this case, the primary tumor never exists, which is known as “no primary theory.” This may explain why many CUP patients in clinical settings, despite undergoing various diagnostic procedures, are still unable to trace the primary tumor site. In the second scenario, mobile cells migrate to metastatic sites at an early stage and reprogram the tumor microenvironment to enhance the growth of metastasis [<a href="#mco270161-bib-0060" class="usa-link" aria-describedby="mco270161-bib-0060">60</a>]. Further, distant metastasis inhibits the development of local growth [<a href="#mco270161-bib-0058" class="usa-link" aria-describedby="mco270161-bib-0058">58</a>, <a href="#mco270161-bib-0061" class="usa-link" aria-describedby="mco270161-bib-0061">61</a>] and finally contributes to the occult capacity of the primary tumors, which lays the foundation for the identification of the primary tumor site and site‐specific therapy. In this situation, approximately 4–25% of cases with CUP finally identify the primary lesions during the course of disease [<a href="#mco270161-bib-0062" class="usa-link" aria-describedby="mco270161-bib-0062">62</a>], which was acknowledged as “parallel progression theory” [<a href="#mco270161-bib-0060" class="usa-link" aria-describedby="mco270161-bib-0060">60</a>] (Figure <a href="#mco270161-fig-0001" class="usa-link">1</a>). However, it is important to note that the aforementioned theories have not been confirmed and still need further exploration and validation.</p>
<figure class="fig xbox font-sm" id="mco270161-fig-0001"><h3 class="obj_head">FIGURE 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9adc/12000684/155d5e419d5a/MCO2-6-e70161-g004.jpg" loading="lazy" id="jats-graphic-3" height="444" width="560" alt="FIGURE 1"></p>
<div class="p text-right font-secondary"><a href="figure/mco270161-fig-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The underlying mechanisms involved in the carcinogenesis and progression of CUP. In the first scenario, the “no primary theory” suggests that deregulated, premalignant, or cancerous stem cells may migrate to a distant site and give rise to a new neoplasm, without forming a tumor at the primary site. While in the second scenario, the “parallel progression theory” agrees that mobile cells migrate to metastatic sites at an early stage and suppress the development of the primary tumor, leading to undetectable local lesions. The percentage in the figure represents the probability of the primary tumors occurring among all cases of CUP, and the graphic was created with BioRender.</p></figcaption></figure></section><section id="mco270161-sec-0040"><h2 class="pmc_sec_title">4. Histologic, Genetic, and Clinical Features of Cup</h2>
<p>According to the morphological features, CUP can be categorized into four histological types: well and moderately differentiated adenocarcinomas (50%), undifferentiated or poorly differentiated adenocarcinomas (30%), squamous cell carcinomas (15%), and undifferentiated neoplasms (5%) [<a href="#mco270161-bib-0004" class="usa-link" aria-describedby="mco270161-bib-0004">4</a>, <a href="#mco270161-bib-0008" class="usa-link" aria-describedby="mco270161-bib-0008">8</a>, <a href="#mco270161-bib-0063" class="usa-link" aria-describedby="mco270161-bib-0063">63</a>]. Sarcomas, melanomas, neuroendocrine tumors, germ cell tumors, and hematological malignancies with unknown primary sites are excluded from the definition of CUP. One particular concern is approximately 3% of melanomas lack an identifiable primary were defined as melanoma of unknown primary, which seems to present better outcomes compared with those with stage‐matched melanoma of known primary [<a href="#mco270161-bib-0064" class="usa-link" aria-describedby="mco270161-bib-0064">64</a>]. Actually, different histological subtypes of CUP exhibit varying responses to treatment. Survival is worse for patients with adenocarcinoma and undifferentiated carcinoma in comparison with those with squamous cell carcinomas (1‐year survival rate of 19 and 46%, respectively) [<a href="#mco270161-bib-0055" class="usa-link" aria-describedby="mco270161-bib-0055">55</a>], which is primarily due to the varied genetic characteristics and different activated oncogenic signaling pathway among distinct histological types of CUP.</p>
<p>From genetic perspective, the most frequent genomic alterations observed were <em>TP53</em>, <em>KRAS</em>, <em>CDKN2A</em>, <em>MET</em>, <em>MYC, ERBB2, PIK3CA, FGFR2, BRAF</em>, and <em>ARID1A</em> [<a href="#mco270161-bib-0019" class="usa-link" aria-describedby="mco270161-bib-0019">19</a>, <a href="#mco270161-bib-0065" class="usa-link" aria-describedby="mco270161-bib-0065">65</a>‐<a href="#mco270161-bib-0070" class="usa-link" aria-describedby="mco270161-bib-0070"><sup>70</sup></a>]. Among these, approximately half of the patients with CUP experienced <em>TP53</em> mutation, while <em>CDKN2A</em> was the most frequently deleted gene in CUP [<a href="#mco270161-bib-0071" class="usa-link" aria-describedby="mco270161-bib-0071">71</a>]. In addition, alterations of <em>ERBB2</em>, <em>EGFR</em> and <em>BRAF</em> are more common in adenocarcinoma of unknown primary (ACUP) compared with non‐ACUP, whereas alteration of <em>MLL2</em> is more frequent in non‐ACUP [<a href="#mco270161-bib-0019" class="usa-link" aria-describedby="mco270161-bib-0019">19</a>]. In cases of CUP, the most frequently observed oncogenic gene partner is <em>FGFR2</em>, followed by ALK [<a href="#mco270161-bib-0071" class="usa-link" aria-describedby="mco270161-bib-0071">71</a>], providing evidence for targeted therapy. Usually, the intact kinase domain of <em>FGFR2</em> forms a fusion with another gene, which provides a dimerization domain to activate RAS/MAPK and PI3K/AKT downstream pathways. Previous study demonstrated that ACUP showed elevated activation of the RAS/MAPK signaling pathway in comparison with those with non‐ACUP [<a href="#mco270161-bib-0019" class="usa-link" aria-describedby="mco270161-bib-0019">19</a>], which may be attributed to the increased expression of <em>FGFR2</em>, <em>KRAS</em>, and <em>ALK</em> in cases of ACUP. Further, high expression of PD‐L1 (TPS &gt; 50%) has been documented to be present in approximately 14% patients of CUP [<a href="#mco270161-bib-0065" class="usa-link" aria-describedby="mco270161-bib-0065">65</a>], with the positivity rate showing no significant differences among different histological subtypes [<a href="#mco270161-bib-0072" class="usa-link" aria-describedby="mco270161-bib-0072">72</a>]. Meanwhile, about 16% of CUP exhibited high tumor mutational burden (TMB) (&gt;10 mutations/Mb) [<a href="#mco270161-bib-0073" class="usa-link" aria-describedby="mco270161-bib-0073">73</a>]. In fact, previously published studies documented that about 28% of patients with CUP harbor one or more predictive biomarkers (PD‐L1, microsatellite instability [MSI]‐high, and/or TMB‐high) for immune checkpoint inhibitors (ICIs) treatment [<a href="#mco270161-bib-0074" class="usa-link" aria-describedby="mco270161-bib-0074">74</a>]. PD‐L1 expression, MSI, and TMB status are acknowledged as predictive biomarkers when ICIs application is considered. Furthermore, chromosomal instability (CIN) is not frequently observed in CUP [<a href="#mco270161-bib-0012" class="usa-link" aria-describedby="mco270161-bib-0012">12</a>, <a href="#mco270161-bib-0075" class="usa-link" aria-describedby="mco270161-bib-0075">75</a>]. CIN is considered as a driver of immunosuppression and cancer metastasis [<a href="#mco270161-bib-0076" class="usa-link" aria-describedby="mco270161-bib-0076">76</a>, <a href="#mco270161-bib-0077" class="usa-link" aria-describedby="mco270161-bib-0077">77</a>, <a href="#mco270161-bib-0078" class="usa-link" aria-describedby="mco270161-bib-0078">78</a>], which may make ICIs more beneficial for individuals with CUP. Recently, Professor Mileshkin applied immunotherapy response (IR) score (defined according to specific immune gene‐expression profiles), TMB status, and ICI‐responsive cancer types as predominant biomarkers to predict the ICIs response in CUP, achieving an overall response rate (ORR) of 29% [<a href="#mco270161-bib-0073" class="usa-link" aria-describedby="mco270161-bib-0073">73</a>]. IR score, in particular, was more sensitive than TMB and cancer types to predict response to ICIs. Furthermore, HER‐2 was found to be overexpressed in approximately 10% of CUP [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0079" class="usa-link" aria-describedby="mco270161-bib-0079">79</a>], which provides opportunities for HER2‐targeting antibody–drug conjugate (ADC) treatment for patients with CUP. From the protein level, cell cycle proteins (TP53, BCL2) [<a href="#mco270161-bib-0080" class="usa-link" aria-describedby="mco270161-bib-0080">80</a>], oncoproteins (MYC, RAS) [<a href="#mco270161-bib-0081" class="usa-link" aria-describedby="mco270161-bib-0081">81</a>], and matrix metalloproteinases (MMP‐2, MMP‐9, and TIMP‐1) [<a href="#mco270161-bib-0082" class="usa-link" aria-describedby="mco270161-bib-0082">82</a>] were found to be highly expressed in patients with CUP, which may contribute to the development and progression of CUP.</p>
<p>For CUP, the average onset of the disease is around the age of 60 years [<a href="#mco270161-bib-0048" class="usa-link" aria-describedby="mco270161-bib-0048">48</a>, <a href="#mco270161-bib-0054" class="usa-link" aria-describedby="mco270161-bib-0054">54</a>], with a higher incidence observed in males compared with females. Patients with CUP often present to the clinic for symptoms and signs of metastatic tumors, including lymphadenopathy, local mass, bloating, pain, jaundice, weight loss, or hoarseness [<a href="#mco270161-bib-0083" class="usa-link" aria-describedby="mco270161-bib-0083">83</a>]. Among these, lymph nodes are the most commonly involved lesions of metastasis, accounting for approximately 14–41.8% of all cases [<a href="#mco270161-bib-0048" class="usa-link" aria-describedby="mco270161-bib-0048">48</a>, <a href="#mco270161-bib-0084" class="usa-link" aria-describedby="mco270161-bib-0084">84</a>, <a href="#mco270161-bib-0085" class="usa-link" aria-describedby="mco270161-bib-0085">85</a>]. As a result, lymphadenopathy plays a crucial role in tracing the primary lesions of CUP, and our group was the first to propose the concept of the “sentinel node theory” to tract the primary for patients with CUP [<a href="#mco270161-bib-0086" class="usa-link" aria-describedby="mco270161-bib-0086">86</a>, <a href="#mco270161-bib-0087" class="usa-link" aria-describedby="mco270161-bib-0087">87</a>]. Lung [<a href="#mco270161-bib-0085" class="usa-link" aria-describedby="mco270161-bib-0085">85</a>, <a href="#mco270161-bib-0088" class="usa-link" aria-describedby="mco270161-bib-0088">88</a>], gastrointestinal tract [<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>], liver [<a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>], pancreas [<a href="#mco270161-bib-0089" class="usa-link" aria-describedby="mco270161-bib-0089">89</a>], and breast [<a href="#mco270161-bib-0030" class="usa-link" aria-describedby="mco270161-bib-0030">30</a>] were predicted as the most frequently identified primary sites for CUP, providing a solid foundation for site‐specific therapy. In addition, patients with CUP were divided into favorable (15–20%) and unfavorable (80–85%) subsets according to the clinical and pathologic characteristics of CUP [<a href="#mco270161-bib-0001" class="usa-link" aria-describedby="mco270161-bib-0001">1</a>]. Patients with CUP in the favorable subgroup include women with papillary adenocarcinoma of the peritoneal cavity, women with adenocarcinoma involving the axillary lymph nodes, poorly differentiated carcinoma with midline distribution, squamous‐cell carcinoma involving cervical lymph nodes, men with blastic bone metastases and elevated prostate‐specific antigen (PSA), isolated inguinal adenopathy (squamous carcinoma), adenocarcinoma with a colon‐cancer profile (CK20+, CK7−, CDX2+) (adenocarcinoma), and patients with one small, potentially resectable tumor. Recently, new favorable subsets of CUP seem to emerge, which include colorectal, lung, and renal CUP [<a href="#mco270161-bib-0011" class="usa-link" aria-describedby="mco270161-bib-0011">11</a>]. However, patients with multiple cerebral metastases (adenocarcinoma or squamous carcinoma), adenocarcinoma metastatic to the liver or other organs, multiple metastatic lytic bone disease (adenocarcinoma), pleural metastases (adenocarcinoma), squamous‐cell carcinoma of the abdominopelvic cavity, and nonpapillary malignant ascites (adenocarcinoma) belong to the prognostically unfavorable subset [<a href="#mco270161-bib-0001" class="usa-link" aria-describedby="mco270161-bib-0001">1</a>, <a href="#mco270161-bib-0009" class="usa-link" aria-describedby="mco270161-bib-0009">9</a>].</p></section><section id="mco270161-sec-0050"><h2 class="pmc_sec_title">5. Diagnosis of Patients With Cup</h2>
<section id="mco270161-sec-0060"><h3 class="pmc_sec_title">5.1. Medical history taking and physical examination</h3>
<p>Medical history taking includes a thorough evaluation of symptoms and signs, previous examinations, preexisting conditions, medical and surgical history, and the family history of cancer. Specialist physical examinations should involve the assessment of local masses, superficial lymph nodes, breast, urogenital tract, and rectum to provide clues for identifying the primary lesions for CUP. In cases with CUP, lymphadenopathy is the most commonly observed and crucial positive sign [<a href="#mco270161-bib-0090" class="usa-link" aria-describedby="mco270161-bib-0090">90</a>]. Cancer cells frequently disseminate through the lymphatic system to initiate secondary tumors in distant sites, separate from the primary tumor. The drainage pathway for tumor typically follows a predictable pattern throughout the body, providing valuable clues for tracking the primary tumor site for CUP. For instance, cervical lymphadenopathy often indicates head and neck squamous carcinoma, as well as metastases from salivary gland, thyroid, lung, breast, gastrointestinal, and genitourinary tract tumors. In fact, a previous study conducted by our center confirmed that the predictive accuracy of “sentinel node theory,” particularly for differentiated carcinoma, was 95% in tracking the primary tumors [<a href="#mco270161-bib-0086" class="usa-link" aria-describedby="mco270161-bib-0086">86</a>].</p></section><section id="mco270161-sec-0070"><h3 class="pmc_sec_title">5.2. Serum tumor markers detection</h3>
<p>Since their discovery in 1978, serum tumor markers have been widely utilized in clinical settings for tumor screening, diagnosing, recurrence monitoring, and treatment efficacy assessing. In certain cases, the expression level of specific tumor markers, such as lactate dehydrogenase and carcinoembryonic antigen, may have prognostic significance for survival [<a href="#mco270161-bib-0091" class="usa-link" aria-describedby="mco270161-bib-0091">91</a>]. However, tumor markers do not provide adequate diagnostic assistance for patients with CUP due to their limited sensitivity and specificity. Indeed, tumor markers were often detected as a reference indicator alongside other examinations including pathology and imaging. In some certain types of cancer, specific tumor markers, for instance, alpha‐fetoprotein in hepatic carcinoma and PSA in prostate cancer, have shown high sensitivity and specificity for specific tumor types, which provides valuable clues for identifying the primary site for CUP. In clinical practice, continuous monitoring of tumor markers is performed to assess the efficacy of anticancer therapy and to monitor tumor recurrence for CUP.</p></section><section id="mco270161-sec-0080"><h3 class="pmc_sec_title">5.3. Positron emission tomography scan</h3>
<p>Contrast‐enhanced computed tomography (CT) and magnetic resonance imaging (MRI) are commonly used in the routine diagnosis of tumors. Since the great advancements of molecular imaging in recent years, positron emission tomography (PET), combined with CT or MRI, has emerged as a widely used approach for diagnosing and staging tumors. <sup>18</sup>F‐fluorodeoxyglucose (FDG) PET/CT has been applied extensively in the diagnosis, therapy monitoring, and prognostic assessment in patients with CUP [<a href="#mco270161-bib-0092" class="usa-link" aria-describedby="mco270161-bib-0092">92</a>, <a href="#mco270161-bib-0093" class="usa-link" aria-describedby="mco270161-bib-0093">93</a>, <a href="#mco270161-bib-0094" class="usa-link" aria-describedby="mco270161-bib-0094">94</a>, <a href="#mco270161-bib-0095" class="usa-link" aria-describedby="mco270161-bib-0095">95</a>, <a href="#mco270161-bib-0096" class="usa-link" aria-describedby="mco270161-bib-0096">96</a>, <a href="#mco270161-bib-0097" class="usa-link" aria-describedby="mco270161-bib-0097">97</a>, <a href="#mco270161-bib-0098" class="usa-link" aria-describedby="mco270161-bib-0098">98</a>]. For patients presenting with lymph node metastases of unknown primary sites, the overall sensitivity, specificity, and accuracy rates of <sup>18</sup>F‐FDG PET/CT were 73, 89, and 81%, respectively [<a href="#mco270161-bib-0092" class="usa-link" aria-describedby="mco270161-bib-0092">92</a>]. In particular, for patients with cervical lymph node metastases of unknown primary, <sup>18</sup>F‐FDG PET/CT illustrated a higher overall sensitivity and specificity of 88.3 and 74.9%, along with an accuracy of 78.8%, respectively. Meanwhile, another retrospective study involving 31 CUP patients with cervical lymph node metastasis suggested that the sensitivity and specificity of <sup>18</sup>F‐FDG PET/CT in detecting the primary site were 67 and 91%, respectively [<a href="#mco270161-bib-0095" class="usa-link" aria-describedby="mco270161-bib-0095">95</a>]. A point worth emphasizing is that in approximately 25% of patients with CUP, <sup>18</sup>F‐FDG PET/CT accurately identified the primary lesions that had gone undetected by other procedures. And, it revealed previously unrecognized regional or distant metastases in 27% of patients [<a href="#mco270161-bib-0094" class="usa-link" aria-describedby="mco270161-bib-0094">94</a>]. SUV<sub>max</sub> on pretreatment <sup>18</sup>FDG‐PET/CT scanning has been accepted as a prognostic indicator in certain cancer types, such as and non‐small‐cell lung cancer (NSCLC) [<a href="#mco270161-bib-0099" class="usa-link" aria-describedby="mco270161-bib-0099">99</a>], salivary gland carcinoma [<a href="#mco270161-bib-0100" class="usa-link" aria-describedby="mco270161-bib-0100">100</a>], and epithelial ovarian cancer [<a href="#mco270161-bib-0101" class="usa-link" aria-describedby="mco270161-bib-0101">101</a>]. In patients with CUP, an SUV<sub>max</sub> above 20 on <sup>18</sup>F‐FDG PET/CT has been proven to be associated with a favorable OS [<a href="#mco270161-bib-0093" class="usa-link" aria-describedby="mco270161-bib-0093">93</a>], which may be attributed to the predictive value of SUV<sub>max</sub> in determining the tumor chemosensitivity. In addition, <sup>68</sup>Ga‐fibroblast activation protein inhibitor (FAPI) PET/CT has been proven to be a clear preference in imaging the primary, metastatic, and recurrent tumors across 22 different types of cancers [<a href="#mco270161-bib-0102" class="usa-link" aria-describedby="mco270161-bib-0102">102</a>, <a href="#mco270161-bib-0103" class="usa-link" aria-describedby="mco270161-bib-0103">103</a>, <a href="#mco270161-bib-0104" class="usa-link" aria-describedby="mco270161-bib-0104">104</a>]. In particular, <sup>68</sup>Ga FAPI PET/CT outperforms <sup>18</sup>F‐FDG PET/CT in identifying the primary lesions for head and neck CUP with more reliable, sensitive, and reproducible imaging modality [<a href="#mco270161-bib-0103" class="usa-link" aria-describedby="mco270161-bib-0103">103</a>]. Likewise, study from our center verified that <sup>68</sup>Ga‐FAPI PET/CT improved the detection efficiency of primary lesions in head and neck CUP with negative <sup>18</sup>F‐FDG PET/CT findings [<a href="#mco270161-bib-0104" class="usa-link" aria-describedby="mco270161-bib-0104">104</a>].</p></section><section id="mco270161-sec-0090"><h3 class="pmc_sec_title">5.4. Histology and IHC staining</h3>
<p>IHC analysis on biopsy specimens are required, with histopathological analysis serving as the gold standard for diagnosing CUP before the era of molecular diagnostics [<a href="#mco270161-bib-0105" class="usa-link" aria-describedby="mco270161-bib-0105">105</a>, <a href="#mco270161-bib-0106" class="usa-link" aria-describedby="mco270161-bib-0106">106</a>]. Morphological features of malignancies occasionally offer insights into the tumor type and tissue of origin (ToO). For instance, signet‐ring cancer cells are commonly observed in glandular epithelium of gastrointestinal tract, whereas papillary neoplastic cells are primarily observed in breast and thyroid cancers [<a href="#mco270161-bib-0107" class="usa-link" aria-describedby="mco270161-bib-0107">107</a>]. However, for poorly differentiated and undifferentiated tumors, relying solely on the morphological analysis is far from sufficient. IHC analysis, based on lineage‐ and organ‐specific markers, was then proposed as a recommendation for classifying the lineage or determining the tumor tissue origin for CUP [<a href="#mco270161-bib-0021" class="usa-link" aria-describedby="mco270161-bib-0021">21</a>, <a href="#mco270161-bib-0108" class="usa-link" aria-describedby="mco270161-bib-0108">108</a>].</p>
<p>Currently, the step‐by‐step process of IHC staining is widely utilized and acknowledged as highly efficient [<a href="#mco270161-bib-0008" class="usa-link" aria-describedby="mco270161-bib-0008">8</a>]. In the first step, lineage‐specific markers (CK, S100, LCA, and Vimentin) are screened to distinguish carcinoma from lymphoma, sarcoma, and melanoma. For patients with sarcomas of undefined primary, the pathologies are highly variable with histologic heterogeneity [<a href="#mco270161-bib-0109" class="usa-link" aria-describedby="mco270161-bib-0109">109</a>], which may due to the smallness of the primary tumor to evade detection.</p>
<p>In the second step, organ‐specific markers are applied to assist in identifying the tissue origin of CUP, which can help narrow down the potential tissue origin of tumors (Figure <a href="#mco270161-fig-0002" class="usa-link">2</a>). Once identified as an epithelial malignancy, a combination of CK7 and CK20 is used to speculate on the tissue origin of metastatic tumors [<a href="#mco270161-bib-0024" class="usa-link" aria-describedby="mco270161-bib-0024">24</a>]. CK20 is predominantly expressed in the urothelial cancer, gastrointestinal tract cancer, and Merkel cell carcinoma, whereas CK7 is primarily negative in colorectal cancer and prostate cancer [<a href="#mco270161-bib-0110" class="usa-link" aria-describedby="mco270161-bib-0110">110</a>]. Meanwhile, additional markers such as TTF1, p63, GATA3, PSA, β‐HCG, and Hepar1 were applied to infer the primary lesions of CUP [<a href="#mco270161-bib-0111" class="usa-link" aria-describedby="mco270161-bib-0111">111</a>]. For cancers that are CK20 negative and CK7 positive, the presence of p63 often suggests lung squamous carcinoma, while the presence of TTF1 largely indicates lung adenocarcinoma [<a href="#mco270161-bib-0112" class="usa-link" aria-describedby="mco270161-bib-0112">112</a>]. IHC analysis demonstrated high accuracy in identifying lesions derived from NSCLC, breast cancer, colorectal cancer, ovarian cancer, and renal cancer. However, the diagnostic accuracy of IHC analysis alone for identifying metastatic tumors originating from gastric cancer, pancreatic cancer, or cholangiocarcinoma still remains relatively low [<a href="#mco270161-bib-0113" class="usa-link" aria-describedby="mco270161-bib-0113">113</a>]. In fact, previous studies have shown that the overall diagnostic accuracy of multiple IHC markers alone for diagnosing CUP was approximately 77% [<a href="#mco270161-bib-0025" class="usa-link" aria-describedby="mco270161-bib-0025">25</a>]. However, using more than 10–12 markers does not substantially enhance diagnostic accuracy for CUP. In addition, factors such as tissue antigen instability, tumor heterogeneity, and subjective interpretation of IHC staining by different pathologists have been confirmed as commonly observed factors contributing to decreased accuracy in CUP diagnosis using IHC staining.</p>
<figure class="fig xbox font-sm" id="mco270161-fig-0002"><h4 class="obj_head">FIGURE 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9adc/12000684/acc23432a5c1/MCO2-6-e70161-g005.jpg" loading="lazy" id="jats-graphic-5" height="514" width="600" alt="FIGURE 2"></p>
<div class="p text-right font-secondary"><a href="figure/mco270161-fig-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Advisable step‐by‐step IHC screening to identify the tissue origin of CUP. Step one: lineage‐specific markers were recommended to distinguish carcinoma from lymphoma, melanoma, and sarcoma. Step two: organ‐specific markers were applied to identify the tissue origin of CUP.</p></figcaption></figure></section><section id="mco270161-sec-0100"><h3 class="pmc_sec_title">5.5. Molecular tumor profiling</h3>
<p>In the past two decades, significant advancements have been made in tumor molecular diagnostics, resulting in the wide application of MTP as a potential diagnostic method for identifying the tissue origin of CUP [<a href="#mco270161-bib-0025" class="usa-link" aria-describedby="mco270161-bib-0025">25</a>, <a href="#mco270161-bib-0071" class="usa-link" aria-describedby="mco270161-bib-0071">71</a>, <a href="#mco270161-bib-0114" class="usa-link" aria-describedby="mco270161-bib-0114">114</a>] (Figure <a href="#mco270161-fig-0003" class="usa-link">3</a>). MTP that applied in the diagnosis of CUP includes various methodologies such as GEP by microarray [<a href="#mco270161-bib-0115" class="usa-link" aria-describedby="mco270161-bib-0115">115</a>, <a href="#mco270161-bib-0116" class="usa-link" aria-describedby="mco270161-bib-0116">116</a>] and quantitative reverse transcription PCR (RT‐PCR) [<a href="#mco270161-bib-0117" class="usa-link" aria-describedby="mco270161-bib-0117">117</a>], as well as the genomic and epigenomic analysis by microarray [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036">36</a>] or NGS [<a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>, <a href="#mco270161-bib-0040" class="usa-link" aria-describedby="mco270161-bib-0040">40</a>, <a href="#mco270161-bib-0118" class="usa-link" aria-describedby="mco270161-bib-0118">118</a>]. Compared with IHC, MTP requires a smaller amount of tumor tissue and provides higher accuracy in identifying the tissue origin for CUP [<a href="#mco270161-bib-0025" class="usa-link" aria-describedby="mco270161-bib-0025">25</a>]. MTP has been applied to lay a foundation for guiding site‐specific therapy for CUP due to its outstanding performance in identifying the primary site of CUP [<a href="#mco270161-bib-0020" class="usa-link" aria-describedby="mco270161-bib-0020">20</a>, <a href="#mco270161-bib-0021" class="usa-link" aria-describedby="mco270161-bib-0021">21</a>, <a href="#mco270161-bib-0119" class="usa-link" aria-describedby="mco270161-bib-0119">119</a>], refining the management of CUP in the molecular era.</p>
<figure class="fig xbox font-sm" id="mco270161-fig-0003"><h4 class="obj_head">FIGURE 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9adc/12000684/c529f036b6d3/MCO2-6-e70161-g003.jpg" loading="lazy" id="jats-graphic-7" height="363" width="560" alt="FIGURE 3"></p>
<div class="p text-right font-secondary"><a href="figure/mco270161-fig-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Tumor biopsy‐directed diagnosis and treatment of CUP. In the current era of precision medicine, IHC or MTP‐based methodologies were suggested to assist in identifying the tissue origin of CUP and guiding site‐specific therapy for CUP. <em>Abbreviations</em>: AI, artificial Intelligence; GEP, gene expression profiling; IHC, immunohistochemistry; MTP, molecular tumor profiling; NGS, next‐generation sequencing; ToO, tissue of origin.</p></figcaption></figure><p>GEP, primarily performed on tumor specimens by RT‐PCR or microarray technologies, involves the detection of gene expression from a panel of genes ranging from 10 to 2000 to aid in identifying the tissue origin of CUP (Table <a href="#mco270161-tbl-0001" class="usa-link">1</a>). Previous studies have demonstrated that a 10‐gene assay identified a putative tissue origin in 60.6% of cases with CUP [<a href="#mco270161-bib-0117" class="usa-link" aria-describedby="mco270161-bib-0117">117</a>], while the diagnostic accuracy of the CupPrint<sup>TM</sup> array that includes 495 tissue‐specific genes can reach up to 92.3% [<a href="#mco270161-bib-0120" class="usa-link" aria-describedby="mco270161-bib-0120">120</a>]. However, the utilization of expanded gene panels did not enhance the diagnostic accuracy of GEP in assisting with the diagnosis of CUP. Indeed, the ToO Test Kit, comprising 2000 genes [<a href="#mco270161-bib-0121" class="usa-link" aria-describedby="mco270161-bib-0121">121</a>], demonstrated an accuracy of 76.2% [<a href="#mco270161-bib-0122" class="usa-link" aria-describedby="mco270161-bib-0122">122</a>]. Gene combination with smaller panels and more robust representation, therefore, is urgently demanded for diagnosing patients with CUP. Furthermore, the CancerTYPE ID assay that contained 92 genes was developed [<a href="#mco270161-bib-0026" class="usa-link" aria-describedby="mco270161-bib-0026">26</a>] and used for classifying CUP and directing site‐specific therapy for patients with CUP [<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>]. In fact, the accuracy of the 92‐gene panel has been demonstrated to be over 80% [<a href="#mco270161-bib-0123" class="usa-link" aria-describedby="mco270161-bib-0123">123</a>]. The ToO Test Kit, which was cleared by the US Food and Drug Administration (US FDA) in March 2018, was one of the two approved assays for identifying the tissue origin of CUP (Table <a href="#mco270161-tbl-0002" class="usa-link">2</a>). Another one, the Canhelp‐Origin assay, containing 90 specific genes, was cleared by the China National Medical Products Administration (NMPA) in July 2022. Recent studies have revealed the robust performance of the 90‐gene assay in accurately identifying the tissue origin and tumor classification of CUP [<a href="#mco270161-bib-0085" class="usa-link" aria-describedby="mco270161-bib-0085">85</a>, <a href="#mco270161-bib-0124" class="usa-link" aria-describedby="mco270161-bib-0124">124</a>], with overall accuracies ranging from 82.3 to 94.4%, as reported in previous studies [<a href="#mco270161-bib-0030" class="usa-link" aria-describedby="mco270161-bib-0030">30</a>, <a href="#mco270161-bib-0048" class="usa-link" aria-describedby="mco270161-bib-0048">48</a>, <a href="#mco270161-bib-0085" class="usa-link" aria-describedby="mco270161-bib-0085">85</a>, <a href="#mco270161-bib-0124" class="usa-link" aria-describedby="mco270161-bib-0124">124</a>‐<a href="#mco270161-bib-0126" class="usa-link" aria-describedby="mco270161-bib-0126"><sup>126</sup></a>]. On the whole, the 90‐gene assay demonstrated promising performance, exhibiting higher diagnostic accuracy with a smaller gene panel, which provides a solid foundation for the application of 90‐gene array‐based site‐specific treatment in the clinical therapy of CUP. MicroRNA panels, consisting of 47–89 microRNAs, have been employed to accurately determine the primary site of CUP, exhibiting prediction accuracies ranging from 75 to 95% [<a href="#mco270161-bib-0127" class="usa-link" aria-describedby="mco270161-bib-0127">127</a>, <a href="#mco270161-bib-0128" class="usa-link" aria-describedby="mco270161-bib-0128">128</a>, <a href="#mco270161-bib-0129" class="usa-link" aria-describedby="mco270161-bib-0129">129</a>, <a href="#mco270161-bib-0130" class="usa-link" aria-describedby="mco270161-bib-0130">130</a>, <a href="#mco270161-bib-0131" class="usa-link" aria-describedby="mco270161-bib-0131">131</a>] (Table <a href="#mco270161-tbl-0001" class="usa-link">1</a>). Overall, data above indicate that GEP exhibits superior performance compared with traditional histopathological techniques in identifying the primary site of CUP, setting a solid foundation for GEP‐guided site‐specific treatment for CUP.</p>
<section class="tw xbox font-sm" id="mco270161-tbl-0001"><h4 class="obj_head">TABLE 1.</h4>
<div class="caption p"><p>Summary of MTP‐based methodologies applied to identify the tumor tissue origin of CUP and associated prediction accuracy.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead><tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">Year</th>
<th align="center" rowspan="1" colspan="1">Patient (<em>N</em>)</th>
<th align="center" rowspan="1" colspan="1">Sample</th>
<th align="center" rowspan="1" colspan="1">Method</th>
<th align="center" rowspan="1" colspan="1">Analyte</th>
<th align="center" rowspan="1" colspan="1">Panel</th>
<th align="center" rowspan="1" colspan="1">Accuracy</th>
<th align="center" rowspan="1" colspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="center" rowspan="1" colspan="1">13</td>
<td align="center" rowspan="1" colspan="1">FF, FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">79 genes</td>
<td align="center" rowspan="1" colspan="1">84.7%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0132" class="usa-link" aria-describedby="mco270161-bib-0132">132</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="center" rowspan="1" colspan="1">38</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">495 genes</td>
<td align="center" rowspan="1" colspan="1">76.3%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0115" class="usa-link" aria-describedby="mco270161-bib-0115">115</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="center" rowspan="1" colspan="1">21</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">495 genes</td>
<td align="center" rowspan="1" colspan="1">85.7%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0116" class="usa-link" aria-describedby="mco270161-bib-0116">116</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="center" rowspan="1" colspan="1">104</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">10 genes</td>
<td align="center" rowspan="1" colspan="1">60.6%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0117" class="usa-link" aria-describedby="mco270161-bib-0117">117</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="center" rowspan="1" colspan="1">13</td>
<td align="center" rowspan="1" colspan="1">FF, FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">495 genes</td>
<td align="center" rowspan="1" colspan="1">92.3%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0120" class="usa-link" aria-describedby="mco270161-bib-0120">120</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="center" rowspan="1" colspan="1">20</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">495 genes</td>
<td align="center" rowspan="1" colspan="1">65.0%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0133" class="usa-link" aria-describedby="mco270161-bib-0133">133</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="center" rowspan="1" colspan="1">21</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">2000 genes</td>
<td align="center" rowspan="1" colspan="1">76.2%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0122" class="usa-link" aria-describedby="mco270161-bib-0122">122</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="center" rowspan="1" colspan="1">7</td>
<td align="center" rowspan="1" colspan="1">FF</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">2000 genes</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0134" class="usa-link" aria-describedby="mco270161-bib-0134">134</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="center" rowspan="1" colspan="1">16</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">microRNA</td>
<td align="center" rowspan="1" colspan="1">47 miRNAs</td>
<td align="center" rowspan="1" colspan="1">75.0%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0127" class="usa-link" aria-describedby="mco270161-bib-0127">127</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="center" rowspan="1" colspan="1">74</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">microRNA</td>
<td align="center" rowspan="1" colspan="1">48 miRNAs</td>
<td align="center" rowspan="1" colspan="1">83.7%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0128" class="usa-link" aria-describedby="mco270161-bib-0128">128</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="center" rowspan="1" colspan="1">42</td>
<td align="center" rowspan="1" colspan="1">FF, FFPE</td>
<td align="center" rowspan="1" colspan="1">Methylation array</td>
<td align="center" rowspan="1" colspan="1">DNA</td>
<td align="center" rowspan="1" colspan="1">1505 CpGs</td>
<td align="center" rowspan="1" colspan="1">77.8%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0135" class="usa-link" aria-describedby="mco270161-bib-0135">135</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="center" rowspan="1" colspan="1">52</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">microRNA</td>
<td align="center" rowspan="1" colspan="1">48 miRNAs</td>
<td align="center" rowspan="1" colspan="1">88.5%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0130" class="usa-link" aria-describedby="mco270161-bib-0130">130</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="center" rowspan="1" colspan="1">42</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">92 genes</td>
<td align="center" rowspan="1" colspan="1">&gt;80%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0123" class="usa-link" aria-describedby="mco270161-bib-0123">123</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="center" rowspan="1" colspan="1">24</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">92 genes</td>
<td align="center" rowspan="1" colspan="1">75.0%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0025" class="usa-link" aria-describedby="mco270161-bib-0025">25</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="center" rowspan="1" colspan="1">252</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">92 genes</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="center" rowspan="1" colspan="1">65</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">495 genes</td>
<td align="center" rowspan="1" colspan="1">81.5%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0136" class="usa-link" aria-describedby="mco270161-bib-0136">136</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="center" rowspan="1" colspan="1">192</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (Microarray)</td>
<td align="center" rowspan="1" colspan="1">microRNA</td>
<td align="center" rowspan="1" colspan="1">64 miRNAs</td>
<td align="center" rowspan="1" colspan="1">85.9%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0131" class="usa-link" aria-describedby="mco270161-bib-0131">131</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2015</td>
<td align="center" rowspan="1" colspan="1">49</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">WGS</td>
<td align="center" rowspan="1" colspan="1">77.3%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0137" class="usa-link" aria-describedby="mco270161-bib-0137">137</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2016</td>
<td align="center" rowspan="1" colspan="1">216</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">Methylation array</td>
<td align="center" rowspan="1" colspan="1">DNA</td>
<td align="center" rowspan="1" colspan="1">450,000 CpGs</td>
<td align="center" rowspan="1" colspan="1">87.0%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2020</td>
<td align="center" rowspan="1" colspan="1">141</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">90 genes</td>
<td align="center" rowspan="1" colspan="1">82.3%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0030" class="usa-link" aria-describedby="mco270161-bib-0030">30</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2021</td>
<td align="center" rowspan="1" colspan="1">44</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">90 genes</td>
<td align="center" rowspan="1" colspan="1">95.4%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0124" class="usa-link" aria-describedby="mco270161-bib-0124">124</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2021</td>
<td align="center" rowspan="1" colspan="1">53</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">microRNA</td>
<td align="center" rowspan="1" colspan="1">89 miRNAs</td>
<td align="center" rowspan="1" colspan="1">80–95%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0129" class="usa-link" aria-describedby="mco270161-bib-0129">129</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2022</td>
<td align="center" rowspan="1" colspan="1">1417</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">GEP (qRT‐PCR)</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">90 genes</td>
<td align="center" rowspan="1" colspan="1">94.4%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0085" class="usa-link" aria-describedby="mco270161-bib-0085">85</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2023</td>
<td align="center" rowspan="1" colspan="1">68</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">Methylation Sequencing</td>
<td align="center" rowspan="1" colspan="1">DNA</td>
<td align="center" rowspan="1" colspan="1">WGBS</td>
<td align="center" rowspan="1" colspan="1">81–93%</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036">36</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/mco270161-tbl-0001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="mco270161-tbl1-note-0001"><p>
<em>Abbreviations</em>: FF, fresh frozen; FFPE, formalin fixation and paraffin embedding; GEP, gene expression profiling; MTP, molecular tumor profiling; NA, not available; WGBS, whole genome bisulfite sequencing.; WGS, whole genome sequencing.</p></div></div></section><section class="tw xbox font-sm" id="mco270161-tbl-0002"><h4 class="obj_head">TABLE 2.</h4>
<div class="caption p"><p>Products translated from the laboratory to the clinic for diagnosing CUP.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead><tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">Product</th>
<th align="center" rowspan="1" colspan="1">Method</th>
<th align="center" rowspan="1" colspan="1">Sample</th>
<th align="center" rowspan="1" colspan="1">Analyte</th>
<th align="center" rowspan="1" colspan="1">Cancer types</th>
<th align="center" rowspan="1" colspan="1">Panel</th>
<th align="center" rowspan="1" colspan="1">Accuracy</th>
<th align="center" rowspan="1" colspan="1">Clearance</th>
<th align="center" rowspan="1" colspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">CupPrint<sup>TM</sup>
</td>
<td align="center" rowspan="1" colspan="1">Array</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">47</td>
<td align="center" rowspan="1" colspan="1">495 genes</td>
<td align="center" rowspan="1" colspan="1">65.0–92.3%</td>
<td align="center" rowspan="1" colspan="1">No</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0133" class="usa-link" aria-describedby="mco270161-bib-0133">133</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">CancerTYPE ID<sup>®</sup>
</td>
<td align="center" rowspan="1" colspan="1">qRT‐PCR</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">50</td>
<td align="center" rowspan="1" colspan="1">92 genes</td>
<td align="center" rowspan="1" colspan="1">75.0–87.0%</td>
<td align="center" rowspan="1" colspan="1">No</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0123" class="usa-link" aria-describedby="mco270161-bib-0123">123</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Tissue of Origin Test Kit</td>
<td align="center" rowspan="1" colspan="1">Assay</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">58</td>
<td align="center" rowspan="1" colspan="1">2000 genes</td>
<td align="center" rowspan="1" colspan="1">76.2–90.8%</td>
<td align="center" rowspan="1" colspan="1">Yes (US FDA)</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0034" class="usa-link" aria-describedby="mco270161-bib-0034">34</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Canhelp‐Origin<sup>TM</sup>
</td>
<td align="center" rowspan="1" colspan="1">qRT‐PCR</td>
<td align="center" rowspan="1" colspan="1">FFPE</td>
<td align="center" rowspan="1" colspan="1">RNA</td>
<td align="center" rowspan="1" colspan="1">21</td>
<td align="center" rowspan="1" colspan="1">90 genes</td>
<td align="center" rowspan="1" colspan="1">82.3–94.4%</td>
<td align="center" rowspan="1" colspan="1">Yes (NMPA)</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0125" class="usa-link" aria-describedby="mco270161-bib-0125">125</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/mco270161-tbl-0002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="mco270161-tbl2-note-0001"><p>
<em>Abbreviations</em>: US FDA, the US Food and Drug Administration; FFPE, formalin fixation and paraffin embedding; NMPA, China National Medical Products Administration.</p></div></div></section><p>In addition to GEP, microarray‐ and NGS‐based genomic and epigenomic profiling have also been used to predict the primary site for CUP [<a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>, <a href="#mco270161-bib-0071" class="usa-link" aria-describedby="mco270161-bib-0071">71</a>, <a href="#mco270161-bib-0137" class="usa-link" aria-describedby="mco270161-bib-0137">137</a>]. Compared with GEP, DNA sequencing shows greater diagnostic value, which may attribute to atypical transcriptional profiles of CUP [<a href="#mco270161-bib-0138" class="usa-link" aria-describedby="mco270161-bib-0138">138</a>]. Genomic profiling revealed gene mutations, gene rearrangements, and TMB in tumors, allowing for prediction of tumor origin and the guidance of molecularly targeted therapy and ICIs therapy. In addition to genomic profiles, epigenomic alterations, such as DNA methylation (especially decrease in 5‐methylcytosine in tumor cells), have been recognized as a promising target for the development of predictive biomarkers in patients with CUP [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0118" class="usa-link" aria-describedby="mco270161-bib-0118">118</a>, <a href="#mco270161-bib-0135" class="usa-link" aria-describedby="mco270161-bib-0135">135</a>, <a href="#mco270161-bib-0139" class="usa-link" aria-describedby="mco270161-bib-0139">139</a>]. Recent studies proved that DNA methylation profile‐based machine learning models successfully predicted the tissue origin in 81–93% of patients with CUP [<a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036">36</a>, <a href="#mco270161-bib-0140" class="usa-link" aria-describedby="mco270161-bib-0140">140</a>‐<a href="#mco270161-bib-0142" class="usa-link" aria-describedby="mco270161-bib-0142"><sup>142</sup></a>]. Importantly, a multicenter, retrospective study revealed that cases of CUP who received DNA methylation microarray‐guided site‐specific first‐line therapy showed obvious improved OS compared with those who received empirical treatment [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0143" class="usa-link" aria-describedby="mco270161-bib-0143">143</a>]. Furthermore, for tumors where obtaining biopsy specimens is challenging or the sample size is insufficient, cell‐free DNA (cfDNA) methylome sequencing presents a more effective solution to address these issues [<a href="#mco270161-bib-0144" class="usa-link" aria-describedby="mco270161-bib-0144">144</a>].</p>
<p>Over the past 20 years, scientists have primarily focused on single‐omics research to seek more accurate diagnostic methods for CUP. Recent studies classified CUP based on comprehensive genomic and epigenomic analysis in a prospective observational study and direct personalized therapy for CUP [<a href="#mco270161-bib-0071" class="usa-link" aria-describedby="mco270161-bib-0071">71</a>]. While we observed the preliminary attempt and great potential of multiomics analysis in primary site identification of CUP, it is essential to acknowledge that this approach often involves higher economic costs and longer time courses for patients. Multiomics analysis in clinical practice may pose challenges unless it significantly improves diagnostic accuracy and remains relatively affordable.</p></section><section id="mco270161-sec-0110"><h3 class="pmc_sec_title">5.6. Artificial intelligence</h3>
<p>AI have exhibited accurate, reliable, and reproducible performance in cancer diagnosis and therapy guidance [<a href="#mco270161-bib-0145" class="usa-link" aria-describedby="mco270161-bib-0145">145</a>, <a href="#mco270161-bib-0146" class="usa-link" aria-describedby="mco270161-bib-0146">146</a>]. For instance, AI‐based algorithms have been successful used in identifying early lung cancers [<a href="#mco270161-bib-0147" class="usa-link" aria-describedby="mco270161-bib-0147">147</a>], predicting number of lymph node metastasis in locally advanced gastric cancer [<a href="#mco270161-bib-0148" class="usa-link" aria-describedby="mco270161-bib-0148">148</a>], skin diseases [<a href="#mco270161-bib-0149" class="usa-link" aria-describedby="mco270161-bib-0149">149</a>], and CUP [<a href="#mco270161-bib-0150" class="usa-link" aria-describedby="mco270161-bib-0150">150</a>, <a href="#mco270161-bib-0151" class="usa-link" aria-describedby="mco270161-bib-0151">151</a>], conditions that are not easily recognized by human experts. In the field of CUP, machine learning and deep learning models based on GEP [<a href="#mco270161-bib-0028" class="usa-link" aria-describedby="mco270161-bib-0028">28</a>, <a href="#mco270161-bib-0031" class="usa-link" aria-describedby="mco270161-bib-0031">31</a>], genomics [<a href="#mco270161-bib-0033" class="usa-link" aria-describedby="mco270161-bib-0033">33</a>, <a href="#mco270161-bib-0034" class="usa-link" aria-describedby="mco270161-bib-0034">34</a>], epigenomic [<a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036">36</a>, <a href="#mco270161-bib-0152" class="usa-link" aria-describedby="mco270161-bib-0152">152</a>], cytology, and pathology [<a href="#mco270161-bib-0032" class="usa-link" aria-describedby="mco270161-bib-0032">32</a>, <a href="#mco270161-bib-0035" class="usa-link" aria-describedby="mco270161-bib-0035">35</a>] were developed to identify the tumor tissue origin of CUP. The CUP‐AI‐Dx classifier and TOD‐CUP algorithm, both utilizing RNA features, were the first two machine learning models developed for predicting the primary of metastatic cancers. Indeed, the CUP‐AI‐Dx model achieved a top‐1 accuracy of 72.46–98.54% in validation set [<a href="#mco270161-bib-0028" class="usa-link" aria-describedby="mco270161-bib-0028">28</a>], while the TOD‐CUP algorithm achieved an overall accuracy of 91–96% [<a href="#mco270161-bib-0031" class="usa-link" aria-describedby="mco270161-bib-0031">31</a>]. However, the performance of both of these two models has not been validated in external CUP cohorts, indicating limited clinical applicability. CUPLR, a genomic profile‐based tumor ToO classifier, achieved an accuracy of over 90% based on cross‐validation and test set with 35 cancer subtypes, successfully determining the primary tumor site for 58% of patients with CUP [<a href="#mco270161-bib-0034" class="usa-link" aria-describedby="mco270161-bib-0034">34</a>]. In addition, the OncoNPC model, another genomic profile‐based machine learning classifier, illustrated a high level of accuracy in predicting the primary cancer types, achieving a confidence rate of 41.2% across all CUP cases. Significantly, the OncoNPC classifier effectively stratified patients into groups with notable prognostic differences and accurately predicted the survival benefit from OncoNPC‐concordant therapy [<a href="#mco270161-bib-0033" class="usa-link" aria-describedby="mco270161-bib-0033">33</a>]. Besides, a DNA methylation profile‐based support vector classifier exhibited an excellent performance, with overall accuracies ranging from 81 to 93% in CUP cohort [<a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036">36</a>], offering potential for clinical decision support in managing CUP.</p>
<p>In addition to molecular features, pathology‐based models were developed when GEP and genomic testing had not yet penetrated clinical practice in low‐resource settings. TOAD, a histology ‐based deep learning model, achieved a top‐1 accuracy of 80% in external validation set and resulted in concordance for 61% of patients with CUP [<a href="#mco270161-bib-0032" class="usa-link" aria-describedby="mco270161-bib-0032">32</a>]. Histological analysis, in fact, requires less tumor tissue sampling, has a shorter turnaround time, and is more cost‐effective, which may serve as a reliable alternate option for patients without access to MTP. A recent study showed that a cytological histology‐based deep‐learning model (TORCH) predicted the tissue origin in both hydrothorax and ascites with a top‐1 accuracy of 82.6%, which was found to be superior to results obtained by pathologists [<a href="#mco270161-bib-0035" class="usa-link" aria-describedby="mco270161-bib-0035">35</a>]. Importantly, patients who received TORCH‐guided therapy had better OS than those who did not, highlighting its potential role as a valuable auxiliary method for individualized treatment schemes. In addition to biopsies, the circulating cfDNA methylation‐based machine learning classifier (CUPiD) achieved an agreement of 88.5% with a subsequent or suspected primary tumor diagnosis in patients with CUP [<a href="#mco270161-bib-0152" class="usa-link" aria-describedby="mco270161-bib-0152">152</a>]. AI enhances diagnostic efficiency in oncology by leveraging machine or deep learning algorithms to analyze large datasets, improve image recognition, and identify patterns in histopathology. By automating routine tasks and providing decision support, AI reduces the time required for diagnosis and minimizes human error. Additionally, AI can optimize resource allocation, leading to cost savings in laboratory and clinical settings. Integrating AI tools into clinical workflows ultimately facilitates early detection and personalized treatment, thereby improving patient outcomes and reducing healthcare expenditures. Researches above indicate that the transcriptomic, genomic, epigenomic characteristics of tumor tissue, as well as pathological and clinical features, play an important role in identifying the primary of CUP.</p></section></section><section id="mco270161-sec-0120"><h2 class="pmc_sec_title">6. Treatment of Patients With Cup</h2>
<section id="mco270161-sec-0130"><h3 class="pmc_sec_title">6.1. First‐line treatment</h3>
<p>Patients with CUP typically present with symptoms and signs of metastatic lesions, leading to a diagnosis at an advanced stage. Surgery, therefore, is only considered applicable to specific subtypes of patients with circumscribed and resectable lesions [<a href="#mco270161-bib-0002" class="usa-link" aria-describedby="mco270161-bib-0002">2</a>]. Based on previous perspective, patients with CUP were categorized into favorable and unfavorable subgroups with distinct survival according to the clinicopathological criteria for better clinical management [<a href="#mco270161-bib-0001" class="usa-link" aria-describedby="mco270161-bib-0001">1</a>]. Patients in the favorable group have a median OS of 12 months, whereas those in the unfavorable subgroup only exhibit a median OS of 4 months [<a href="#mco270161-bib-0063" class="usa-link" aria-describedby="mco270161-bib-0063">63</a>]. Patients in the favorable group receive locoregional treatment or systemic platinum‐based treatment, achieving a similar OS to those of patients with relevant known primary tumors. However, patients in unfavorable subset are typically administered empirical chemotherapy with combination regimens of platinum or taxane. Unfortunately, the responses and survival rates in these cases are generally poor. Site‐specific therapy was therefore widely studied to explore whether it could be superior to empirical therapy in improving patient outcomes.</p>
<section id="mco270161-sec-0140"><h4 class="pmc_sec_title">6.1.1. Empirical chemotherapy</h4>
<p>Empirical chemotherapy, containing gemcitabine/platinum or taxane/platinum regimens based on the histological types of CUP, has been recognized as the cornerstone of therapy before site‐specific first‐line therapy is proposed [<a href="#mco270161-bib-0153" class="usa-link" aria-describedby="mco270161-bib-0153">153</a>, <a href="#mco270161-bib-0154" class="usa-link" aria-describedby="mco270161-bib-0154">154</a>, <a href="#mco270161-bib-0155" class="usa-link" aria-describedby="mco270161-bib-0155">155</a>]. Indeed, there is no consensus on chemotherapy regimens for CUP in the early stages. After more than 30 years of exploration, empirical chemotherapy regimens containing platinum or taxane achieved an ORR of 10–42% [<a href="#mco270161-bib-0156" class="usa-link" aria-describedby="mco270161-bib-0156">156</a>, <a href="#mco270161-bib-0157" class="usa-link" aria-describedby="mco270161-bib-0157">157</a>], along with a median PFS of 2–6.1 months [<a href="#mco270161-bib-0158" class="usa-link" aria-describedby="mco270161-bib-0158">158</a>, <a href="#mco270161-bib-0159" class="usa-link" aria-describedby="mco270161-bib-0159">159</a>] and a median OS of 6.5–13 months [<a href="#mco270161-bib-0155" class="usa-link" aria-describedby="mco270161-bib-0155">155</a>, <a href="#mco270161-bib-0160" class="usa-link" aria-describedby="mco270161-bib-0160">160</a>], respectively (Table <a href="#mco270161-tbl-0003" class="usa-link">3</a>).</p>
<section class="tw xbox font-sm" id="mco270161-tbl-0003"><h5 class="obj_head">TABLE 3.</h5>
<div class="caption p"><p>Summary of clinical efficacy of empirical chemotherapy regimens for CUP.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead><tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">Year</th>
<th align="center" rowspan="1" colspan="1">Chemotherapy regimens</th>
<th align="center" rowspan="1" colspan="1">ORR (%)</th>
<th align="center" rowspan="1" colspan="1">mPFS (months)</th>
<th align="center" rowspan="1" colspan="1">mOS (months)</th>
<th align="center" rowspan="1" colspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">1980</td>
<td align="center" rowspan="1" colspan="1">Cyclophosphamide + methotrexate + 5‐fluorouracil (CMF) vs. doxorubicin + mitomycin C (DM)</td>
<td align="center" rowspan="1" colspan="1">4.5 vs. 36.0</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">13 vs. 18</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0161" class="usa-link" aria-describedby="mco270161-bib-0161">161</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1986</td>
<td align="center" rowspan="1" colspan="1">5‐Fluorouracil + driamycin + mitomycin (FAM)</td>
<td align="center" rowspan="1" colspan="1">30</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">10</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0162" class="usa-link" aria-describedby="mco270161-bib-0162">162</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1991</td>
<td align="center" rowspan="1" colspan="1">Cisplatin</td>
<td align="center" rowspan="1" colspan="1">19</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">7.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0163" class="usa-link" aria-describedby="mco270161-bib-0163">163</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1997</td>
<td align="center" rowspan="1" colspan="1">Carboplatin + paclitaxel + etoposide</td>
<td align="center" rowspan="1" colspan="1">47</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">13.4</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0164" class="usa-link" aria-describedby="mco270161-bib-0164">164</a>, <a href="#mco270161-bib-0165" class="usa-link" aria-describedby="mco270161-bib-0165">165</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1998</td>
<td align="center" rowspan="1" colspan="1">Carboplatin + epirubicin + etoposide</td>
<td align="center" rowspan="1" colspan="1">37</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">10</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0166" class="usa-link" aria-describedby="mco270161-bib-0166">166</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1998</td>
<td align="center" rowspan="1" colspan="1">Carboplatin + etoposide (EC)</td>
<td align="center" rowspan="1" colspan="1">23</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">5.6</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0167" class="usa-link" aria-describedby="mco270161-bib-0167">167</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1998</td>
<td align="center" rowspan="1" colspan="1">Mitomycin C + epirubicin + cisplatin vs. mitomycin C</td>
<td align="center" rowspan="1" colspan="1">50 vs. 17</td>
<td align="center" rowspan="1" colspan="1">4.5 vs. 2.5</td>
<td align="center" rowspan="1" colspan="1">9.4 vs. 5.4</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0168" class="usa-link" aria-describedby="mco270161-bib-0168">168</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1999</td>
<td align="center" rowspan="1" colspan="1">5‐Fluorouracil + cisplatin (CFTam)</td>
<td align="center" rowspan="1" colspan="1">27</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">4</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0169" class="usa-link" aria-describedby="mco270161-bib-0169">169</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2000</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + carboplatin (TC)</td>
<td align="center" rowspan="1" colspan="1">38.7</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">13</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0155" class="usa-link" aria-describedby="mco270161-bib-0155">155</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2000</td>
<td align="center" rowspan="1" colspan="1">Docetaxel + cisplatin (TC) vs. docetaxel + carboplatin (TP)</td>
<td align="center" rowspan="1" colspan="1">26 vs. 22</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">8 vs. 8</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0153" class="usa-link" aria-describedby="mco270161-bib-0153">153</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2001</td>
<td align="center" rowspan="1" colspan="1">Etoposide + carboplatin (EC) vs. paclitaxel + 5‐fluorouracil + leucovorin</td>
<td align="center" rowspan="1" colspan="1">19 vs. 19</td>
<td align="center" rowspan="1" colspan="1">8.4 vs. 6.5</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0170" class="usa-link" aria-describedby="mco270161-bib-0170">170</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2001</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + carboplatin (TC)/docetaxel + cisplatin (TP)/docetaxel + carboplatin (TC)</td>
<td align="center" rowspan="1" colspan="1">27</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">10</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0154" class="usa-link" aria-describedby="mco270161-bib-0154">154</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2002</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + carboplatin + paclitaxel</td>
<td align="center" rowspan="1" colspan="1">25</td>
<td align="center" rowspan="1" colspan="1">6</td>
<td align="center" rowspan="1" colspan="1">9</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0171" class="usa-link" aria-describedby="mco270161-bib-0171">171</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2003</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + cisplatin (GP) vs. irinotecan + cisplatin (IP)</td>
<td align="center" rowspan="1" colspan="1">5 vs. 38</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">8 vs. 6</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0158" class="usa-link" aria-describedby="mco270161-bib-0158">158</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2003</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + cisplatin + etoposide</td>
<td align="center" rowspan="1" colspan="1">36.6</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">7.2</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0172" class="usa-link" aria-describedby="mco270161-bib-0172">172</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + docetaxel (GT)</td>
<td align="center" rowspan="1" colspan="1">40</td>
<td align="center" rowspan="1" colspan="1">2</td>
<td align="center" rowspan="1" colspan="1">10</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0173" class="usa-link" aria-describedby="mco270161-bib-0173">173</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + carboplatin + etoposide + gemcitabine + irinotecan</td>
<td align="center" rowspan="1" colspan="1">29.7</td>
<td align="center" rowspan="1" colspan="1">5.7</td>
<td align="center" rowspan="1" colspan="1">9.1</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0174" class="usa-link" aria-describedby="mco270161-bib-0174">174</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="center" rowspan="1" colspan="1">Etoposide + carboplatin + doxorubicin</td>
<td align="center" rowspan="1" colspan="1">26.5</td>
<td align="center" rowspan="1" colspan="1">4</td>
<td align="center" rowspan="1" colspan="1">9</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0159" class="usa-link" aria-describedby="mco270161-bib-0159">159</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + cisplatin (TP)</td>
<td align="center" rowspan="1" colspan="1">42</td>
<td align="center" rowspan="1" colspan="1">4</td>
<td align="center" rowspan="1" colspan="1">11</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0175" class="usa-link" aria-describedby="mco270161-bib-0175">175</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + irinotecan</td>
<td align="center" rowspan="1" colspan="1">10</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">4.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0176" class="usa-link" aria-describedby="mco270161-bib-0176">176</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + carboplatin (TC)</td>
<td align="center" rowspan="1" colspan="1">23</td>
<td align="center" rowspan="1" colspan="1">4.1</td>
<td align="center" rowspan="1" colspan="1">6.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0156" class="usa-link" aria-describedby="mco270161-bib-0156">156</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + oxaliplatin (GemOx)</td>
<td align="center" rowspan="1" colspan="1">29</td>
<td align="center" rowspan="1" colspan="1">3.1</td>
<td align="center" rowspan="1" colspan="1">12.8</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0177" class="usa-link" aria-describedby="mco270161-bib-0177">177</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2006</td>
<td align="center" rowspan="1" colspan="1">Cisplatin + gemcitabine + paclitaxel vs. cisplatin + gemcitabine + vinorelbine</td>
<td align="center" rowspan="1" colspan="1">48.5 vs. 42.3</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">9.6 vs. 13.6</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0178" class="usa-link" aria-describedby="mco270161-bib-0178">178</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="center" rowspan="1" colspan="1">Docetaxel + carboplatin (TC)</td>
<td align="center" rowspan="1" colspan="1">32</td>
<td align="center" rowspan="1" colspan="1">5.5</td>
<td align="center" rowspan="1" colspan="1">16.2</td>
<td align="center" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="center" rowspan="1" colspan="1">Oxaliplatin + irinotecan</td>
<td align="center" rowspan="1" colspan="1">13</td>
<td align="center" rowspan="1" colspan="1">2.7</td>
<td align="center" rowspan="1" colspan="1">9.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0157" class="usa-link" aria-describedby="mco270161-bib-0157">157</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + carboplatin + bevacizumab + erlotinib</td>
<td align="center" rowspan="1" colspan="1">63.0</td>
<td align="center" rowspan="1" colspan="1">8.0</td>
<td align="center" rowspan="1" colspan="1">12.6</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0179" class="usa-link" aria-describedby="mco270161-bib-0179">179</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="center" rowspan="1" colspan="1">Oxaliplatin + capecitabine (XELOX)</td>
<td align="center" rowspan="1" colspan="1">11.7</td>
<td align="center" rowspan="1" colspan="1">2.5</td>
<td align="center" rowspan="1" colspan="1">7.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0180" class="usa-link" aria-describedby="mco270161-bib-0180">180</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="center" rowspan="1" colspan="1">Paclitaxel + carboplatin (TC) vs. gemcitabine + vinorelbine (GN)</td>
<td align="center" rowspan="1" colspan="1">23.8 vs. 20.0</td>
<td align="center" rowspan="1" colspan="1">6.1 vs. 3.2</td>
<td align="center" rowspan="1" colspan="1">11.0 vs. 7.0</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0181" class="usa-link" aria-describedby="mco270161-bib-0181">181</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="center" rowspan="1" colspan="1">Oxaliplatin + capecitabine (XELOX)</td>
<td align="center" rowspan="1" colspan="1">18.8</td>
<td align="center" rowspan="1" colspan="1">3.7</td>
<td align="center" rowspan="1" colspan="1">9.7</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0182" class="usa-link" aria-describedby="mco270161-bib-0182">182</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="center" rowspan="1" colspan="1">Cisplatin vs. gemcitabine + cisplatin (GP)</td>
<td align="center" rowspan="1" colspan="1">16 vs. 19</td>
<td align="center" rowspan="1" colspan="1">3 vs. 5</td>
<td align="center" rowspan="1" colspan="1">8 vs. 11</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0183" class="usa-link" aria-describedby="mco270161-bib-0183">183</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2015</td>
<td align="center" rowspan="1" colspan="1">Belinostat + carboplatin + paclitaxel (BelCaP) vs. carboplatin + paclitaxel (CaP)</td>
<td align="center" rowspan="1" colspan="1">45 vs. 21</td>
<td align="center" rowspan="1" colspan="1">5.4 vs. 5.3</td>
<td align="center" rowspan="1" colspan="1">12.4 vs. 9.1</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0184" class="usa-link" aria-describedby="mco270161-bib-0184">184</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2016</td>
<td align="center" rowspan="1" colspan="1">Oxaliplatin + leucovorin + 5‐fluorouracil (mFOLFOX6)</td>
<td align="center" rowspan="1" colspan="1">35.0</td>
<td align="center" rowspan="1" colspan="1">3.0</td>
<td align="center" rowspan="1" colspan="1">9.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0185" class="usa-link" aria-describedby="mco270161-bib-0185">185</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/mco270161-tbl-0003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="mco270161-tbl3-note-0001"><p>
<em>Abbreviations</em>: NA, not available; ORR, overall response rate; OS, overall survival; PFS, progression‐free survival.</p></div></div></section><p>Since adenocarcinoma is the most common histological type of CUP, the initial treatment approach typically emphasizes the use of regimens specifically designed for adenocarcinoma. Classical combination therapy of monthly circles of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF), first applied as first‐line chemotherapy for breast cancer [<a href="#mco270161-bib-0186" class="usa-link" aria-describedby="mco270161-bib-0186">186</a>], was utilized to treat ACUP and achieved a median OS of 13 months. In 1980, Professor Brodie conducted a study comparing the response rate and survival benefit of CMF regimen with a combination therapy of doxorubicin and mitomycin C (DM), and they proved that patients who received the DM therapy experienced a significantly improved median OS of 18 months [<a href="#mco270161-bib-0161" class="usa-link" aria-describedby="mco270161-bib-0161">161</a>]. In addition, FAM (5‐fluorouracil, adriamycin, and mitomycin) combination regimen was recommended as an empiric therapy for patients with ACUP. In 1986, Professor Schein observed a median OS of 10 months on 45 patients who received the FAM regimen as first‐line therapy [<a href="#mco270161-bib-0162" class="usa-link" aria-describedby="mco270161-bib-0162">162</a>]. In fact, no significant advantages of FAM regimen have been identified, even though it was prominently evidenced in adenocarcinomas with specific primaries. Subsequently, cisplatin‐based regimens were applied in the clinical treatment of CUP, but the prognosis remained unsatisfactory [<a href="#mco270161-bib-0163" class="usa-link" aria-describedby="mco270161-bib-0163">163</a>]. Considering the wide application of oxaliplatin‐based therapy in gastrointestinal tumors, the combination of oxaliplatin with capecitabine (XELOX) and the combination of oxaliplatin, leucovorin, and 5‐fluorouracil (mFOLFOX6) have been attempted for CUP, achieving a median PFS of 2.5–3.7 months and a median OS of 7.5–9.7 months, respectively [<a href="#mco270161-bib-0180" class="usa-link" aria-describedby="mco270161-bib-0180">180</a>, <a href="#mco270161-bib-0182" class="usa-link" aria-describedby="mco270161-bib-0182">182</a>, <a href="#mco270161-bib-0185" class="usa-link" aria-describedby="mco270161-bib-0185">185</a>].</p>
<p>Since 2000, the paclitaxel plus carboplatin (TC) regimen has been widely used in the treatment of patients with CUP, owing to its demonstrated antitumor effects in various types of cancer. In a phase II study, the ORR was 38.7%, and the median OS was 13 months. Patients with nodal or pleural metastasis, in particular, exhibited a better response rate to TC treatment [<a href="#mco270161-bib-0155" class="usa-link" aria-describedby="mco270161-bib-0155">155</a>]. From then on, taxane plus platinum therapy emerged as a cornerstone in managing CUP, with no significant difference observed between cisplatin and carboplatin in terms of improving patient outcomes [<a href="#mco270161-bib-0153" class="usa-link" aria-describedby="mco270161-bib-0153">153</a>, <a href="#mco270161-bib-0156" class="usa-link" aria-describedby="mco270161-bib-0156">156</a>, <a href="#mco270161-bib-0160" class="usa-link" aria-describedby="mco270161-bib-0160">160</a>, <a href="#mco270161-bib-0170" class="usa-link" aria-describedby="mco270161-bib-0170">170</a>, <a href="#mco270161-bib-0171" class="usa-link" aria-describedby="mco270161-bib-0171">171</a>, <a href="#mco270161-bib-0175" class="usa-link" aria-describedby="mco270161-bib-0175">175</a>, <a href="#mco270161-bib-0181" class="usa-link" aria-describedby="mco270161-bib-0181">181</a>, <a href="#mco270161-bib-0185" class="usa-link" aria-describedby="mco270161-bib-0185">185</a>]. Further, gemcitabine‐ and platinum‐based regimens have shown promise as alternative treatment options for CUP, with a median OS ranging from 6 to 13.6 months [<a href="#mco270161-bib-0158" class="usa-link" aria-describedby="mco270161-bib-0158">158</a>, <a href="#mco270161-bib-0171" class="usa-link" aria-describedby="mco270161-bib-0171">171</a>, <a href="#mco270161-bib-0174" class="usa-link" aria-describedby="mco270161-bib-0174">174</a>, <a href="#mco270161-bib-0177" class="usa-link" aria-describedby="mco270161-bib-0177">177</a>, <a href="#mco270161-bib-0178" class="usa-link" aria-describedby="mco270161-bib-0178">178</a>, <a href="#mco270161-bib-0183" class="usa-link" aria-describedby="mco270161-bib-0183">183</a>]. Despite the application of multiple chemotherapeutic regimens in the clinical management of CUP, there has been no significant improvement in prognosis, which has planted the seeds for the proposal of site‐specific therapy.</p></section><section id="mco270161-sec-0150"><h4 class="pmc_sec_title">6.1.2. Site‐specific therapy</h4>
<p>With the advancements in treatment options for certain cancer types, such as ICIs being accepted as the first‐line therapy for metastatic NSCLC [<a href="#mco270161-bib-0187" class="usa-link" aria-describedby="mco270161-bib-0187">187</a>] and hepatocellular carcinoma [<a href="#mco270161-bib-0188" class="usa-link" aria-describedby="mco270161-bib-0188">188</a>], site‐specific treatment is anticipated to play a significant role in improving patient outcomes of CUP. In order to guide site‐specific therapy, MTP has been utilized, employing methods such as GEP, as well as genomic and epigenomic profiling by NGS [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>–<a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>, <a href="#mco270161-bib-0119" class="usa-link" aria-describedby="mco270161-bib-0119">119</a>]. In the last decade, several clinical trials have been conducted globally to investigate and determine the efficacy and safety of site‐specific therapy compared with empirical chemotherapy for CUP (Table <a href="#mco270161-tbl-0004" class="usa-link">4</a>).</p>
<section class="tw xbox font-sm" id="mco270161-tbl-0004"><h5 class="obj_head">TABLE 4.</h5>
<div class="caption p"><p>Comparisons of efficacy between empirical chemotherapy and site‐specific therapy in patients with previously untreated CUP.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead>
<tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="center" rowspan="1" colspan="1"></th>
<th colspan="2" style="border-bottom:solid 1px #000000" align="center" rowspan="1">Patient (N)</th>
<th colspan="2" style="border-bottom:solid 1px #000000" align="center" rowspan="1">Median PFS (months)</th>
<th colspan="2" style="border-bottom:solid 1px #000000" align="center" rowspan="1">Median OS (months)</th>
<th align="center" rowspan="1" colspan="1"></th>
</tr>
<tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">Year</th>
<th align="center" rowspan="1" colspan="1">Method</th>
<th align="center" rowspan="1" colspan="1">Empiric</th>
<th align="center" rowspan="1" colspan="1">Site‐specific</th>
<th align="center" rowspan="1" colspan="1">Empiric</th>
<th align="center" rowspan="1" colspan="1">Site‐specific</th>
<th align="center" rowspan="1" colspan="1">Empiric</th>
<th align="center" rowspan="1" colspan="1">Site‐specific</th>
<th align="center" rowspan="1" colspan="1">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">2013</td>
<td align="center" rowspan="1" colspan="1">GEP</td>
<td align="center" rowspan="1" colspan="1">396</td>
<td align="center" rowspan="1" colspan="1">194</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">9.1</td>
<td align="center" rowspan="1" colspan="1">12.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2016</td>
<td align="center" rowspan="1" colspan="1">Microarray</td>
<td align="center" rowspan="1" colspan="1">61</td>
<td align="center" rowspan="1" colspan="1">31</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">6.0</td>
<td align="center" rowspan="1" colspan="1">13.6</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2018</td>
<td align="center" rowspan="1" colspan="1">IHC</td>
<td align="center" rowspan="1" colspan="1">34</td>
<td align="center" rowspan="1" colspan="1">56</td>
<td align="center" rowspan="1" colspan="1">4.2</td>
<td align="center" rowspan="1" colspan="1">5.1</td>
<td align="center" rowspan="1" colspan="1">10.7</td>
<td align="center" rowspan="1" colspan="1">20.3</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0119" class="usa-link" aria-describedby="mco270161-bib-0119">119</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2019</td>
<td align="center" rowspan="1" colspan="1">GEP</td>
<td align="center" rowspan="1" colspan="1">51</td>
<td align="center" rowspan="1" colspan="1">50</td>
<td align="center" rowspan="1" colspan="1">4.8</td>
<td align="center" rowspan="1" colspan="1">5.1</td>
<td align="center" rowspan="1" colspan="1">12.5</td>
<td align="center" rowspan="1" colspan="1">9.8</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0038" class="usa-link" aria-describedby="mco270161-bib-0038">38</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2020</td>
<td align="center" rowspan="1" colspan="1">NGS</td>
<td align="center" rowspan="1" colspan="1">/</td>
<td align="center" rowspan="1" colspan="1">97</td>
<td align="center" rowspan="1" colspan="1">/</td>
<td align="center" rowspan="1" colspan="1">5.2</td>
<td align="center" rowspan="1" colspan="1">/</td>
<td align="center" rowspan="1" colspan="1">13.7</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2022</td>
<td align="center" rowspan="1" colspan="1">NGS</td>
<td align="center" rowspan="1" colspan="1">78</td>
<td align="center" rowspan="1" colspan="1">17</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">NA</td>
<td align="center" rowspan="1" colspan="1">14.7</td>
<td align="center" rowspan="1" colspan="1">23.6</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0040" class="usa-link" aria-describedby="mco270161-bib-0040">40</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2024</td>
<td align="center" rowspan="1" colspan="1">GEP</td>
<td align="center" rowspan="1" colspan="1">91</td>
<td align="center" rowspan="1" colspan="1">91</td>
<td align="center" rowspan="1" colspan="1">6.6</td>
<td align="center" rowspan="1" colspan="1">9.6</td>
<td align="center" rowspan="1" colspan="1">19.0</td>
<td align="center" rowspan="1" colspan="1">28.2</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0041" class="usa-link" aria-describedby="mco270161-bib-0041">41</a>, <a href="#mco270161-bib-0042" class="usa-link" aria-describedby="mco270161-bib-0042">42</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/mco270161-tbl-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="mco270161-tbl4-note-0001"><p>
<em>Abbreviations</em>: GEP, gene expression profiling; IHC, immunohistochemistry; NGS, next‐generation sequencing; OS, overall survival; PFS, progression‐free survival.</p></div></div></section><p>Indeed, among the various MTP, GEP was the first to be used in predicting the tissue origin and providing guidance for site‐specific therapy in patients with CUP. In a prospective clinical trial performed by the Sarah Cannon Research Institute in 2013, a 92‐gene expression profile was used to guide standard site‐specific first‐line therapy for CUP [<a href="#mco270161-bib-0037" class="usa-link" aria-describedby="mco270161-bib-0037">37</a>]. In this trial, patients who received assay‐directed site‐specific therapy achieved a median OS of 12.5 months, which was superior to the median OS of 9.1 months observed in the historical control group receiving empirical chemotherapy. However, it is essential to acknowledge that comparisons with historical results may introduce potential biases. Therefore, it is crucial to conduct further studies to determine whether site‐specific therapy improves patient outcomes of CUP. Furthermore, findings from a prospective, multicenter, randomized phase II clinical trial conducted in Japan indicated that GEP‐directed site‐specific therapy did not significantly improve the median PFS (5.1 vs. 4.8 months, <em>p</em> = 0.550) and OS (9.8 vs. 12.5 months, <em>p</em> = 0.896) of CUP compared with empirical paclitaxel and carboplatin therapy [<a href="#mco270161-bib-0038" class="usa-link" aria-describedby="mco270161-bib-0038">38</a>]. Nevertheless, it is important to note that this research still has certain limitations. These include the small sample size and the limited predictive accuracy of the diagnostic model which was found to be only 78.6%, as applied in this study. However, it is encouraging to note that patients in the favorable subgroup who received GEP‐guided site‐specific therapy achieved better median OS and PFS compared with those in the unfavorable subset, which provides some evidence of the superiority of site‐specific therapy for CUP. In a later study from the same group, researchers conducted a phase II clinical trial to assess the clinical value of NGS‐based site‐specific and targeted therapy in previously untreated CUP within the unfavorable subset [<a href="#mco270161-bib-0039" class="usa-link" aria-describedby="mco270161-bib-0039">39</a>]. In this study, patients with CUP achieved a high 1‐year survival rate of 53.1%, along with a median PFS of 5.2 months and a median OS of 13.7 months. However, this study did not include a comparator group to evaluate the efficacy of NGS‐based site‐specific and targeted therapy in comparison with empirical therapy. Furthermore, in another retrospective study, patients received IHC‐directed site‐specific therapy showed improved median OS compared with those who received empirical therapy in unfavorable subset (20.3 vs. 10.7 months, <em>p</em> = 0.03) [<a href="#mco270161-bib-0119" class="usa-link" aria-describedby="mco270161-bib-0119">119</a>]. Again, a multicenter, retrospective analysis illustrated that DNA methylation profile (EPICUP)‐based site‐specific therapy significantly improved the median OS of patients with CUP compared with those who received empirical therapy (13.6 vs. 6.0 months, <em>p</em> = 0.0051) [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>]. However, it is important to note that both of these previously mentioned retrospective clinical trials have small sample sizes, which limits the availability of strong evidence regarding the potential improvement of patient prognosis with site‐specific therapy. To summarize, currently available studies comparing site‐specific therapy with empiric chemotherapy exhibit significant deficiencies and notable limitations, which include study design, patient recruitment criteria, heterogeneity among the CUP classifiers, as well as incomparable therapies. Given the inherent limitations of the present researches and the urgent demand to optimize therapeutic strategies for CUP, further well‐designed studies are needed to establish the status of site‐specific therapy for clinical management of patients with CUP.</p>
<p>To address this challenge, our center designed the pioneering worldwide prospective randomized phase III study, which was known as Fudan CUP‐001, to investigate the clinical efficacy and safety of 90‐gene expression assay‐directed site‐specific therapy compared with empirical chemotherapy [<a href="#mco270161-bib-0041" class="usa-link" aria-describedby="mco270161-bib-0041">41</a>, <a href="#mco270161-bib-0189" class="usa-link" aria-describedby="mco270161-bib-0189">189</a>, <a href="#mco270161-bib-0190" class="usa-link" aria-describedby="mco270161-bib-0190">190</a>]. Our study proved that site‐specific therapy contributed to a significantly longer median PFS compared with empirical chemotherapy (9.6 vs. 6.6 months, <em>p</em> = 0.017). Furthermore, patients who received site‐specific treatment exhibited a favorable median OS compared with those treated with empirical chemotherapy (28.2 vs. 19.0 months, <em>p</em> = 0.099). Taken together, our study represents a milestone to show improved PFS and favorable OS based on GEP‐guided site‐specific treatment, as opposed to empirical chemotherapy, in the first‐line therapy for CUP across the globe to date. This significant breakthrough not only opens a new chapter for the clinical management of CUP, but also establishes site‐specific first‐line treatment as a cornerstone in improving patient prognosis for CUP.</p></section><section id="mco270161-sec-0160"><h4 class="pmc_sec_title">6.1.3. Molecularly guided therapy</h4>
<p>ICIs and targeted therapy have improved the prognosis and survival of several cancer types in recent years, especially for patients with advanced NSCLC [<a href="#mco270161-bib-0191" class="usa-link" aria-describedby="mco270161-bib-0191">191</a>] and hepatocellular carcinoma [<a href="#mco270161-bib-0188" class="usa-link" aria-describedby="mco270161-bib-0188">188</a>]. In CUP, the median OS for those receiving NGS‐based molecularly guided therapy (MGT) was 23.6 months [<a href="#mco270161-bib-0040" class="usa-link" aria-describedby="mco270161-bib-0040">40</a>]. However, it remains uncertain whether first‐line MGT can enhance patient outcomes in cases of CUP. To address this challenge, an open‐label, randomized, phase II study called CUPISCO was conducted to compare the efficacy and safety of genomic profiling‐guided therapy versus empirical chemotherapy in patients with newly diagnosed, unfavorable, nonsquamous CUP [<a href="#mco270161-bib-0003" class="usa-link" aria-describedby="mco270161-bib-0003">3</a>, <a href="#mco270161-bib-0192" class="usa-link" aria-describedby="mco270161-bib-0192">192</a>]. In the intention‐to‐treat population, patients in the MGT group achieved a median PFS of 6.1 months, whereas patients in the empirical group achieved a median PFS of 4.4 months (<em>p</em> = 0.0079). CUPISCO emphasized the significant importance of including genomic profiling in the initial diagnostic work‐up for patients with newly diagnosed, unfavorable CUP to expand therapy strategies and improve prognosis. In summary, both the CUP‐001 and CUPISCO studies confirmed that precision treatment (GEP‐guided site‐specific therapy or MGT) leads to improved patient outcomes for previously untreated CUP when compared with empirical chemotherapy. However, there are some differences between the two studies in terms of study design, patient recruitment, and treatment regimens. The CUPISCO study no longer emphasizes the importance of identifying the primary tumor; instead, it places greater focus on finding therapeutic targets.</p>
<p>In addition, ICIs‐based therapy is also a promising choice for CUP [<a href="#mco270161-bib-0193" class="usa-link" aria-describedby="mco270161-bib-0193">193</a>]. Previous studies confirmed that CUP patients treated with ICIs achieved an ORR of 29% [<a href="#mco270161-bib-0073" class="usa-link" aria-describedby="mco270161-bib-0073">73</a>]. Indeed, studies have validated that 28% of patients with CUP exhibit one or more predictive biomarkers for ICIs [<a href="#mco270161-bib-0194" class="usa-link" aria-describedby="mco270161-bib-0194">194</a>]. Among them, 14% show high expression of PD‐L1 (TPS &gt; 50%), 1.8% present with MSI‐high and 11.8% have a TMB of 17 or more mutations per megabase [<a href="#mco270161-bib-0065" class="usa-link" aria-describedby="mco270161-bib-0065">65</a>], which provide a foundation for the future application of combination immunotherapy in patients with CUP. Further, HER2‐targeting ADC may be another promising therapeutic option for patients with CUP, as previous studies have documented that HER2 is overexpressed in 10% of CUP [<a href="#mco270161-bib-0027" class="usa-link" aria-describedby="mco270161-bib-0027">27</a>, <a href="#mco270161-bib-0079" class="usa-link" aria-describedby="mco270161-bib-0079">79</a>], which needs to be further investigated.</p></section></section><section id="mco270161-sec-0170"><h3 class="pmc_sec_title">6.2. Second‐line treatment</h3>
<p>From four decades of efforts, amount of clinical trials had been conducted to enhance the patient outcomes of CUP. CUP‐001 establishes the status of site‐specific therapy in first‐line treatment of patients with CUP. However, despite the administration of site‐specific first‐line therapy, the median PFS for CUP remains less than one year. Research on effective second‐line therapy aimed at improving patient outcomes has emerged over the past 20 years (Table <a href="#mco270161-tbl-0005" class="usa-link">5</a>).</p>
<section class="tw xbox font-sm" id="mco270161-tbl-0005"><h4 class="obj_head">TABLE 5.</h4>
<div class="caption p"><p>Efficacy of second‐line treatment for patients with previously treated or recurrent CUP.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<thead><tr style="border-bottom:solid 1px #000000">
<th align="left" rowspan="1" colspan="1">Year</th>
<th align="center" rowspan="1" colspan="1">Regimens</th>
<th align="center" rowspan="1" colspan="1">Patient (<em>N</em>)</th>
<th align="center" rowspan="1" colspan="1">ORR</th>
<th align="center" rowspan="1" colspan="1">Median PFS (months)</th>
<th align="center" rowspan="1" colspan="1">Median OS (months)</th>
<th align="center" rowspan="1" colspan="1">References</th>
</tr></thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">2001</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine</td>
<td align="center" rowspan="1" colspan="1">39</td>
<td align="center" rowspan="1" colspan="1">7.7%</td>
<td align="center" rowspan="1" colspan="1">5</td>
<td align="center" rowspan="1" colspan="1">/</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0195" class="usa-link" aria-describedby="mco270161-bib-0195">195</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="center" rowspan="1" colspan="1">Gemcitabine + irinotecan</td>
<td align="center" rowspan="1" colspan="1">40</td>
<td align="center" rowspan="1" colspan="1">10.0%</td>
<td align="center" rowspan="1" colspan="1">/</td>
<td align="center" rowspan="1" colspan="1">4.5</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0176" class="usa-link" aria-describedby="mco270161-bib-0176">176</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="center" rowspan="1" colspan="1">Bevacizumab + erlotinib</td>
<td align="center" rowspan="1" colspan="1">51</td>
<td align="center" rowspan="1" colspan="1">9.8%</td>
<td align="center" rowspan="1" colspan="1">3.9</td>
<td align="center" rowspan="1" colspan="1">7.4</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0196" class="usa-link" aria-describedby="mco270161-bib-0196">196</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="center" rowspan="1" colspan="1">Capecitabine + oxaliplatin</td>
<td align="center" rowspan="1" colspan="1">25</td>
<td align="center" rowspan="1" colspan="1">13.6%</td>
<td align="center" rowspan="1" colspan="1">2.3</td>
<td align="center" rowspan="1" colspan="1">3.9</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0197" class="usa-link" aria-describedby="mco270161-bib-0197">197</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="center" rowspan="1" colspan="1">Capecitabine + oxaliplatin</td>
<td align="center" rowspan="1" colspan="1">48</td>
<td align="center" rowspan="1" colspan="1">18.8%</td>
<td align="center" rowspan="1" colspan="1">3.7</td>
<td align="center" rowspan="1" colspan="1">9.7</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0182" class="usa-link" aria-describedby="mco270161-bib-0182">182</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2022</td>
<td align="center" rowspan="1" colspan="1">Nivolumab</td>
<td align="center" rowspan="1" colspan="1">45</td>
<td align="center" rowspan="1" colspan="1">22.2%</td>
<td align="center" rowspan="1" colspan="1">4.0</td>
<td align="center" rowspan="1" colspan="1">15.9</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0198" class="usa-link" aria-describedby="mco270161-bib-0198">198</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2022</td>
<td align="center" rowspan="1" colspan="1">Pembrolizumab</td>
<td align="center" rowspan="1" colspan="1">29</td>
<td align="center" rowspan="1" colspan="1">20.0%</td>
<td align="center" rowspan="1" colspan="1">4.1</td>
<td align="center" rowspan="1" colspan="1">11.3</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0199" class="usa-link" aria-describedby="mco270161-bib-0199">199</a>]</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2023</td>
<td align="center" rowspan="1" colspan="1">Nivolumab + ipilimumab</td>
<td align="center" rowspan="1" colspan="1">31</td>
<td align="center" rowspan="1" colspan="1">15.9%</td>
<td align="center" rowspan="1" colspan="1">2.5</td>
<td align="center" rowspan="1" colspan="1">3.8</td>
<td align="center" rowspan="1" colspan="1">[<a href="#mco270161-bib-0200" class="usa-link" aria-describedby="mco270161-bib-0200">200</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/mco270161-tbl-0005/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="mco270161-tbl5-note-0001"><p>
<em>Abbreviations</em>: ORR, overall response rate; OS, overall survival; PFS, progression‐free survival.</p></div></div></section><p>In the past chemotherapy‐based therapy eras, gemcitabine and gemcitabine in combination with irinotecan achieved an ORR of 7.7–10.0% in patients with previously treated CUP [<a href="#mco270161-bib-0176" class="usa-link" aria-describedby="mco270161-bib-0176">176</a>, <a href="#mco270161-bib-0195" class="usa-link" aria-describedby="mco270161-bib-0195">195</a>], which showed modest activity for recurrent or refractory CUP. In the later era of targeted therapy, the combination inhibition of vascular endothelial growth factor and EGFR with bevacizumab and erlotinib did not significantly improve patient outcomes, achieving an ORR of only 9.8% [<a href="#mco270161-bib-0196" class="usa-link" aria-describedby="mco270161-bib-0196">196</a>]. With the recent development of immunotherapy, nivolumab and nivolumab in combination with ipilimumab demonstrated superior efficacy, achieving an ORR of 15.9–22.2%, in comparison with earlier studies [<a href="#mco270161-bib-0198" class="usa-link" aria-describedby="mco270161-bib-0198">198</a>, <a href="#mco270161-bib-0200" class="usa-link" aria-describedby="mco270161-bib-0200">200</a>]. Additionally, pembrolizumab monotherapy demonstrated a similar late benefit in investigator‐assessed ORR of 20.0% for recurrent or refractory CUP [<a href="#mco270161-bib-0199" class="usa-link" aria-describedby="mco270161-bib-0199">199</a>]. However, it still requires further investigation to determine whether patients with previously treated CUP could derive greater benefits from combination therapy involving chemotherapy, targeted therapy, and immunotherapy, which would be of great interest in future studies of later‐line therapy for CUP.</p></section></section><section id="mco270161-sec-0180"><h2 class="pmc_sec_title">7. Future Perspectives</h2>
<p>Indeed, the diagnostic approaches and therapeutic optimization for CUP have experienced five decades of evolution. Following the continuous advancements in tumor diagnosis since 2000, CUP diagnosis has transitioned from the era of IHC to the era of MTP, which lays the foundation of site‐specific first‐line therapy to improve patient outcomes of CUP. Despite the superior accuracy of GEP‐based testing in CUP diagnosis, as well as genomic and epigenomic profile‐based procedures, the standard diagnostic techniques still remain inconclusive. Hot directions for future researches in CUP still focus on how to turn CUP into known primary by revolutionary diagnostic approaches, in order to guide therapeutic optimization. Considered together, we propose here the three core questions in the field of CUP that should be further explored in future studies, as detailed below.</p>
<p>First, in terms of diagnosis of CUP, we have observed excellent results with the highest diagnostic accuracy exceeding 90% of methods based on cytology, histology, GEP, genomic, and epigenomic analysis of CUP. Among various panels of GEP‐based methods, the 90‐gene assay stands out as the most prominent, boasting a diagnostic accuracy of 94.4% [<a href="#mco270161-bib-0085" class="usa-link" aria-describedby="mco270161-bib-0085">85</a>]. However, the 90‐gene testing has several limitations, including its coverage of only 21 common solid tumors, its inability to differentiate between breast cancer and sweat gland cancer, and its low diagnostic efficiency for squamous cell carcinoma, among others. Further studies will aim to apply smaller panels of tumor specific genes to achieve higher diagnostic accuracy and provide improved guidance for site‐specific treatment. Currently, approaches utilizing deep learning or machine learning algorithms have been developed to apply GEP or DNA methylation profiles in the clinical practice for determining the tumor tissue origin of CUP. In addition, even though AI models based on cytology, histology, genomic and epigenomic profiles of CUP have illustrated excellent performance in clinical diagnosis CUP [<a href="#mco270161-bib-0032" class="usa-link" aria-describedby="mco270161-bib-0032">32</a>‐<a href="#mco270161-bib-0036" class="usa-link" aria-describedby="mco270161-bib-0036"><sup>36</sup></a><sup>, </sup><a href="#mco270161-bib-0152" class="usa-link" aria-describedby="mco270161-bib-0152"><sup>152</sup></a>], however, these methodologies are primarily at the research stage and are still far from actual clinical application. Although AI‐based multimodal predictive models have illustrated great potential in tumor diagnosis and treatment decision‐making, the application of these approaches in the diagnosis of CUP still has a long way to go due to the high heterogeneity associated with CUP.</p>
<p>Second, it is crucial to shift our perspectives on the relationship between diagnosis and treatment. For patients who can definitely determine the primary site, a standard site‐specific first‐line therapy is recommended as the CUP‐001 documented. However, despite the application of comprehensive examinations, approximately 30% of patients still cannot trace back to the primary site prior to therapy. Most of these cases were histopathologically confirmed as poorly and undifferentiated carcinomas. In this case, palliative care should be prioritized to diagnosis to improve quality of life and prolong OS of patients, especially in the current era of immunotherapy and MGT. As demonstrated by CUPISCO study, even without identifying the primary tumor, patients can achieve good treatment outcomes as long as effective therapeutic targets are identified. Therefore, the question arises: Should we focus on identifying the primary tumor or on finding therapeutic targets? Actually, a few of these patients will progressively present with symptoms and signs associated with the primary tumors as the disease advances. We are therefore currently dedicating our efforts to establish a hierarchical management system for patients based on the histologic, genetic, and clinical features of CUP in the clinical practice, which aims at improving the prognosis and survival of patients with CUP (Figure <a href="#mco270161-fig-0004" class="usa-link">4</a>).</p>
<figure class="fig xbox font-sm" id="mco270161-fig-0004"><h3 class="obj_head">FIGURE 4.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9adc/12000684/03312653f90a/MCO2-6-e70161-g002.jpg" loading="lazy" id="jats-graphic-9" height="234" width="560" alt="FIGURE 4"></p>
<div class="p text-right font-secondary"><a href="figure/mco270161-fig-0004/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Proposed workflow for the diagnosis and management of CUP. Patients present to the clinic for symptoms and signs of metastatic tumors. A precise diagnosis starts with a comprehensive approach, including routine tests like medical history, physical examination, blood tests, tumor marker detection, imaging examinations, and a step‐by‐step manner immunohistochemistry (IHC) staining. In certain cases, when deemed necessary, molecular tumor profiling (MTP) is recommended. After diagnosis, patients received surgery, site‐specific treatment or MGT according to the clinical and pathologic features. Follow‐up content included response evaluation of antitumoral therapy per the Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 and surveillance guidelines to monitor for recurrence.</p></figcaption></figure><p>Third, the current CUP‐001 and CUPISCO studies confirmed the role of site‐specific therapy and MGT in the first‐line treatment for CUP. Nevertheless, even with the application of site‐specific or MGT first‐line therapy, the median PFS for patients with CUP remains at no more than 1 year. Existing studies have not yet provided effective options for second‐line treatment for patients with CUP after failure of first‐line treatment. Present studies on chemotherapy, targeted therapy, and ICIs‐based treatment, documented an ORR of 7.7–22.2% for previously treated CUP [<a href="#mco270161-bib-0176" class="usa-link" aria-describedby="mco270161-bib-0176">176</a>, <a href="#mco270161-bib-0195" class="usa-link" aria-describedby="mco270161-bib-0195">195</a>, <a href="#mco270161-bib-0196" class="usa-link" aria-describedby="mco270161-bib-0196">196</a>, <a href="#mco270161-bib-0198" class="usa-link" aria-describedby="mco270161-bib-0198">198</a>‐<a href="#mco270161-bib-0200" class="usa-link" aria-describedby="mco270161-bib-0200"><sup>200</sup></a>]. However, further investigation is needed to determine whether combination therapy involving chemotherapy, targeted therapy, and immunotherapy results in better outcomes for previously treated or recurrent CUP. To address this challenge, our center conducted a prospective, open‐label, single‐arm phase II study to assess the efficacy and safety of combination therapy for patients with CUP who had failed first‐line treatment or experienced disease progression. Findings of this study will be released in the near future and are expected to provide strong evidence for second‐line therapy in CUP.</p>
<p>In summary, we encounter both significant opportunities and challenges in the diagnosis and further‐line treatment of CUP in the current era of precision medicine, and there is still much progress to be made in this field.</p></section><section id="mco270161-sec-0190"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>T. Z., X. W. Z., and Z. G. L. designed the literature, arranged the studies, and drafted the manuscript. X. L., Q. F. W., and X. C. H. prepared the figures and revised the manuscript. All the authors contributed to this manuscript. All authors read and approved the final version of the manuscript.</p></section><section id="mco270161-sec-0210"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="mco270161-sec-0220"><h2 class="pmc_sec_title">Ethics Statement</h2>
<p>Not applicable.</p></section><section id="mco270161-sec-0200" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors have nothing to report.</p></section><section id="notes1"><section id="fn-group1" class="fn-group"><div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="mco270161-note-0001"><p>Ting Zhao, and Xiaowei Zhang, These authors contributed equally to this work.</p></div>
<div class="fn p" id="mco270161-note-0002"><p>
<strong>Funding</strong>: This work was supported by Shanghai Anticancer Association Program (grant number: SACA‐AX202206 to Z. G. L.), National Natural Science Foundation of China (grant number: 8240111596 to T. Z.), China Postdoctoral Science Foundation (grant number: 2023M730675 to T. Z.), and Shanghai Sailing Program (grant number: 23YF1406800 to T. Z.).</p></div>
</div></section></section><section id="mco270161-sec-0240"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>Not applicable.</p></section><section id="mco270161-bibl-0001" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="mco270161-bibl-0001_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="mco270161-bib-0001">
<span class="label">1.</span><cite>
Pavlidis N. and Pentheroudakis G., “Cancer of Unknown Primary Site,” Lancet
379 (2012): 1428–1435.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(11)61178-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22414598/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Cancer%20of%20Unknown%20Primary%20Site&amp;author=N.%20Pavlidis&amp;author=G.%20Pentheroudakis&amp;volume=379&amp;publication_year=2012&amp;pages=1428-1435&amp;pmid=22414598&amp;doi=10.1016/S0140-6736(11)61178-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0002">
<span class="label">2.</span><cite>
Kramer A., Bochtler T., Pauli C., et al., “Cancer of Unknown Primary: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow‐up,” Annals of Oncology
34 (2023): 228–246.
</cite> [<a href="https://doi.org/10.1016/j.annonc.2022.11.013" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36563965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Cancer%20of%20Unknown%20Primary:%20ESMO%20Clinical%20Practice%20Guideline%20for%20Diagnosis,%20Treatment%20and%20Follow%E2%80%90up&amp;author=A.%20Kramer&amp;author=T.%20Bochtler&amp;author=C.%20Pauli&amp;volume=34&amp;publication_year=2023&amp;pages=228-246&amp;pmid=36563965&amp;doi=10.1016/j.annonc.2022.11.013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0003">
<span class="label">3.</span><cite>
Kramer A., Bochtler T., Pauli C., et al., “Molecularly Guided Therapy versus Chemotherapy After Disease Control in Unfavourable Cancer of Unknown Primary (CUPISCO): An Open‐label, Randomised, Phase 2 Study,” Lancet
404 (2024): 527–539.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(24)00814-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39096924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Molecularly%20Guided%20Therapy%20versus%20Chemotherapy%20After%20Disease%20Control%20in%20Unfavourable%20Cancer%20of%20Unknown%20Primary%20(CUPISCO):%20An%20Open%E2%80%90label,%20Randomised,%20Phase%202%20Study&amp;author=A.%20Kramer&amp;author=T.%20Bochtler&amp;author=C.%20Pauli&amp;volume=404&amp;publication_year=2024&amp;pages=527-539&amp;pmid=39096924&amp;doi=10.1016/S0140-6736(24)00814-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0004">
<span class="label">4.</span><cite>
Binder C., Matthes K. L., Korol D., Rohrmann S., and Moch H., “Cancer of Unknown Primary‐Epidemiological Trends and Relevance of Comprehensive Genomic Profiling,” Cancer Medicine
7 (2018): 4814–4824.
</cite> [<a href="https://doi.org/10.1002/cam4.1689" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6144156/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30019510/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Medicine&amp;title=Cancer%20of%20Unknown%20Primary%E2%80%90Epidemiological%20Trends%20and%20Relevance%20of%20Comprehensive%20Genomic%20Profiling&amp;author=C.%20Binder&amp;author=K.%20L.%20Matthes&amp;author=D.%20Korol&amp;author=S.%20Rohrmann&amp;author=H.%20Moch&amp;volume=7&amp;publication_year=2018&amp;pages=4814-4824&amp;pmid=30019510&amp;doi=10.1002/cam4.1689&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0005">
<span class="label">5.</span><cite>
Rassy E. and Pavlidis N., “The Currently Declining Incidence of Cancer of Unknown Primary,” Cancer Epidemiology
61 (2019): 139–141.
</cite> [<a href="https://doi.org/10.1016/j.canep.2019.06.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31254795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Epidemiology&amp;title=The%20Currently%20Declining%20Incidence%20of%20Cancer%20of%20Unknown%20Primary&amp;author=E.%20Rassy&amp;author=N.%20Pavlidis&amp;volume=61&amp;publication_year=2019&amp;pages=139-141&amp;pmid=31254795&amp;doi=10.1016/j.canep.2019.06.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0006">
<span class="label">6.</span><cite>
Lee M. S. and Sanoff H. K., “Cancer of Unknown Primary,” Bmj
371 (2020): m4050.
</cite> [<a href="https://doi.org/10.1136/bmj.m4050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33288500/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bmj&amp;title=Cancer%20of%20Unknown%20Primary&amp;author=M.%20S.%20Lee&amp;author=H.%20K.%20Sanoff&amp;volume=371&amp;publication_year=2020&amp;pages=m4050&amp;pmid=33288500&amp;doi=10.1136/bmj.m4050&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0007">
<span class="label">7.</span><cite>
Hemminki K., Ji J., Sundquist J., and Shu X., “Familial Risks in Cancer of Unknown Primary: Tracking the Primary Sites,” Journal of Clinical Oncology
29 (2011): 435–440.
</cite> [<a href="https://doi.org/10.1200/JCO.2010.31.5614" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21189391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Familial%20Risks%20in%20Cancer%20of%20Unknown%20Primary:%20Tracking%20the%20Primary%20Sites&amp;author=K.%20Hemminki&amp;author=J.%20Ji&amp;author=J.%20Sundquist&amp;author=X.%20Shu&amp;volume=29&amp;publication_year=2011&amp;pages=435-440&amp;pmid=21189391&amp;doi=10.1200/JCO.2010.31.5614&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0008">
<span class="label">8.</span><cite>
Pavlidis N. and Pentheroudakis G., “Cancer of Unknown Primary Site: 20 Questions to be Answered,” Annals of Oncology
21, no. Suppl 7 (2010): vii303–vii307.
</cite> [<a href="https://doi.org/10.1093/annonc/mdq278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20943633/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Cancer%20of%20Unknown%20Primary%20Site:%2020%20Questions%20to%20be%20Answered&amp;author=N.%20Pavlidis&amp;author=G.%20Pentheroudakis&amp;volume=21&amp;issue=7&amp;publication_year=2010&amp;pages=vii303-vii307&amp;pmid=20943633&amp;doi=10.1093/annonc/mdq278&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0009">
<span class="label">9.</span><cite>
Rassy E. and Pavlidis N., “Progress in Refining the Clinical Management of Cancer of Unknown Primary in the Molecular Era,” Nature Reviews Clinical Oncology
17 (2020): 541–554.</cite> [<a href="https://doi.org/10.1038/s41571-020-0359-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32350398/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Progress%20in%20Refining%20the%20Clinical%20Management%20of%20Cancer%20of%20Unknown%20Primary%20in%20the%20Molecular%20Era&amp;author=E.%20Rassy&amp;author=N.%20Pavlidis&amp;volume=17&amp;publication_year=2020&amp;pages=541-554&amp;pmid=32350398&amp;doi=10.1038/s41571-020-0359-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0010">
<span class="label">10.</span><cite>
Varadhachary G. R. and Raber M. N., “Cancer of Unknown Primary Site,” New England Journal of Medicine
371 (2014): 757–765.
</cite> [<a href="https://doi.org/10.1056/NEJMra1303917" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25140961/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Cancer%20of%20Unknown%20Primary%20Site&amp;author=G.%20R.%20Varadhachary&amp;author=M.%20N.%20Raber&amp;volume=371&amp;publication_year=2014&amp;pages=757-765&amp;pmid=25140961&amp;doi=10.1056/NEJMra1303917&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0011">
<span class="label">11.</span><cite>
Rassy E., Parent P., Lefort F., Boussios S., Baciarello G., and Pavlidis N., “New Rising Entities in Cancer of Unknown Primary: Is There a Real Therapeutic Benefit?,” Critical Reviews in Oncology/Hematology
147 (2020): 102882.
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2020.102882" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32106012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Critical%20Reviews%20in%20Oncology/Hematology&amp;title=New%20Rising%20Entities%20in%20Cancer%20of%20Unknown%20Primary:%20Is%20There%20a%20Real%20Therapeutic%20Benefit?&amp;author=E.%20Rassy&amp;author=P.%20Parent&amp;author=F.%20Lefort&amp;author=S.%20Boussios&amp;author=G.%20Baciarello&amp;volume=147&amp;publication_year=2020&amp;pages=102882&amp;pmid=32106012&amp;doi=10.1016/j.critrevonc.2020.102882&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0012">
<span class="label">12.</span><cite>
Vikesa J., Moller A. K., Kaczkowski B., et al., “Cancers of Unknown Primary Origin (CUP) Are Characterized by Chromosomal Instability (CIN) Compared to Metastasis of Know Origin,” BMC Cancer
15 (2015): 151.
</cite> [<a href="https://doi.org/10.1186/s12885-015-1128-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4404593/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25885340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Cancers%20of%20Unknown%20Primary%20Origin%20(CUP)%20Are%20Characterized%20by%20Chromosomal%20Instability%20(CIN)%20Compared%20to%20Metastasis%20of%20Know%20Origin&amp;author=J.%20Vikesa&amp;author=A.%20K.%20Moller&amp;author=B.%20Kaczkowski&amp;volume=15&amp;publication_year=2015&amp;pages=151&amp;pmid=25885340&amp;doi=10.1186/s12885-015-1128-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0013">
<span class="label">13.</span><cite>
Hermans K., Kazemzadeh F., Loef C., et al., “Risk Factors for Cancer of Unknown Primary: A Literature Review,” BMC Cancer
23 (2023): 314.
</cite> [<a href="https://doi.org/10.1186/s12885-023-10794-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10077635/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37020279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Risk%20Factors%20for%20Cancer%20of%20Unknown%20Primary:%20A%20Literature%20Review&amp;author=K.%20Hermans&amp;author=F.%20Kazemzadeh&amp;author=C.%20Loef&amp;volume=23&amp;publication_year=2023&amp;pages=314&amp;pmid=37020279&amp;doi=10.1186/s12885-023-10794-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0014">
<span class="label">14.</span><cite>
Hemminki K., Sundquist K., Sundquist J., and Ji J., “Risk of Cancer of Unknown Primary After Hospitalization for Autoimmune Diseases,” International Journal of Cancer
137 (2015): 2885–2895.
</cite> [<a href="https://doi.org/10.1002/ijc.29657" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26103152/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Cancer&amp;title=Risk%20of%20Cancer%20of%20Unknown%20Primary%20After%20Hospitalization%20for%20Autoimmune%20Diseases&amp;author=K.%20Hemminki&amp;author=K.%20Sundquist&amp;author=J.%20Sundquist&amp;author=J.%20Ji&amp;volume=137&amp;publication_year=2015&amp;pages=2885-2895&amp;pmid=26103152&amp;doi=10.1002/ijc.29657&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0015">
<span class="label">15.</span><cite>
Pavlidis N., Rassy E., and Smith‐Gagen J., “Cancer of Unknown Primary: Incidence Rates, Risk Factors and Survival Among Adolescents and Young Adults,” International Journal of Cancer
146 (2020): 1490–1498.
</cite> [<a href="https://doi.org/10.1002/ijc.32482" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31144291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Cancer&amp;title=Cancer%20of%20Unknown%20Primary:%20Incidence%20Rates,%20Risk%20Factors%20and%20Survival%20Among%20Adolescents%20and%20Young%20Adults&amp;author=N.%20Pavlidis&amp;author=E.%20Rassy&amp;author=J.%20Smith%E2%80%90Gagen&amp;volume=146&amp;publication_year=2020&amp;pages=1490-1498&amp;pmid=31144291&amp;doi=10.1002/ijc.32482&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0016">
<span class="label">16.</span><cite>
Hemminki K., Chen B., Melander O., Manjer J., Hallmans G., and Hemminki A., “Smoking and Body Mass Index as Risk Factors for Subtypes of Cancer of Unknown Primary,” International Journal of Cancer
136 (2015): 246–247.
</cite> [<a href="https://doi.org/10.1002/ijc.28969" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24828693/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Cancer&amp;title=Smoking%20and%20Body%20Mass%20Index%20as%20Risk%20Factors%20for%20Subtypes%20of%20Cancer%20of%20Unknown%20Primary&amp;author=K.%20Hemminki&amp;author=B.%20Chen&amp;author=O.%20Melander&amp;author=J.%20Manjer&amp;author=G.%20Hallmans&amp;volume=136&amp;publication_year=2015&amp;pages=246-247&amp;pmid=24828693&amp;doi=10.1002/ijc.28969&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0017">
<span class="label">17.</span><cite>
Rassy E., Kattan J., and Pavlidis N., “Familial Cancer of Unknown Primary,” International Journal of Clinical Oncology
24 (2019): 1328–1331.
</cite> [<a href="https://doi.org/10.1007/s10147-019-01491-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31203526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Clinical%20Oncology&amp;title=Familial%20Cancer%20of%20Unknown%20Primary&amp;author=E.%20Rassy&amp;author=J.%20Kattan&amp;author=N.%20Pavlidis&amp;volume=24&amp;publication_year=2019&amp;pages=1328-1331&amp;pmid=31203526&amp;doi=10.1007/s10147-019-01491-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0018">
<span class="label">18.</span><cite>
Tothill R. W., Li J., Mileshkin L., et al., “Massively‐parallel Sequencing Assists the Diagnosis and Guided Treatment of Cancers of Unknown Primary,” Journal of Pathology
231 (2013): 413–423.
</cite> [<a href="https://doi.org/10.1002/path.4251" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24037760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pathology&amp;title=Massively%E2%80%90parallel%20Sequencing%20Assists%20the%20Diagnosis%20and%20Guided%20Treatment%20of%20Cancers%20of%20Unknown%20Primary&amp;author=R.%20W.%20Tothill&amp;author=J.%20Li&amp;author=L.%20Mileshkin&amp;volume=231&amp;publication_year=2013&amp;pages=413-423&amp;pmid=24037760&amp;doi=10.1002/path.4251&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0019">
<span class="label">19.</span><cite>
Ross J. S., Wang K., Gay L., et al., “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies,” JAMA Oncology
1 (2015): 40–49.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2014.216" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26182302/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncology&amp;title=Comprehensive%20Genomic%20Profiling%20of%20Carcinoma%20of%20Unknown%20Primary%20Site:%20New%20Routes%20to%20Targeted%20Therapies&amp;author=J.%20S.%20Ross&amp;author=K.%20Wang&amp;author=L.%20Gay&amp;volume=1&amp;publication_year=2015&amp;pages=40-49&amp;pmid=26182302&amp;doi=10.1001/jamaoncol.2014.216&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0020">
<span class="label">20.</span><cite>
Chiang W. M., Kapadia M., Laver N. V., and Nystrom J. S., “Cancer of Unknown Primary: From Immunohistochemistry to Gene Expression Profiling,” Journal of Clinical Oncology
30 (2012): e300–302.
</cite> [<a href="https://doi.org/10.1200/JCO.2011.41.1827" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22965966/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Cancer%20of%20Unknown%20Primary:%20From%20Immunohistochemistry%20to%20Gene%20Expression%20Profiling&amp;author=W.%20M.%20Chiang&amp;author=M.%20Kapadia&amp;author=N.%20V.%20Laver&amp;author=J.%20S.%20Nystrom&amp;volume=30&amp;publication_year=2012&amp;pages=e300-302&amp;pmid=22965966&amp;doi=10.1200/JCO.2011.41.1827&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0021">
<span class="label">21.</span><cite>
Handorf C. R., “Gene Expression Analysis and Immunohistochemistry in Evaluation of Cancer of Unknown Primary: Time for a Patient‐centered Approach,” Journal of the National Comprehensive Cancer Network: JNCCN
9 (2011): 1415–1420.
</cite> [<a href="https://doi.org/10.6004/jnccn.2011.0120" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22157559/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20National%20Comprehensive%20Cancer%20Network:%20JNCCN&amp;title=Gene%20Expression%20Analysis%20and%20Immunohistochemistry%20in%20Evaluation%20of%20Cancer%20of%20Unknown%20Primary:%20Time%20for%20a%20Patient%E2%80%90centered%20Approach&amp;author=C.%20R.%20Handorf&amp;volume=9&amp;publication_year=2011&amp;pages=1415-1420&amp;pmid=22157559&amp;doi=10.6004/jnccn.2011.0120&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0022">
<span class="label">22.</span><cite>
Stelow E. B. and Yaziji H., “Immunohistochemistry, Carcinomas of Unknown Primary, and Incidence Rates,” Seminars in Diagnostic Pathology
35 (2018): 143–152.
</cite> [<a href="https://doi.org/10.1053/j.semdp.2017.11.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29224972/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Seminars%20in%20Diagnostic%20Pathology&amp;title=Immunohistochemistry,%20Carcinomas%20of%20Unknown%20Primary,%20and%20Incidence%20Rates&amp;author=E.%20B.%20Stelow&amp;author=H.%20Yaziji&amp;volume=35&amp;publication_year=2018&amp;pages=143-152&amp;pmid=29224972&amp;doi=10.1053/j.semdp.2017.11.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0023">
<span class="label">23.</span><cite>
Conner J. R. and Hornick J. L., “Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry,” Advances in Anatomic Pathology
22 (2015): 149–167.
</cite> [<a href="https://doi.org/10.1097/PAP.0000000000000069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25844674/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Advances%20in%20Anatomic%20Pathology&amp;title=Metastatic%20Carcinoma%20of%20Unknown%20Primary:%20Diagnostic%20Approach%20Using%20Immunohistochemistry&amp;author=J.%20R.%20Conner&amp;author=J.%20L.%20Hornick&amp;volume=22&amp;publication_year=2015&amp;pages=149-167&amp;pmid=25844674&amp;doi=10.1097/PAP.0000000000000069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0024">
<span class="label">24.</span><cite>
Dum D., Menz A., Volkel C., et al., “Cytokeratin 7 and Cytokeratin 20 Expression in Cancer: A Tissue Microarray Study on 15,424 Cancers,” Experimental and Molecular Pathology
126 (2022): 104762.
</cite> [<a href="https://doi.org/10.1016/j.yexmp.2022.104762" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35390310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Experimental%20and%20Molecular%20Pathology&amp;title=Cytokeratin%207%20and%20Cytokeratin%2020%20Expression%20in%20Cancer:%20A%20Tissue%20Microarray%20Study%20on%2015,424%20Cancers&amp;author=D.%20Dum&amp;author=A.%20Menz&amp;author=C.%20Volkel&amp;volume=126&amp;publication_year=2022&amp;pages=104762&amp;pmid=35390310&amp;doi=10.1016/j.yexmp.2022.104762&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0025">
<span class="label">25.</span><cite>
Greco F. A., Lennington W. J., Spigel D. R., and Hainsworth J. D., “Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology,” JNCI: Journal of the National Cancer Institute
105 (2013): 782–790.
</cite> [<a href="https://doi.org/10.1093/jnci/djt099" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23641043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JNCI:%20Journal%20of%20the%20National%20Cancer%20Institute&amp;title=Molecular%20Profiling%20Diagnosis%20in%20Unknown%20Primary%20Cancer:%20Accuracy%20and%20Ability%20to%20Complement%20Standard%20Pathology&amp;author=F.%20A.%20Greco&amp;author=W.%20J.%20Lennington&amp;author=D.%20R.%20Spigel&amp;author=J.%20D.%20Hainsworth&amp;volume=105&amp;publication_year=2013&amp;pages=782-790&amp;pmid=23641043&amp;doi=10.1093/jnci/djt099&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0026">
<span class="label">26.</span><cite>
Kerr S. E., Schnabel C. A., Sullivan P. S., et al., “Multisite Validation Study to Determine Performance Characteristics of a 92‐gene Molecular Cancer Classifier,” Clinical Cancer Research
18 (2012): 3952–3960.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-12-0920" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22648269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Cancer%20Research&amp;title=Multisite%20Validation%20Study%20to%20Determine%20Performance%20Characteristics%20of%20a%2092%E2%80%90gene%20Molecular%20Cancer%20Classifier&amp;author=S.%20E.%20Kerr&amp;author=C.%20A.%20Schnabel&amp;author=P.%20S.%20Sullivan&amp;volume=18&amp;publication_year=2012&amp;pages=3952-3960&amp;pmid=22648269&amp;doi=10.1158/1078-0432.CCR-12-0920&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0027">
<span class="label">27.</span><cite>
Moran S., Martinez‐Cardus A., Sayols S., et al., “Epigenetic Profiling to Classify Cancer of Unknown Primary: A Multicentre, Retrospective Analysis,” The Lancet Oncology
17 (2016): 1386–1395.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(16)30297-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27575023/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet%20Oncology&amp;title=Epigenetic%20Profiling%20to%20Classify%20Cancer%20of%20Unknown%20Primary:%20A%20Multicentre,%20Retrospective%20Analysis&amp;author=S.%20Moran&amp;author=A.%20Martinez%E2%80%90Cardus&amp;author=S.%20Sayols&amp;volume=17&amp;publication_year=2016&amp;pages=1386-1395&amp;pmid=27575023&amp;doi=10.1016/S1470-2045(16)30297-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0028">
<span class="label">28.</span><cite>
Zhao Y., Pan Z., Namburi S., et al., “CUP‐AI‐Dx: A Tool for Inferring Cancer Tissue of Origin and Molecular Subtype Using RNA Gene‐expression Data and Artificial Intelligence,” EBioMedicine
61 (2020): 103030.
</cite> [<a href="https://doi.org/10.1016/j.ebiom.2020.103030" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7553237/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33039710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EBioMedicine&amp;title=CUP%E2%80%90AI%E2%80%90Dx:%20A%20Tool%20for%20Inferring%20Cancer%20Tissue%20of%20Origin%20and%20Molecular%20Subtype%20Using%20RNA%20Gene%E2%80%90expression%20Data%20and%20Artificial%20Intelligence&amp;author=Y.%20Zhao&amp;author=Z.%20Pan&amp;author=S.%20Namburi&amp;volume=61&amp;publication_year=2020&amp;pages=103030&amp;pmid=33039710&amp;doi=10.1016/j.ebiom.2020.103030&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0029">
<span class="label">29.</span><cite>
Handorf C. R., Kulkarni A., Grenert J. P., et al., “A Multicenter Study Directly Comparing the Diagnostic Accuracy of Gene Expression Profiling and Immunohistochemistry for Primary Site Identification in Metastatic Tumors,” American Journal of Surgical Pathology
37 (2013): 1067–1075.
</cite> [<a href="https://doi.org/10.1097/PAS.0b013e31828309c4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5266589/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23648464/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Surgical%20Pathology&amp;title=A%20Multicenter%20Study%20Directly%20Comparing%20the%20Diagnostic%20Accuracy%20of%20Gene%20Expression%20Profiling%20and%20Immunohistochemistry%20for%20Primary%20Site%20Identification%20in%20Metastatic%20Tumors&amp;author=C.%20R.%20Handorf&amp;author=A.%20Kulkarni&amp;author=J.%20P.%20Grenert&amp;volume=37&amp;publication_year=2013&amp;pages=1067-1075&amp;pmid=23648464&amp;doi=10.1097/PAS.0b013e31828309c4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0030">
<span class="label">30.</span><cite>
Ye Q., Wang Q., Qi P., et al., “Development and Clinical Validation of a 90‐Gene Expression Assay for Identifying Tumor Tissue Origin,” The Journal of Molecular Diagnostics
22 (2020): 1139–1150.
</cite> [<a href="https://doi.org/10.1016/j.jmoldx.2020.06.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32610162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Journal%20of%20Molecular%20Diagnostics&amp;title=Development%20and%20Clinical%20Validation%20of%20a%2090%E2%80%90Gene%20Expression%20Assay%20for%20Identifying%20Tumor%20Tissue%20Origin&amp;author=Q.%20Ye&amp;author=Q.%20Wang&amp;author=P.%20Qi&amp;volume=22&amp;publication_year=2020&amp;pages=1139-1150&amp;pmid=32610162&amp;doi=10.1016/j.jmoldx.2020.06.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0031">
<span class="label">31.</span><cite>
Shen Y., Chu Q., Yin X., et al., “TOD‐CUP: A Gene Expression Rank‐based Majority Vote Algorithm for Tissue Origin Diagnosis of Cancers of Unknown Primary,” Briefings in Bioinformatics
22 (2021): 2106–2118.
</cite> [<a href="https://doi.org/10.1093/bib/bbaa031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32266390/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Briefings%20in%20Bioinformatics&amp;title=TOD%E2%80%90CUP:%20A%20Gene%20Expression%20Rank%E2%80%90based%20Majority%20Vote%20Algorithm%20for%20Tissue%20Origin%20Diagnosis%20of%20Cancers%20of%20Unknown%20Primary&amp;author=Y.%20Shen&amp;author=Q.%20Chu&amp;author=X.%20Yin&amp;volume=22&amp;publication_year=2021&amp;pages=2106-2118&amp;pmid=32266390&amp;doi=10.1093/bib/bbaa031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0032">
<span class="label">32.</span><cite>
Lu M. Y., Chen T. Y., Williamson D. F. K., et al., “AI‐based Pathology Predicts Origins for Cancers of Unknown Primary,” Nature
594 (2021): 106–110.
</cite> [<a href="https://doi.org/10.1038/s41586-021-03512-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33953404/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=AI%E2%80%90based%20Pathology%20Predicts%20Origins%20for%20Cancers%20of%20Unknown%20Primary&amp;author=M.%20Y.%20Lu&amp;author=T.%20Y.%20Chen&amp;author=D.%20F.%20K.%20Williamson&amp;volume=594&amp;publication_year=2021&amp;pages=106-110&amp;pmid=33953404&amp;doi=10.1038/s41586-021-03512-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0033">
<span class="label">33.</span><cite>
Moon I., LoPiccolo J., Baca S. C., et al., “Machine Learning for Genetics‐based Classification and Treatment Response Prediction in Cancer of Unknown Primary,” Nature Medicine
29 (2023): 2057–2067.</cite> [<a href="https://doi.org/10.1038/s41591-023-02482-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11484892/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37550415/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Machine%20Learning%20for%20Genetics%E2%80%90based%20Classification%20and%20Treatment%20Response%20Prediction%20in%20Cancer%20of%20Unknown%20Primary&amp;author=I.%20Moon&amp;author=J.%20LoPiccolo&amp;author=S.%20C.%20Baca&amp;volume=29&amp;publication_year=2023&amp;pages=2057-2067&amp;pmid=37550415&amp;doi=10.1038/s41591-023-02482-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0034">
<span class="label">34.</span><cite>
Nguyen L., Van Hoeck A., and Cuppen E., “Machine Learning‐based Tissue of Origin Classification for Cancer of Unknown Primary Diagnostics Using Genome‐wide Mutation Features,” Nature Communications
13 (2022): 4013.</cite> [<a href="https://doi.org/10.1038/s41467-022-31666-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9273599/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35817764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Machine%20Learning%E2%80%90based%20Tissue%20of%20Origin%20Classification%20for%20Cancer%20of%20Unknown%20Primary%20Diagnostics%20Using%20Genome%E2%80%90wide%20Mutation%20Features&amp;author=L.%20Nguyen&amp;author=A.%20Van%20Hoeck&amp;author=E.%20Cuppen&amp;volume=13&amp;publication_year=2022&amp;pages=4013&amp;pmid=35817764&amp;doi=10.1038/s41467-022-31666-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0035">
<span class="label">35.</span><cite>
Tian F., Liu D., Wei N., et al., “Prediction of Tumor Origin in Cancers of Unknown Primary Origin With Cytology‐based Deep Learning,” Nature Medicine
30 (2024): 1309–1319.</cite> [<a href="https://doi.org/10.1038/s41591-024-02915-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11108774/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38627559/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=Prediction%20of%20Tumor%20Origin%20in%20Cancers%20of%20Unknown%20Primary%20Origin%20With%20Cytology%E2%80%90based%20Deep%20Learning&amp;author=F.%20Tian&amp;author=D.%20Liu&amp;author=N.%20Wei&amp;volume=30&amp;publication_year=2024&amp;pages=1309-1319&amp;pmid=38627559&amp;doi=10.1038/s41591-024-02915-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0036">
<span class="label">36.</span><cite>
Zhang S., He S., Zhu X., et al., “DNA Methylation Profiling to Determine the Primary Sites of Metastatic Cancers Using Formalin‐fixed Paraffin‐embedded Tissues,” Nature Communications
14 (2023): 5686.</cite> [<a href="https://doi.org/10.1038/s41467-023-41015-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10502058/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37709764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=DNA%20Methylation%20Profiling%20to%20Determine%20the%20Primary%20Sites%20of%20Metastatic%20Cancers%20Using%20Formalin%E2%80%90fixed%20Paraffin%E2%80%90embedded%20Tissues&amp;author=S.%20Zhang&amp;author=S.%20He&amp;author=X.%20Zhu&amp;volume=14&amp;publication_year=2023&amp;pages=5686&amp;pmid=37709764&amp;doi=10.1038/s41467-023-41015-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0037">
<span class="label">37.</span><cite>
Hainsworth J. D., Rubin M. S., Spigel D. R., et al., “Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site‐specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute,” Journal of Clinical Oncology
31 (2013): 217–223.
</cite> [<a href="https://doi.org/10.1200/JCO.2012.43.3755" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23032625/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Molecular%20Gene%20Expression%20Profiling%20to%20Predict%20the%20Tissue%20of%20Origin%20and%20Direct%20Site%E2%80%90specific%20Therapy%20in%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site:%20A%20Prospective%20Trial%20of%20the%20Sarah%20Cannon%20Research%20Institute&amp;author=J.%20D.%20Hainsworth&amp;author=M.%20S.%20Rubin&amp;author=D.%20R.%20Spigel&amp;volume=31&amp;publication_year=2013&amp;pages=217-223&amp;pmid=23032625&amp;doi=10.1200/JCO.2012.43.3755&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0038">
<span class="label">38.</span><cite>
Hayashi H., Kurata T., Takiguchi Y., et al., “Randomized Phase II Trial Comparing Site‐Specific Treatment Based on Gene Expression Profiling with Carboplatin and Paclitaxel for Patients with Cancer of Unknown Primary Site,” Journal of Clinical Oncology
37 (2019): 570–579.
</cite> [<a href="https://doi.org/10.1200/JCO.18.00771" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30653423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Randomized%20Phase%20II%20Trial%20Comparing%20Site%E2%80%90Specific%20Treatment%20Based%20on%20Gene%20Expression%20Profiling%20with%20Carboplatin%20and%20Paclitaxel%20for%20Patients%20with%20Cancer%20of%20Unknown%20Primary%20Site&amp;author=H.%20Hayashi&amp;author=T.%20Kurata&amp;author=Y.%20Takiguchi&amp;volume=37&amp;publication_year=2019&amp;pages=570-579&amp;pmid=30653423&amp;doi=10.1200/JCO.18.00771&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0039">
<span class="label">39.</span><cite>
Hayashi H., Takiguchi Y., Minami H., et al., “Site‐Specific and Targeted Therapy Based on Molecular Profiling by Next‐Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial,” JAMA Oncology
6 (2020): 1931–1938.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2020.4643" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7563669/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33057591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncology&amp;title=Site%E2%80%90Specific%20and%20Targeted%20Therapy%20Based%20on%20Molecular%20Profiling%20by%20Next%E2%80%90Generation%20Sequencing%20for%20Cancer%20of%20Unknown%20Primary%20Site:%20A%20Nonrandomized%20Phase%202%20Clinical%20Trial&amp;author=H.%20Hayashi&amp;author=Y.%20Takiguchi&amp;author=H.%20Minami&amp;volume=6&amp;publication_year=2020&amp;pages=1931-1938&amp;pmid=33057591&amp;doi=10.1001/jamaoncol.2020.4643&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0040">
<span class="label">40.</span><cite>
Fusco M. J., Knepper T. C., Balliu J., et al., “Evaluation of Targeted Next‐Generation Sequencing for the Management of Patients Diagnosed With a Cancer of Unknown Primary,” The Oncologist
27 (2022): e9–e17.
</cite> [<a href="https://doi.org/10.1093/oncolo/oyab014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8842368/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35305098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Oncologist&amp;title=Evaluation%20of%20Targeted%20Next%E2%80%90Generation%20Sequencing%20for%20the%20Management%20of%20Patients%20Diagnosed%20With%20a%20Cancer%20of%20Unknown%20Primary&amp;author=M.%20J.%20Fusco&amp;author=T.%20C.%20Knepper&amp;author=J.%20Balliu&amp;volume=27&amp;publication_year=2022&amp;pages=e9-e17&amp;pmid=35305098&amp;doi=10.1093/oncolo/oyab014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0041">
<span class="label">41.</span><cite>
XL Z. L., Zhang X., Jiang S., et al., “A Randomized Phase III Trial of Site‐specific Therapy Guided by the 90‐gene Expression Assay versus Empiric Chemotherapy in Patients With Cancer of Unknown Primary,” Annals of Oncology
34 (2023): S711–S731.</cite> [<a href="https://doi.org/10.1016/S1470-2045(24)00313-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39068945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=A%20Randomized%20Phase%20III%20Trial%20of%20Site%E2%80%90specific%20Therapy%20Guided%20by%20the%2090%E2%80%90gene%20Expression%20Assay%20versus%20Empiric%20Chemotherapy%20in%20Patients%20With%20Cancer%20of%20Unknown%20Primary&amp;author=Z.%20L.%20XL&amp;author=X.%20Zhang&amp;author=S.%20Jiang&amp;volume=34&amp;publication_year=2023&amp;pages=S711-S731&amp;pmid=39068945&amp;doi=10.1016/S1470-2045(24)00313-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0042">
<span class="label">42.</span><cite>
Liu X., Zhang X., Jiang S., et al., “Site‐specific Therapy Guided by a 90‐gene Expression Assay versus Empirical Chemotherapy in Patients With Cancer of Unknown Primary (Fudan CUP‐001): A Randomised Controlled Trial,” The Lancet Oncology (2024).</cite> [<a href="https://doi.org/10.1016/S1470-2045(24)00313-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39068945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet%20Oncology&amp;title=Site%E2%80%90specific%20Therapy%20Guided%20by%20a%2090%E2%80%90gene%20Expression%20Assay%20versus%20Empirical%20Chemotherapy%20in%20Patients%20With%20Cancer%20of%20Unknown%20Primary%20(Fudan%20CUP%E2%80%90001):%20A%20Randomised%20Controlled%20Trial&amp;author=X.%20Liu&amp;author=X.%20Zhang&amp;author=S.%20Jiang&amp;publication_year=2024&amp;pmid=39068945&amp;doi=10.1016/S1470-2045(24)00313-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0043">
<span class="label">43.</span><cite>
Rassy E., Labaki C., Chebel R., et al., “Systematic Review of the CUP Trials Characteristics and Perspectives for next‐generation Studies,” Cancer Treatment Reviews
107 (2022): 102407.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2022.102407" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35569387/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treatment%20Reviews&amp;title=Systematic%20Review%20of%20the%20CUP%20Trials%20Characteristics%20and%20Perspectives%20for%20next%E2%80%90generation%20Studies&amp;author=E.%20Rassy&amp;author=C.%20Labaki&amp;author=R.%20Chebel&amp;volume=107&amp;publication_year=2022&amp;pages=102407&amp;pmid=35569387&amp;doi=10.1016/j.ctrv.2022.102407&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0044">
<span class="label">44.</span><cite>
Urban D., Rao A., Bressel M., Lawrence Y. R., and Mileshkin L., “Cancer of Unknown Primary: A Population‐based Analysis of Temporal Change and Socioeconomic Disparities,” British Journal of Cancer
109 (2013): 1318–1324.
</cite> [<a href="https://doi.org/10.1038/bjc.2013.386" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3778275/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23860528/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Cancer%20of%20Unknown%20Primary:%20A%20Population%E2%80%90based%20Analysis%20of%20Temporal%20Change%20and%20Socioeconomic%20Disparities&amp;author=D.%20Urban&amp;author=A.%20Rao&amp;author=M.%20Bressel&amp;author=Y.%20R.%20Lawrence&amp;author=L.%20Mileshkin&amp;volume=109&amp;publication_year=2013&amp;pages=1318-1324&amp;pmid=23860528&amp;doi=10.1038/bjc.2013.386&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0045">
<span class="label">45.</span><cite>
Brewster D. H., Lang J., Bhatti L. A., Thomson C. S., and Oien K. A., “Descriptive Epidemiology of Cancer of Unknown Primary Site in Scotland, 1961–2010,” Cancer Epidemiology
38 (2014): 227–234.
</cite> [<a href="https://doi.org/10.1016/j.canep.2014.03.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24726751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Epidemiology&amp;title=Descriptive%20Epidemiology%20of%20Cancer%20of%20Unknown%20Primary%20Site%20in%20Scotland,%201961%E2%80%932010&amp;author=D.%20H.%20Brewster&amp;author=J.%20Lang&amp;author=L.%20A.%20Bhatti&amp;author=C.%20S.%20Thomson&amp;author=K.%20A.%20Oien&amp;volume=38&amp;publication_year=2014&amp;pages=227-234&amp;pmid=24726751&amp;doi=10.1016/j.canep.2014.03.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0046">
<span class="label">46.</span><cite>
Randen M., Rutqvist L. E., and Johansson H., “Cancer Patients Without a Known Primary: Incidence and Survival Trends in Sweden 1960–2007,” Acta Oncologica
48 (2009): 915–920.
</cite> [<a href="https://doi.org/10.1080/02841860902862503" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19363713/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Oncologica&amp;title=Cancer%20Patients%20Without%20a%20Known%20Primary:%20Incidence%20and%20Survival%20Trends%20in%20Sweden%201960%E2%80%932007&amp;author=M.%20Randen&amp;author=L.%20E.%20Rutqvist&amp;author=H.%20Johansson&amp;volume=48&amp;publication_year=2009&amp;pages=915-920&amp;pmid=19363713&amp;doi=10.1080/02841860902862503&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0047">
<span class="label">47.</span><cite>
Mnatsakanyan E., Tung W. C., Caine B., and Smith‐Gagen J., “Cancer of Unknown Primary: Time Trends in Incidence, United States,” Cancer Causes &amp; Control
25 (2014): 747–757.
</cite> [<a href="https://doi.org/10.1007/s10552-014-0378-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24710663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Causes%20&amp;%20Control&amp;title=Cancer%20of%20Unknown%20Primary:%20Time%20Trends%20in%20Incidence,%20United%20States&amp;author=E.%20Mnatsakanyan&amp;author=W.%20C.%20Tung&amp;author=B.%20Caine&amp;author=J.%20Smith%E2%80%90Gagen&amp;volume=25&amp;publication_year=2014&amp;pages=747-757&amp;pmid=24710663&amp;doi=10.1007/s10552-014-0378-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0048">
<span class="label">48.</span><cite>
Qi P., Sun Y., Liu X., et al., “Clinicopathological, Molecular and Prognostic Characteristics of Cancer of Unknown Primary in China: An Analysis of 1420 Cases,” Cancer Medicine
12 (2023): 1177–1188.
</cite> [<a href="https://doi.org/10.1002/cam4.4973" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9883567/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35822433/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Medicine&amp;title=Clinicopathological,%20Molecular%20and%20Prognostic%20Characteristics%20of%20Cancer%20of%20Unknown%20Primary%20in%20China:%20An%20Analysis%20of%201420%20Cases&amp;author=P.%20Qi&amp;author=Y.%20Sun&amp;author=X.%20Liu&amp;volume=12&amp;publication_year=2023&amp;pages=1177-1188&amp;pmid=35822433&amp;doi=10.1002/cam4.4973&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0049">
<span class="label">49.</span><cite>
El Rassy E., Kattan J., and Pavlidis N., “A New Entity of Abdominal Squamous Cell Carcinoma of Unknown Primary,” European Journal of Clinical Investigation
49 (2019): 13111.</cite> [<a href="https://doi.org/10.1111/eci.13111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30908618/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Clinical%20Investigation&amp;title=A%20New%20Entity%20of%20Abdominal%20Squamous%20Cell%20Carcinoma%20of%20Unknown%20Primary&amp;author=E.%20El%20Rassy&amp;author=J.%20Kattan&amp;author=N.%20Pavlidis&amp;volume=49&amp;publication_year=2019&amp;pages=13111&amp;pmid=30908618&amp;doi=10.1111/eci.13111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0050">
<span class="label">50.</span><cite>
Chen A. M., “Management of Unknown Primary Head and Neck Cancer With Radiation Therapy in the Era of human Papillomavirus (HPV): No Longer Cutting Down the Tree to Get an Apple,” Radiotherapy and Oncology
189 (2023): 109952.
</cite> [<a href="https://doi.org/10.1016/j.radonc.2023.109952" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37844736/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Radiotherapy%20and%20Oncology&amp;title=Management%20of%20Unknown%20Primary%20Head%20and%20Neck%20Cancer%20With%20Radiation%20Therapy%20in%20the%20Era%20of%20human%20Papillomavirus%20(HPV):%20No%20Longer%20Cutting%20Down%20the%20Tree%20to%20Get%20an%20Apple&amp;author=A.%20M.%20Chen&amp;volume=189&amp;publication_year=2023&amp;pages=109952&amp;pmid=37844736&amp;doi=10.1016/j.radonc.2023.109952&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0051">
<span class="label">51.</span><cite>
Filippini D. M., Broseghini E., Carosi F., et al., “A Systematic Review of Diagnostic and Prognostic Biomarkers for Head and Neck Cancer of Unknown Primary: An Unmet Clinical Need,” Diagnostics (Basel)
13 (2023).</cite> [<a href="https://doi.org/10.3390/diagnostics13081492" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10138245/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37189593/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics%20(Basel)&amp;title=A%20Systematic%20Review%20of%20Diagnostic%20and%20Prognostic%20Biomarkers%20for%20Head%20and%20Neck%20Cancer%20of%20Unknown%20Primary:%20An%20Unmet%20Clinical%20Need&amp;author=D.%20M.%20Filippini&amp;author=E.%20Broseghini&amp;author=F.%20Carosi&amp;volume=13&amp;publication_year=2023&amp;pmid=37189593&amp;doi=10.3390/diagnostics13081492&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0052">
<span class="label">52.</span><cite>
Kaaks R., Sookthai D., Hemminki K., et al., “Risk Factors for Cancers of Unknown Primary Site: Results From the Prospective EPIC Cohort,” International Journal of Cancer
135 (2014): 2475–2481.
</cite> [<a href="https://doi.org/10.1002/ijc.28874" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24692151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Cancer&amp;title=Risk%20Factors%20for%20Cancers%20of%20Unknown%20Primary%20Site:%20Results%20From%20the%20Prospective%20EPIC%20Cohort&amp;author=R.%20Kaaks&amp;author=D.%20Sookthai&amp;author=K.%20Hemminki&amp;volume=135&amp;publication_year=2014&amp;pages=2475-2481&amp;pmid=24692151&amp;doi=10.1002/ijc.28874&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0053">
<span class="label">53.</span><cite>
Hermans K., van den Brandt P. A., Loef C., Jansen R. L. H., and Schouten L. J., “Alcohol Consumption, Cigarette Smoking and Cancer of Unknown Primary Risk: Results From the Netherlands Cohort Study,” International Journal of Cancer
148 (2021): 1586–1597.
</cite> [<a href="https://doi.org/10.1002/ijc.33328" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7894525/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33022785/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Cancer&amp;title=Alcohol%20Consumption,%20Cigarette%20Smoking%20and%20Cancer%20of%20Unknown%20Primary%20Risk:%20Results%20From%20the%20Netherlands%20Cohort%20Study&amp;author=K.%20Hermans&amp;author=P.%20A.%20van%20den%20Brandt&amp;author=C.%20Loef&amp;author=R.%20L.%20H.%20Jansen&amp;author=L.%20J.%20Schouten&amp;volume=148&amp;publication_year=2021&amp;pages=1586-1597&amp;pmid=33022785&amp;doi=10.1002/ijc.33328&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0054">
<span class="label">54.</span><cite>
Hemminki K., Pavlidis N., Tsilidis K. K., Sundquist K., and Ji J., “Age‐Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model,” Scientific Reports
6 (2016): 23725.
</cite> [<a href="https://doi.org/10.1038/srep23725" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4806321/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27009354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Age%E2%80%90Dependent%20Metastatic%20Spread%20and%20Survival:%20Cancer%20of%20Unknown%20Primary%20as%20a%20Model&amp;author=K.%20Hemminki&amp;author=N.%20Pavlidis&amp;author=K.%20K.%20Tsilidis&amp;author=K.%20Sundquist&amp;author=J.%20Ji&amp;volume=6&amp;publication_year=2016&amp;pages=23725&amp;pmid=27009354&amp;doi=10.1038/srep23725&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0055">
<span class="label">55.</span><cite>
Hemminki K., Bevier M., Hemminki A., and Sundquist J., “Survival in Cancer of Unknown Primary Site: Population‐based Analysis by Site and Histology,” Annals of Oncology
23 (2012): 1854–1863.
</cite> [<a href="https://doi.org/10.1093/annonc/mdr536" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22115926/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Survival%20in%20Cancer%20of%20Unknown%20Primary%20Site:%20Population%E2%80%90based%20Analysis%20by%20Site%20and%20Histology&amp;author=K.%20Hemminki&amp;author=M.%20Bevier&amp;author=A.%20Hemminki&amp;author=J.%20Sundquist&amp;volume=23&amp;publication_year=2012&amp;pages=1854-1863&amp;pmid=22115926&amp;doi=10.1093/annonc/mdr536&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0056">
<span class="label">56.</span><cite>
Hermans K., van den Brandt P. A., Loef C., Jansen R. L. H., and Schouten L. J., “Anthropometry, Physical Activity and Cancer of Unknown Primary (CUP) Risk: Results From the Netherlands Cohort Study,” Cancer Epidemiology
69 (2020): 101836.
</cite> [<a href="https://doi.org/10.1016/j.canep.2020.101836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33099214/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Epidemiology&amp;title=Anthropometry,%20Physical%20Activity%20and%20Cancer%20of%20Unknown%20Primary%20(CUP)%20Risk:%20Results%20From%20the%20Netherlands%20Cohort%20Study&amp;author=K.%20Hermans&amp;author=P.%20A.%20van%20den%20Brandt&amp;author=C.%20Loef&amp;author=R.%20L.%20H.%20Jansen&amp;author=L.%20J.%20Schouten&amp;volume=69&amp;publication_year=2020&amp;pages=101836&amp;pmid=33099214&amp;doi=10.1016/j.canep.2020.101836&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0057">
<span class="label">57.</span><cite>
Hermans K., van den Brandt P. A., Loef C., Jansen R. L. H., and Schouten L. J., “Vegetable and Fruit Consumption and Cancer of Unknown Primary Risk: Results From the Netherlands Cohort Study on Diet and Cancer,” BMC Cancer
22 (2022): 399.
</cite> [<a href="https://doi.org/10.1186/s12885-022-09502-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9006455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35418049/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Vegetable%20and%20Fruit%20Consumption%20and%20Cancer%20of%20Unknown%20Primary%20Risk:%20Results%20From%20the%20Netherlands%20Cohort%20Study%20on%20Diet%20and%20Cancer&amp;author=K.%20Hermans&amp;author=P.%20A.%20van%20den%20Brandt&amp;author=C.%20Loef&amp;author=R.%20L.%20H.%20Jansen&amp;author=L.%20J.%20Schouten&amp;volume=22&amp;publication_year=2022&amp;pages=399&amp;pmid=35418049&amp;doi=10.1186/s12885-022-09502-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0058">
<span class="label">58.</span><cite>
Lopez‐Lazaro M., “The Migration Ability of Stem Cells Can Explain the Existence of Cancer of Unknown Primary Site. Rethinking Metastasis,” Oncoscience
2 (2015): 467–475.
</cite> [<a href="https://doi.org/10.18632/oncoscience.159" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4468332/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26097879/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncoscience&amp;title=The%20Migration%20Ability%20of%20Stem%20Cells%20Can%20Explain%20the%20Existence%20of%20Cancer%20of%20Unknown%20Primary%20Site.%20Rethinking%20Metastasis&amp;author=M.%20Lopez%E2%80%90Lazaro&amp;volume=2&amp;publication_year=2015&amp;pages=467-475&amp;pmid=26097879&amp;doi=10.18632/oncoscience.159&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0059">
<span class="label">59.</span><cite>
Olivier T., Fernandez E., Labidi‐Galy I., et al., “Redefining Cancer of Unknown Primary: Is Precision Medicine Really Shifting the Paradigm?,” Cancer Treatment Reviews
97 (2021): 102204.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2021.102204" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33866225/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Treatment%20Reviews&amp;title=Redefining%20Cancer%20of%20Unknown%20Primary:%20Is%20Precision%20Medicine%20Really%20Shifting%20the%20Paradigm?&amp;author=T.%20Olivier&amp;author=E.%20Fernandez&amp;author=I.%20Labidi%E2%80%90Galy&amp;volume=97&amp;publication_year=2021&amp;pages=102204&amp;pmid=33866225&amp;doi=10.1016/j.ctrv.2021.102204&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0060">
<span class="label">60.</span><cite>
Rassy E., Assi T., and Pavlidis N., “Exploring the Biological Hallmarks of Cancer of Unknown Primary: Where Do We Stand Today?,” British Journal of Cancer
122 (2020): 1124–1132.
</cite> [<a href="https://doi.org/10.1038/s41416-019-0723-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7156745/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32042068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Exploring%20the%20Biological%20Hallmarks%20of%20Cancer%20of%20Unknown%20Primary:%20Where%20Do%20We%20Stand%20Today?&amp;author=E.%20Rassy&amp;author=T.%20Assi&amp;author=N.%20Pavlidis&amp;volume=122&amp;publication_year=2020&amp;pages=1124-1132&amp;pmid=32042068&amp;doi=10.1038/s41416-019-0723-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0061">
<span class="label">61.</span><cite>
Joosse S. A. and Pantel K., “Genetic Traits for Hematogeneous Tumor Cell Dissemination in Cancer Patients,” Cancer and Metastasis Reviews
35 (2016): 41–48.
</cite> [<a href="https://doi.org/10.1007/s10555-016-9611-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26931653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20and%20Metastasis%20Reviews&amp;title=Genetic%20Traits%20for%20Hematogeneous%20Tumor%20Cell%20Dissemination%20in%20Cancer%20Patients&amp;author=S.%20A.%20Joosse&amp;author=K.%20Pantel&amp;volume=35&amp;publication_year=2016&amp;pages=41-48&amp;pmid=26931653&amp;doi=10.1007/s10555-016-9611-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0062">
<span class="label">62.</span><cite>
Conway A. M., Mitchell C., Kilgour E., Brady G., Dive C., and Cook N., “Molecular Characterisation and Liquid Biomarkers in Carcinoma of Unknown Primary (CUP): Taking the ‘U’ out of ‘CUP’,” British Journal of Cancer
120 (2019): 141–153.
</cite> [<a href="https://doi.org/10.1038/s41416-018-0332-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6342985/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30580378/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Molecular%20Characterisation%20and%20Liquid%20Biomarkers%20in%20Carcinoma%20of%20Unknown%20Primary%20(CUP):%20Taking%20the%20%E2%80%98U%E2%80%99%20out%20of%20%E2%80%98CUP%E2%80%99&amp;author=A.%20M.%20Conway&amp;author=C.%20Mitchell&amp;author=E.%20Kilgour&amp;author=G.%20Brady&amp;author=C.%20Dive&amp;volume=120&amp;publication_year=2019&amp;pages=141-153&amp;pmid=30580378&amp;doi=10.1038/s41416-018-0332-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0063">
<span class="label">63.</span><cite>
Massard C., Loriot Y., and Fizazi K., “Carcinomas of an Unknown Primary Origin–Diagnosis and Treatment,” Nature Reviews Clinical Oncology
8 (2011): 701–710.</cite> [<a href="https://doi.org/10.1038/nrclinonc.2011.158" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22048624/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Carcinomas%20of%20an%20Unknown%20Primary%20Origin%E2%80%93Diagnosis%20and%20Treatment&amp;author=C.%20Massard&amp;author=Y.%20Loriot&amp;author=K.%20Fizazi&amp;volume=8&amp;publication_year=2011&amp;pages=701-710&amp;pmid=22048624&amp;doi=10.1038/nrclinonc.2011.158&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0064">
<span class="label">64.</span><cite>
Boussios S., Rassy E., Samartzis E., et al., “Melanoma of Unknown Primary: New Perspectives for an Old Story,” Critical Reviews in Oncology/Hematology
158 (2021): 103208.
</cite> [<a href="https://doi.org/10.1016/j.critrevonc.2020.103208" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33383207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Critical%20Reviews%20in%20Oncology/Hematology&amp;title=Melanoma%20of%20Unknown%20Primary:%20New%20Perspectives%20for%20an%20Old%20Story&amp;author=S.%20Boussios&amp;author=E.%20Rassy&amp;author=E.%20Samartzis&amp;volume=158&amp;publication_year=2021&amp;pages=103208&amp;pmid=33383207&amp;doi=10.1016/j.critrevonc.2020.103208&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0065">
<span class="label">65.</span><cite>
Ross J. S., Sokol E. S., Moch H., et al., “Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design,” The Oncologist
26 (2021): e394–e402.
</cite> [<a href="https://doi.org/10.1002/onco.13597" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7930409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33219618/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Oncologist&amp;title=Comprehensive%20Genomic%20Profiling%20of%20Carcinoma%20of%20Unknown%20Primary%20Origin:%20Retrospective%20Molecular%20Classification%20Considering%20the%20CUPISCO%20Study%20Design&amp;author=J.%20S.%20Ross&amp;author=E.%20S.%20Sokol&amp;author=H.%20Moch&amp;volume=26&amp;publication_year=2021&amp;pages=e394-e402&amp;pmid=33219618&amp;doi=10.1002/onco.13597&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0066">
<span class="label">66.</span><cite>
Varghese A. M., Arora A., Capanu M., et al., “Clinical and Molecular Characterization of Patients With Cancer of Unknown Primary in the Modern Era,” Annals of Oncology
28 (2017): 3015–3021.
</cite> [<a href="https://doi.org/10.1093/annonc/mdx545" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5834064/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29045506/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Clinical%20and%20Molecular%20Characterization%20of%20Patients%20With%20Cancer%20of%20Unknown%20Primary%20in%20the%20Modern%20Era&amp;author=A.%20M.%20Varghese&amp;author=A.%20Arora&amp;author=M.%20Capanu&amp;volume=28&amp;publication_year=2017&amp;pages=3015-3021&amp;pmid=29045506&amp;doi=10.1093/annonc/mdx545&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0067">
<span class="label">67.</span><cite>
Es H. A., Mahdizadeh H., Asl A. A. H., and Totonchi M., “Genomic Alterations and Possible Druggable Mutations in Carcinoma of Unknown Primary (CUP),” Scientific Reports
11 (2021): 15112.
</cite> [<a href="https://doi.org/10.1038/s41598-021-94678-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8302572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34302033/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scientific%20Reports&amp;title=Genomic%20Alterations%20and%20Possible%20Druggable%20Mutations%20in%20Carcinoma%20of%20Unknown%20Primary%20(CUP)&amp;author=H.%20A.%20Es&amp;author=H.%20Mahdizadeh&amp;author=A.%20A.%20H.%20Asl&amp;author=M.%20Totonchi&amp;volume=11&amp;publication_year=2021&amp;pages=15112&amp;pmid=34302033&amp;doi=10.1038/s41598-021-94678-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0068">
<span class="label">68.</span><cite>
Wang X., Beharry A., Sheffield B. S., and Cheema P. K., “Feasibility of Point‐of‐Care Genomic Profiling in the Diagnosis and Treatment of Cancer of Unknown Primary,” The Oncologist
28 (2023): 474–478.
</cite> [<a href="https://doi.org/10.1093/oncolo/oyad054" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10243757/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36933203/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Oncologist&amp;title=Feasibility%20of%20Point%E2%80%90of%E2%80%90Care%20Genomic%20Profiling%20in%20the%20Diagnosis%20and%20Treatment%20of%20Cancer%20of%20Unknown%20Primary&amp;author=X.%20Wang&amp;author=A.%20Beharry&amp;author=B.%20S.%20Sheffield&amp;author=P.%20K.%20Cheema&amp;volume=28&amp;publication_year=2023&amp;pages=474-478&amp;pmid=36933203&amp;doi=10.1093/oncolo/oyad054&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0069">
<span class="label">69.</span><cite>
Westphalen C. B., Federer‐Gsponer J., Pauli C., et al., “Baseline Mutational Profiles of Patients With Carcinoma of Unknown Primary Origin Enrolled in the CUPISCO Study,” ESMO Open
8 (2023): 102035.
</cite> [<a href="https://doi.org/10.1016/j.esmoop.2023.102035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10774891/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37922692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESMO%20Open&amp;title=Baseline%20Mutational%20Profiles%20of%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Origin%20Enrolled%20in%20the%20CUPISCO%20Study&amp;author=C.%20B.%20Westphalen&amp;author=J.%20Federer%E2%80%90Gsponer&amp;author=C.%20Pauli&amp;volume=8&amp;publication_year=2023&amp;pages=102035&amp;pmid=37922692&amp;doi=10.1016/j.esmoop.2023.102035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0070">
<span class="label">70.</span><cite>
Verginelli F., Pisacane A., Gambardella G., et al., “Cancer of Unknown Primary Stem‐Like Cells Model Multi‐organ Metastasis and Unveil Liability to MEK Inhibition,” Nature Communications
12 (2021): 2498.</cite> [<a href="https://doi.org/10.1038/s41467-021-22643-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8093243/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33941777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Cancer%20of%20Unknown%20Primary%20Stem%E2%80%90Like%20Cells%20Model%20Multi%E2%80%90organ%20Metastasis%20and%20Unveil%20Liability%20to%20MEK%20Inhibition&amp;author=F.%20Verginelli&amp;author=A.%20Pisacane&amp;author=G.%20Gambardella&amp;volume=12&amp;publication_year=2021&amp;pages=2498&amp;pmid=33941777&amp;doi=10.1038/s41467-021-22643-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0071">
<span class="label">71.</span><cite>
Mohrmann L., Werner M., Oles M., et al., “Comprehensive Genomic and Epigenomic Analysis in Cancer of Unknown Primary Guides Molecularly‐informed Therapies Despite Heterogeneity,” Nature Communications
13 (2022): 4485.</cite> [<a href="https://doi.org/10.1038/s41467-022-31866-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9346116/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35918329/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Comprehensive%20Genomic%20and%20Epigenomic%20Analysis%20in%20Cancer%20of%20Unknown%20Primary%20Guides%20Molecularly%E2%80%90informed%20Therapies%20Despite%20Heterogeneity&amp;author=L.%20Mohrmann&amp;author=M.%20Werner&amp;author=M.%20Oles&amp;volume=13&amp;publication_year=2022&amp;pages=4485&amp;pmid=35918329&amp;doi=10.1038/s41467-022-31866-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0072">
<span class="label">72.</span><cite>
Kim H. M. and Koo J. S., “Programmed Death‐ligand 1 Expression in Carcinoma of Unknown Primary,” BMC Cancer
24 (2024): 689.
</cite> [<a href="https://doi.org/10.1186/s12885-024-12437-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11155179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38844907/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Programmed%20Death%E2%80%90ligand%201%20Expression%20in%20Carcinoma%20of%20Unknown%20Primary&amp;author=H.%20M.%20Kim&amp;author=J.%20S.%20Koo&amp;volume=24&amp;publication_year=2024&amp;pages=689&amp;pmid=38844907&amp;doi=10.1186/s12885-024-12437-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0073">
<span class="label">73.</span><cite>
Posner A., Sivakumaran T., Pattison A., et al., “Immune and Genomic Biomarkers of Immunotherapy Response in Cancer of Unknown Primary,” Journal for ImmunoTherapy of Cancer
11 (2023).</cite> [<a href="https://doi.org/10.1136/jitc-2022-005809" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10098268/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36720497/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20for%20ImmunoTherapy%20of%20Cancer&amp;title=Immune%20and%20Genomic%20Biomarkers%20of%20Immunotherapy%20Response%20in%20Cancer%20of%20Unknown%20Primary&amp;author=A.%20Posner&amp;author=T.%20Sivakumaran&amp;author=A.%20Pattison&amp;volume=11&amp;publication_year=2023&amp;pmid=36720497&amp;doi=10.1136/jitc-2022-005809&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0074">
<span class="label">74.</span><cite>
Gatalica Z., Xiu J., Swensen J., and Vranic S., “Comprehensive Analysis of Cancers of Unknown Primary for the Biomarkers of Response to Immune Checkpoint Blockade Therapy,” European Journal of Cancer
94 (2018): 179–186.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2018.02.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29571084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=Comprehensive%20Analysis%20of%20Cancers%20of%20Unknown%20Primary%20for%20the%20Biomarkers%20of%20Response%20to%20Immune%20Checkpoint%20Blockade%20Therapy&amp;author=Z.%20Gatalica&amp;author=J.%20Xiu&amp;author=J.%20Swensen&amp;author=S.%20Vranic&amp;volume=94&amp;publication_year=2018&amp;pages=179-186&amp;pmid=29571084&amp;doi=10.1016/j.ejca.2018.02.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0075">
<span class="label">75.</span><cite>
Chebly A., Yammine T., Boussios S., Pavlidis N., and Rassy E., “Chromosomal Instability in Cancers of Unknown Primary,” European Journal of Cancer
172 (2022): 323–325.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2022.06.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35820241/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=Chromosomal%20Instability%20in%20Cancers%20of%20Unknown%20Primary&amp;author=A.%20Chebly&amp;author=T.%20Yammine&amp;author=S.%20Boussios&amp;author=N.%20Pavlidis&amp;author=E.%20Rassy&amp;volume=172&amp;publication_year=2022&amp;pages=323-325&amp;pmid=35820241&amp;doi=10.1016/j.ejca.2022.06.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0076">
<span class="label">76.</span><cite>
Li J., Hubisz M. J., Earlie E. M., et al., “Non‐cell‐autonomous Cancer Progression From Chromosomal Instability,” Nature
620 (2023): 1080–1088.
</cite> [<a href="https://doi.org/10.1038/s41586-023-06464-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10468402/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37612508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Non%E2%80%90cell%E2%80%90autonomous%20Cancer%20Progression%20From%20Chromosomal%20Instability&amp;author=J.%20Li&amp;author=M.%20J.%20Hubisz&amp;author=E.%20M.%20Earlie&amp;volume=620&amp;publication_year=2023&amp;pages=1080-1088&amp;pmid=37612508&amp;doi=10.1038/s41586-023-06464-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0077">
<span class="label">77.</span><cite>
Vitale I., Galassi C., and Galluzzi L., “Chromosomal Instability Drives Immunosuppression and Metastatic Dissemination,” Cell Research
34 (2024): 7–8.
</cite> [<a href="https://doi.org/10.1038/s41422-023-00876-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10770350/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37739994/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell%20Research&amp;title=Chromosomal%20Instability%20Drives%20Immunosuppression%20and%20Metastatic%20Dissemination&amp;author=I.%20Vitale&amp;author=C.%20Galassi&amp;author=L.%20Galluzzi&amp;volume=34&amp;publication_year=2024&amp;pages=7-8&amp;pmid=37739994&amp;doi=10.1038/s41422-023-00876-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0078">
<span class="label">78.</span><cite>
Al‐Rawi D. H., Lettera E., Li J., DiBona M., and Bakhoum S. F., “Targeting Chromosomal Instability in Patients With Cancer,” Nature Reviews Clinical Oncology
21 (2024): 645–659.</cite> [<a href="https://doi.org/10.1038/s41571-024-00923-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38992122/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Targeting%20Chromosomal%20Instability%20in%20Patients%20With%20Cancer&amp;author=D.%20H.%20Al%E2%80%90Rawi&amp;author=E.%20Lettera&amp;author=J.%20Li&amp;author=M.%20DiBona&amp;author=S.%20F.%20Bakhoum&amp;volume=21&amp;publication_year=2024&amp;pages=645-659&amp;pmid=38992122&amp;doi=10.1038/s41571-024-00923-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0079">
<span class="label">79.</span><cite>
Hainsworth J. D., Lennington W. J., and Greco F. A., “Overexpression of Her‐2 in Patients With Poorly Differentiated Carcinoma or Poorly Differentiated Adenocarcinoma of Unknown Primary Site,” Journal of Clinical Oncology
18 (2000): 632–635.
</cite> [<a href="https://doi.org/10.1200/JCO.2000.18.3.632" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10653878/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Overexpression%20of%20Her%E2%80%902%20in%20Patients%20With%20Poorly%20Differentiated%20Carcinoma%20or%20Poorly%20Differentiated%20Adenocarcinoma%20of%20Unknown%20Primary%20Site&amp;author=J.%20D.%20Hainsworth&amp;author=W.%20J.%20Lennington&amp;author=F.%20A.%20Greco&amp;volume=18&amp;publication_year=2000&amp;pages=632-635&amp;pmid=10653878&amp;doi=10.1200/JCO.2000.18.3.632&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0080">
<span class="label">80.</span><cite>
Briasoulis E., Tsokos M., Fountzilas G., et al., “Bcl2 and p53 Protein Expression in Metastatic Carcinoma of Unknown Primary Origin: Biological and Clinical Implications. A Hellenic Co‐operative Oncology Group Study,” Anticancer Research
18 (1998): 1907–1914.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9677443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Research&amp;title=Bcl2%20and%20p53%20Protein%20Expression%20in%20Metastatic%20Carcinoma%20of%20Unknown%20Primary%20Origin:%20Biological%20and%20Clinical%20Implications.%20A%20Hellenic%20Co%E2%80%90operative%20Oncology%20Group%20Study&amp;author=E.%20Briasoulis&amp;author=M.%20Tsokos&amp;author=G.%20Fountzilas&amp;volume=18&amp;publication_year=1998&amp;pages=1907-1914&amp;pmid=9677443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0081">
<span class="label">81.</span><cite>
Pavlidis N., Briassoulis E., Bai M., Fountzilas G., and Agnantis N., “Overexpression of C‐myc, Ras and C‐erbB‐2 Oncoproteins in Carcinoma of Unknown Primary Origin,” Anticancer Research
15 (1995): 2563–2567.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/8669824/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Research&amp;title=Overexpression%20of%20C%E2%80%90myc,%20Ras%20and%20C%E2%80%90erbB%E2%80%902%20Oncoproteins%20in%20Carcinoma%20of%20Unknown%20Primary%20Origin&amp;author=N.%20Pavlidis&amp;author=E.%20Briassoulis&amp;author=M.%20Bai&amp;author=G.%20Fountzilas&amp;author=N.%20Agnantis&amp;volume=15&amp;publication_year=1995&amp;pages=2563-2567&amp;pmid=8669824&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0082">
<span class="label">82.</span><cite>
Karavasilis V., Malamou‐Mitsi V., Briasoulis E., et al., “Matrix Metalloproteinases in Carcinoma of Unknown Primary,” Cancer
104 (2005): 2282–2287.
</cite> [<a href="https://doi.org/10.1002/cncr.21454" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16220559/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Matrix%20Metalloproteinases%20in%20Carcinoma%20of%20Unknown%20Primary&amp;author=V.%20Karavasilis&amp;author=V.%20Malamou%E2%80%90Mitsi&amp;author=E.%20Briasoulis&amp;volume=104&amp;publication_year=2005&amp;pages=2282-2287&amp;pmid=16220559&amp;doi=10.1002/cncr.21454&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0083">
<span class="label">83.</span><cite>
Qin L., Tian S., Yang L., Fan J., and Zhang J., “Liver Failure as the Initial Presentation in Cancer of Unknown Primary: A Case Report,” BMC Infectious Diseases [Electronic Resource]
23 (2023): 363.
</cite> [<a href="https://doi.org/10.1186/s12879-023-08274-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10228056/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37254054/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Infectious%20Diseases%20%5BElectronic%20Resource%5D&amp;title=Liver%20Failure%20as%20the%20Initial%20Presentation%20in%20Cancer%20of%20Unknown%20Primary:%20A%20Case%20Report&amp;author=L.%20Qin&amp;author=S.%20Tian&amp;author=L.%20Yang&amp;author=J.%20Fan&amp;author=J.%20Zhang&amp;volume=23&amp;publication_year=2023&amp;pages=363&amp;pmid=37254054&amp;doi=10.1186/s12879-023-08274-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0084">
<span class="label">84.</span><cite>
Kolling S., Ventre F., Geuna E., et al., “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer?,” Frontiers in Oncology
9 (2019): 1546.
</cite> [<a href="https://doi.org/10.3389/fonc.2019.01546" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6978906/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32010631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=Metastatic%20Cancer%20of%20Unknown%20Primary%E2%80%9D%20or%20%E2%80%9CPrimary%20Metastatic%20Cancer?&amp;author=S.%20Kolling&amp;author=F.%20Ventre&amp;author=E.%20Geuna&amp;volume=9&amp;publication_year=2019&amp;pages=1546&amp;pmid=32010631&amp;doi=10.3389/fonc.2019.01546&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0085">
<span class="label">85.</span><cite>
Sun W., Wu W., Wang Q., et al., “Clinical Validation of a 90‐gene Expression Test for Tumor Tissue of Origin Diagnosis: A Large‐scale Multicenter Study of 1417 Patients,” Journal of Translational Medicine
20 (2022): 114.
</cite> [<a href="https://doi.org/10.1186/s12967-022-03318-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8900384/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35255924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Translational%20Medicine&amp;title=Clinical%20Validation%20of%20a%2090%E2%80%90gene%20Expression%20Test%20for%20Tumor%20Tissue%20of%20Origin%20Diagnosis:%20A%20Large%E2%80%90scale%20Multicenter%20Study%20of%201417%20Patients&amp;author=W.%20Sun&amp;author=W.%20Wu&amp;author=Q.%20Wang&amp;volume=20&amp;publication_year=2022&amp;pages=114&amp;pmid=35255924&amp;doi=10.1186/s12967-022-03318-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0086">
<span class="label">86.</span><cite>
Shao Y., Liu X., Hu S., et al., “Sentinel Node Theory Helps Tracking of Primary Lesions of Cancers of Unknown Primary,” BMC Cancer
20 (2020): 639.
</cite> [<a href="https://doi.org/10.1186/s12885-020-07042-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7350562/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32646508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Cancer&amp;title=Sentinel%20Node%20Theory%20Helps%20Tracking%20of%20Primary%20Lesions%20of%20Cancers%20of%20Unknown%20Primary&amp;author=Y.%20Shao&amp;author=X.%20Liu&amp;author=S.%20Hu&amp;volume=20&amp;publication_year=2020&amp;pages=639&amp;pmid=32646508&amp;doi=10.1186/s12885-020-07042-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0087">
<span class="label">87.</span><cite>
Galloway T. J. and Ridge J. A., “Management of Squamous Cancer Metastatic to Cervical Nodes with an Unknown Primary Site,” Journal of Clinical Oncology
33 (2015): 3328–3337.
</cite> [<a href="https://doi.org/10.1200/JCO.2015.61.0063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26351351/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Management%20of%20Squamous%20Cancer%20Metastatic%20to%20Cervical%20Nodes%20with%20an%20Unknown%20Primary%20Site&amp;author=T.%20J.%20Galloway&amp;author=J.%20A.%20Ridge&amp;volume=33&amp;publication_year=2015&amp;pages=3328-3337&amp;pmid=26351351&amp;doi=10.1200/JCO.2015.61.0063&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0088">
<span class="label">88.</span><cite>
Pentheroudakis G., Golfinopoulos V., and Pavlidis N., “Switching Benchmarks in Cancer of Unknown Primary: From Autopsy to Microarray,” European Journal of Cancer
43 (2007): 2026–2036.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2007.06.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17698346/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=Switching%20Benchmarks%20in%20Cancer%20of%20Unknown%20Primary:%20From%20Autopsy%20to%20Microarray&amp;author=G.%20Pentheroudakis&amp;author=V.%20Golfinopoulos&amp;author=N.%20Pavlidis&amp;volume=43&amp;publication_year=2007&amp;pages=2026-2036&amp;pmid=17698346&amp;doi=10.1016/j.ejca.2007.06.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0089">
<span class="label">89.</span><cite>
Laprovitera N., Riefolo M., Ambrosini E., Klec C., Pichler M., and Ferracin M., “Cancer of Unknown Primary: Challenges and Progress in Clinical Management,” Cancers (Basel)
13 (2021).</cite> [<a href="https://doi.org/10.3390/cancers13030451" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7866161/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33504059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Cancer%20of%20Unknown%20Primary:%20Challenges%20and%20Progress%20in%20Clinical%20Management&amp;author=N.%20Laprovitera&amp;author=M.%20Riefolo&amp;author=E.%20Ambrosini&amp;author=C.%20Klec&amp;author=M.%20Pichler&amp;volume=13&amp;publication_year=2021&amp;pmid=33504059&amp;doi=10.3390/cancers13030451&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0090">
<span class="label">90.</span><cite>
Hanzalova I. and Matter M., “Peripheral Lymphadenopathy of Unknown Origin in Adults: A Diagnostic Approach Emphasizing the Malignancy Hypothesis,” Swiss Medical Weekly: Official Journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology
154 (2024): 3549.</cite> [<a href="https://doi.org/10.57187/s.3549" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39154257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Swiss%20Medical%20Weekly:%20Official%20Journal%20of%20the%20Swiss%20Society%20of%20Infectious%20Diseases,%20the%20Swiss%20Society%20of%20Internal%20Medicine,%20the%20Swiss%20Society%20of%20Pneumology&amp;title=Peripheral%20Lymphadenopathy%20of%20Unknown%20Origin%20in%20Adults:%20A%20Diagnostic%20Approach%20Emphasizing%20the%20Malignancy%20Hypothesis&amp;author=I.%20Hanzalova&amp;author=M.%20Matter&amp;volume=154&amp;publication_year=2024&amp;pages=3549&amp;pmid=39154257&amp;doi=10.57187/s.3549&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0091">
<span class="label">91.</span><cite>
Milovic M., Popov I., and Jelic S., “Tumor Markers in Metastatic Disease From Cancer of Unknown Primary Origin,” Medical Science Monitor
8 (2002): MT25–30.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/11859288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Medical%20Science%20Monitor&amp;title=Tumor%20Markers%20in%20Metastatic%20Disease%20From%20Cancer%20of%20Unknown%20Primary%20Origin&amp;author=M.%20Milovic&amp;author=I.%20Popov&amp;author=S.%20Jelic&amp;volume=8&amp;publication_year=2002&amp;pages=MT25-30&amp;pmid=11859288&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0092">
<span class="label">92.</span><cite>
Nikolova P. N., Hadzhiyska V. H., Mladenov K. B., et al., “The Impact of 18F‐FDG PET/CT in the Clinical Management of Patients With Lymph Node Metastasis of Unknown Primary Origin,” Neoplasma
68 (2021): 180–189.
</cite> [<a href="https://doi.org/10.4149/neo_2020_200315N263" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32880466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasma&amp;title=The%20Impact%20of%2018F%E2%80%90FDG%20PET/CT%20in%20the%20Clinical%20Management%20of%20Patients%20With%20Lymph%20Node%20Metastasis%20of%20Unknown%20Primary%20Origin&amp;author=P.%20N.%20Nikolova&amp;author=V.%20H.%20Hadzhiyska&amp;author=K.%20B.%20Mladenov&amp;volume=68&amp;publication_year=2021&amp;pages=180-189&amp;pmid=32880466&amp;doi=10.4149/neo_2020_200315N263&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0093">
<span class="label">93.</span><cite>
Zaun G., Weber M., Metzenmacher M., et al., “SUV(max) above 20 in (18)F‐FDG PET/CT at Initial Diagnostic Workup Associates With Favorable Survival in Patients With Cancer of Unknown Primary,” Journal of Nuclear Medicine
64 (2023): 1191–1194.
</cite> [<a href="https://doi.org/10.2967/jnumed.122.265161" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37321823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nuclear%20Medicine&amp;title=SUV(max)%20above%2020%20in%20(18)F%E2%80%90FDG%20PET/CT%20at%20Initial%20Diagnostic%20Workup%20Associates%20With%20Favorable%20Survival%20in%20Patients%20With%20Cancer%20of%20Unknown%20Primary&amp;author=G.%20Zaun&amp;author=M.%20Weber&amp;author=M.%20Metzenmacher&amp;volume=64&amp;publication_year=2023&amp;pages=1191-1194&amp;pmid=37321823&amp;doi=10.2967/jnumed.122.265161&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0094">
<span class="label">94.</span><cite>
Rusthoven K. E., Koshy M., and Paulino A. C., “The Role of Fluorodeoxyglucose Positron Emission Tomography in Cervical Lymph Node Metastases From an Unknown Primary Tumor,” Cancer
101 (2004): 2641–2649.
</cite> [<a href="https://doi.org/10.1002/cncr.20687" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15517576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=The%20Role%20of%20Fluorodeoxyglucose%20Positron%20Emission%20Tomography%20in%20Cervical%20Lymph%20Node%20Metastases%20From%20an%20Unknown%20Primary%20Tumor&amp;author=K.%20E.%20Rusthoven&amp;author=M.%20Koshy&amp;author=A.%20C.%20Paulino&amp;volume=101&amp;publication_year=2004&amp;pages=2641-2649&amp;pmid=15517576&amp;doi=10.1002/cncr.20687&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0095">
<span class="label">95.</span><cite>
Eilsberger F., Noltenius F. E., Librizzi D., et al., “Real‐Life Performance of F‐18‐FDG PET/CT in Patients With Cervical Lymph Node Metastasis of Unknown Primary Tumor,” Biomedicines
10 (2022).</cite> [<a href="https://doi.org/10.3390/biomedicines10092095" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9495705/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36140197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biomedicines&amp;title=Real%E2%80%90Life%20Performance%20of%20F%E2%80%9018%E2%80%90FDG%20PET/CT%20in%20Patients%20With%20Cervical%20Lymph%20Node%20Metastasis%20of%20Unknown%20Primary%20Tumor&amp;author=F.%20Eilsberger&amp;author=F.%20E.%20Noltenius&amp;author=D.%20Librizzi&amp;volume=10&amp;publication_year=2022&amp;pmid=36140197&amp;doi=10.3390/biomedicines10092095&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0096">
<span class="label">96.</span><cite>
Willemse J. R. J., Lambregts D. M. J., Balduzzi S., et al., “Identifying the Primary Tumour in Patients With Cancer of Unknown Primary (CUP) Using [(18)F]FDG PET/CT: A Systematic Review and Individual Patient Data Meta‐analysis,” European Journal of Nuclear Medicine and Molecular Imaging
52 (2024): 225–236.
</cite> [<a href="https://doi.org/10.1007/s00259-024-06860-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11599304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39141069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Nuclear%20Medicine%20and%20Molecular%20Imaging&amp;title=Identifying%20the%20Primary%20Tumour%20in%20Patients%20With%20Cancer%20of%20Unknown%20Primary%20(CUP)%20Using%20%5B(18)F%5DFDG%20PET/CT:%20A%20Systematic%20Review%20and%20Individual%20Patient%20Data%20Meta%E2%80%90analysis&amp;author=J.%20R.%20J.%20Willemse&amp;author=D.%20M.%20J.%20Lambregts&amp;author=S.%20Balduzzi&amp;volume=52&amp;publication_year=2024&amp;pages=225-236&amp;pmid=39141069&amp;doi=10.1007/s00259-024-06860-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0097">
<span class="label">97.</span><cite>
Sivakumaran T., Cardin A., Callahan J., et al., “Evaluating the Utility of (18)F‐FDG PET/CT in Cancer of Unknown Primary,” Journal of Nuclear Medicine
65 (2024): 1557–1563.
</cite> [<a href="https://doi.org/10.2967/jnumed.123.267274" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39237349/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nuclear%20Medicine&amp;title=Evaluating%20the%20Utility%20of%20(18)F%E2%80%90FDG%20PET/CT%20in%20Cancer%20of%20Unknown%20Primary&amp;author=T.%20Sivakumaran&amp;author=A.%20Cardin&amp;author=J.%20Callahan&amp;volume=65&amp;publication_year=2024&amp;pages=1557-1563&amp;pmid=39237349&amp;doi=10.2967/jnumed.123.267274&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0098">
<span class="label">98.</span><cite>
Reinert C. P., Sekler J., la Fougere C., Pfannenberg C., and Gatidis S., “Impact of PET/CT on Clinical Management in Patients With Cancer of Unknown Primary‐a PET/CT Registry Study,” European Radiology
30 (2020): 1325–1333.
</cite> [<a href="https://doi.org/10.1007/s00330-019-06518-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31728688/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Radiology&amp;title=Impact%20of%20PET/CT%20on%20Clinical%20Management%20in%20Patients%20With%20Cancer%20of%20Unknown%20Primary%E2%80%90a%20PET/CT%20Registry%20Study&amp;author=C.%20P.%20Reinert&amp;author=J.%20Sekler&amp;author=C.%20la%20Fougere&amp;author=C.%20Pfannenberg&amp;author=S.%20Gatidis&amp;volume=30&amp;publication_year=2020&amp;pages=1325-1333&amp;pmid=31728688&amp;doi=10.1007/s00330-019-06518-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0099">
<span class="label">99.</span><cite>
van der Leest C., Smit E. F., Baas J., et al., “SUVmax During 18FDG‐PET Scanning in Small Cell Lung Cancer: Similar Information as in Non‐small Cell Lung Cancer?,” Lung Cancer
76 (2012): 67–71.
</cite> [<a href="https://doi.org/10.1016/j.lungcan.2011.09.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21996089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lung%20Cancer&amp;title=SUVmax%20During%2018FDG%E2%80%90PET%20Scanning%20in%20Small%20Cell%20Lung%20Cancer:%20Similar%20Information%20as%20in%20Non%E2%80%90small%20Cell%20Lung%20Cancer?&amp;author=C.%20van%20der%20Leest&amp;author=E.%20F.%20Smit&amp;author=J.%20Baas&amp;volume=76&amp;publication_year=2012&amp;pages=67-71&amp;pmid=21996089&amp;doi=10.1016/j.lungcan.2011.09.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0100">
<span class="label">100.</span><cite>
Cheng N. M., Hsieh C. E., Liao C. T., et al., “Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F‐FDG PET/CT for Salivary Gland Carcinoma with High‐Risk Histology,” Clinical Nuclear Medicine
44 (2019): 351–358.
</cite> [<a href="https://doi.org/10.1097/RLU.0000000000002530" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30932974/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Nuclear%20Medicine&amp;title=Prognostic%20Value%20of%20Tumor%20Heterogeneity%20and%20SUVmax%20of%20Pretreatment%2018F%E2%80%90FDG%20PET/CT%20for%20Salivary%20Gland%20Carcinoma%20with%20High%E2%80%90Risk%20Histology&amp;author=N.%20M.%20Cheng&amp;author=C.%20E.%20Hsieh&amp;author=C.%20T.%20Liao&amp;volume=44&amp;publication_year=2019&amp;pages=351-358&amp;pmid=30932974&amp;doi=10.1097/RLU.0000000000002530&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0101">
<span class="label">101.</span><cite>
Liu S., Feng Z., Wen H., et al., “
<strong>(18)</strong>F‐FDG PET/CT Can Predict Chemosensitivity and Proliferation of Epithelial Ovarian Cancer via SUVmax Value,” Japanese Journal of Radiology
36 (2018): 544–550.
</cite> [<a href="https://doi.org/10.1007/s11604-018-0755-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29943313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Japanese%20Journal%20of%20Radiology&amp;title=(18)F%E2%80%90FDG%20PET/CT%20Can%20Predict%20Chemosensitivity%20and%20Proliferation%20of%20Epithelial%20Ovarian%20Cancer%20via%20SUVmax%20Value&amp;author=S.%20Liu&amp;author=Z.%20Feng&amp;author=H.%20Wen&amp;volume=36&amp;publication_year=2018&amp;pages=544-550&amp;pmid=29943313&amp;doi=10.1007/s11604-018-0755-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0102">
<span class="label">102.</span><cite>
Cermik T. F., Ergul N., Yilmaz B., and Mercanoglu G., “Tumor Imaging with 68Ga‐DOTA‐FAPI‐04 PET/CT: Comparison with 18F‐FDG PET/CT in 22 Different Cancer Types,” Clinical Nuclear Medicine
47 (2022): e333–e339.
</cite> [<a href="https://doi.org/10.1097/RLU.0000000000004073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35085165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Nuclear%20Medicine&amp;title=Tumor%20Imaging%20with%2068Ga%E2%80%90DOTA%E2%80%90FAPI%E2%80%9004%20PET/CT:%20Comparison%20with%2018F%E2%80%90FDG%20PET/CT%20in%2022%20Different%20Cancer%20Types&amp;author=T.%20F.%20Cermik&amp;author=N.%20Ergul&amp;author=B.%20Yilmaz&amp;author=G.%20Mercanoglu&amp;volume=47&amp;publication_year=2022&amp;pages=e333-e339&amp;pmid=35085165&amp;doi=10.1097/RLU.0000000000004073&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0103">
<span class="label">103.</span><cite>
Gu B., Yang Z., Du X., et al., “Imaging of Tumor Stroma Using (68)Ga‐FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial,” Journal of Nuclear Medicine
65 (2024): 365–371.
</cite> [<a href="https://doi.org/10.2967/jnumed.123.266556" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10924163/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38272706/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nuclear%20Medicine&amp;title=Imaging%20of%20Tumor%20Stroma%20Using%20(68)Ga%E2%80%90FAPI%20PET/CT%20to%20Improve%20Diagnostic%20Accuracy%20of%20Primary%20Tumors%20in%20Head%20and%20Neck%20Cancer%20of%20Unknown%20Primary:%20A%20Comparative%20Imaging%20Trial&amp;author=B.%20Gu&amp;author=Z.%20Yang&amp;author=X.%20Du&amp;volume=65&amp;publication_year=2024&amp;pages=365-371&amp;pmid=38272706&amp;doi=10.2967/jnumed.123.266556&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0104">
<span class="label">104.</span><cite>
Gu B., Xu X., Zhang J., et al., “The Added Value of (68)Ga‐FAPI PET/CT in Patients With Head and Neck Cancer of Unknown Primary With (18)F‐FDG‐Negative Findings,” Journal of Nuclear Medicine
63 (2022): 875–881.
</cite> [<a href="https://doi.org/10.2967/jnumed.121.262790" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9157729/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34593594/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Nuclear%20Medicine&amp;title=The%20Added%20Value%20of%20(68)Ga%E2%80%90FAPI%20PET/CT%20in%20Patients%20With%20Head%20and%20Neck%20Cancer%20of%20Unknown%20Primary%20With%20(18)F%E2%80%90FDG%E2%80%90Negative%20Findings&amp;author=B.%20Gu&amp;author=X.%20Xu&amp;author=J.%20Zhang&amp;volume=63&amp;publication_year=2022&amp;pages=875-881&amp;pmid=34593594&amp;doi=10.2967/jnumed.121.262790&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0105">
<span class="label">105.</span><cite>
Rossi G., Nannini N., and Costantini M., “Morphology and More Specific Immunohistochemical Stains Are Fundamental Prerequisites in Detection of Unknown Primary Cancer,” Journal of Clinical Oncology
27 (2009): 649–650. author reply 650‐642.
</cite> [<a href="https://doi.org/10.1200/JCO.2008.20.3604" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19114684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Morphology%20and%20More%20Specific%20Immunohistochemical%20Stains%20Are%20Fundamental%20Prerequisites%20in%20Detection%20of%20Unknown%20Primary%20Cancer&amp;author=G.%20Rossi&amp;author=N.%20Nannini&amp;author=M.%20Costantini&amp;volume=27&amp;publication_year=2009&amp;pages=649-650&amp;pmid=19114684&amp;doi=10.1200/JCO.2008.20.3604&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0106">
<span class="label">106.</span><cite>
Beauchamp K., Moran B., O'Brien T., et al., “Carcinoma of Unknown Primary (CUP): An Update for Histopathologists,” Cancer and Metastasis Reviews
42 (2023): 1189–1200.
</cite> [<a href="https://doi.org/10.1007/s10555-023-10101-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10713813/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37394540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20and%20Metastasis%20Reviews&amp;title=Carcinoma%20of%20Unknown%20Primary%20(CUP):%20An%20Update%20for%20Histopathologists&amp;author=K.%20Beauchamp&amp;author=B.%20Moran&amp;author=T.%20O'Brien&amp;volume=42&amp;publication_year=2023&amp;pages=1189-1200&amp;pmid=37394540&amp;doi=10.1007/s10555-023-10101-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0107">
<span class="label">107.</span><cite>
Seidlitz T., Chen Y. T., Uhlemann H., et al., “Mouse Models of Human Gastric Cancer Subtypes with Stomach‐Specific CreERT2‐Mediated Pathway Alterations,” Gastroenterology
157 (2019): 1599–1614. e1592.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2019.09.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6902245/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31585123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Mouse%20Models%20of%20Human%20Gastric%20Cancer%20Subtypes%20with%20Stomach%E2%80%90Specific%20CreERT2%E2%80%90Mediated%20Pathway%20Alterations&amp;author=T.%20Seidlitz&amp;author=Y.%20T.%20Chen&amp;author=H.%20Uhlemann&amp;volume=157&amp;publication_year=2019&amp;pages=1599-1614&amp;pmid=31585123&amp;doi=10.1053/j.gastro.2019.09.026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0108">
<span class="label">108.</span><cite>
Selves J., Long‐Mira E., Mathieu M. C., Rochaix P., and Ilie M., “Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site,” Cancers (Basel)
10 (2018).</cite> [<a href="https://doi.org/10.3390/cancers10040108" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5923363/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29621151/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers%20(Basel)&amp;title=Immunohistochemistry%20for%20Diagnosis%20of%20Metastatic%20Carcinomas%20of%20Unknown%20Primary%20Site&amp;author=J.%20Selves&amp;author=E.%20Long%E2%80%90Mira&amp;author=M.%20C.%20Mathieu&amp;author=P.%20Rochaix&amp;author=M.%20Ilie&amp;volume=10&amp;publication_year=2018&amp;pmid=29621151&amp;doi=10.3390/cancers10040108&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0109">
<span class="label">109.</span><cite>
Rassy E., Abou‐Jaoude R., Boussios S., et al., “Sarcoma of Unknown Primary: Myth or Reality?,” Journal of the Egyptian National Cancer Institute
34 (2022): 27.
</cite> [<a href="https://doi.org/10.1186/s43046-022-00128-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35754068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20the%20Egyptian%20National%20Cancer%20Institute&amp;title=Sarcoma%20of%20Unknown%20Primary:%20Myth%20or%20Reality?&amp;author=E.%20Rassy&amp;author=R.%20Abou%E2%80%90Jaoude&amp;author=S.%20Boussios&amp;volume=34&amp;publication_year=2022&amp;pages=27&amp;pmid=35754068&amp;doi=10.1186/s43046-022-00128-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0110">
<span class="label">110.</span><cite>
Odze R., “Cytokeratin 7/20 Immunostaining: Barrett's Oesophagus or Gastric Intestinal Metaplasia?,” Lancet
359 (2002): 1711–1713.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(02)08661-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12049855/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Cytokeratin%207/20%20Immunostaining:%20Barrett's%20Oesophagus%20or%20Gastric%20Intestinal%20Metaplasia?&amp;author=R.%20Odze&amp;volume=359&amp;publication_year=2002&amp;pages=1711-1713&amp;pmid=12049855&amp;doi=10.1016/S0140-6736(02)08661-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0111">
<span class="label">111.</span><cite>
Oien K. A. and Dennis J. L., “Diagnostic Work‐up of Carcinoma of Unknown Primary: From Immunohistochemistry to Molecular Profiling,” Annals of Oncology
23, no. Suppl 10 (2012): x271–277.
</cite> [<a href="https://doi.org/10.1093/annonc/mds357" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22987975/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Diagnostic%20Work%E2%80%90up%20of%20Carcinoma%20of%20Unknown%20Primary:%20From%20Immunohistochemistry%20to%20Molecular%20Profiling&amp;author=K.%20A.%20Oien&amp;author=J.%20L.%20Dennis&amp;volume=23&amp;issue=10&amp;publication_year=2012&amp;pages=x271-277&amp;pmid=22987975&amp;doi=10.1093/annonc/mds357&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0112">
<span class="label">112.</span><cite>
Vidarsdottir H., Tran L., Nodin B., et al., “Immunohistochemical Profiles in Primary Lung Cancers and Epithelial Pulmonary Metastases,” Human Pathology
84 (2019): 221–230.
</cite> [<a href="https://doi.org/10.1016/j.humpath.2018.10.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30389437/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Human%20Pathology&amp;title=Immunohistochemical%20Profiles%20in%20Primary%20Lung%20Cancers%20and%20Epithelial%20Pulmonary%20Metastases&amp;author=H.%20Vidarsdottir&amp;author=L.%20Tran&amp;author=B.%20Nodin&amp;volume=84&amp;publication_year=2019&amp;pages=221-230&amp;pmid=30389437&amp;doi=10.1016/j.humpath.2018.10.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0113">
<span class="label">113.</span><cite>
Hainsworth J. D. and Greco F. A., “Gene Expression Profiling in Patients With Carcinoma of Unknown Primary Site: From Translational Research to Standard of Care,” Virchows Archiv
464 (2014): 393–402.
</cite> [<a href="https://doi.org/10.1007/s00428-014-1545-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24487792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Virchows%20Archiv&amp;title=Gene%20Expression%20Profiling%20in%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site:%20From%20Translational%20Research%20to%20Standard%20of%20Care&amp;author=J.%20D.%20Hainsworth&amp;author=F.%20A.%20Greco&amp;volume=464&amp;publication_year=2014&amp;pages=393-402&amp;pmid=24487792&amp;doi=10.1007/s00428-014-1545-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0114">
<span class="label">114.</span><cite>
Dermawan J. K. and Rubin B. P., “The Role of Molecular Profiling in the Diagnosis and Management of Metastatic Undifferentiated Cancer of Unknown Primary(*): Molecular Profiling of Metastatic Cancer of Unknown Primary,” Seminars in Diagnostic Pathology
38 (2021): 193–198.
</cite> [<a href="https://doi.org/10.1053/j.semdp.2020.12.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33309276/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Seminars%20in%20Diagnostic%20Pathology&amp;title=The%20Role%20of%20Molecular%20Profiling%20in%20the%20Diagnosis%20and%20Management%20of%20Metastatic%20Undifferentiated%20Cancer%20of%20Unknown%20Primary(*):%20Molecular%20Profiling%20of%20Metastatic%20Cancer%20of%20Unknown%20Primary&amp;author=J.%20K.%20Dermawan&amp;author=B.%20P.%20Rubin&amp;volume=38&amp;publication_year=2021&amp;pages=193-198&amp;pmid=33309276&amp;doi=10.1053/j.semdp.2020.12.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0115">
<span class="label">115.</span><cite>
Horlings H. M., van Laar R. K., Kerst J. M., et al., “Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary,” Journal of Clinical Oncology
26 (2008): 4435–4441.
</cite> [<a href="https://doi.org/10.1200/JCO.2007.14.6969" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18802156/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Gene%20Expression%20Profiling%20to%20Identify%20the%20Histogenetic%20Origin%20of%20Metastatic%20Adenocarcinomas%20of%20Unknown%20Primary&amp;author=H.%20M.%20Horlings&amp;author=R.%20K.%20van%20Laar&amp;author=J.%20M.%20Kerst&amp;volume=26&amp;publication_year=2008&amp;pages=4435-4441&amp;pmid=18802156&amp;doi=10.1200/JCO.2007.14.6969&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0116">
<span class="label">116.</span><cite>
Bridgewater J., van Laar R., Floore A., and Van T. V. L., “Gene Expression Profiling May Improve Diagnosis in Patients With Carcinoma of Unknown Primary,” British Journal of Cancer
98 (2008): 1425–1430.
</cite> [<a href="https://doi.org/10.1038/sj.bjc.6604315" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2361712/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18414470/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Gene%20Expression%20Profiling%20May%20Improve%20Diagnosis%20in%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary&amp;author=J.%20Bridgewater&amp;author=R.%20van%20Laar&amp;author=A.%20Floore&amp;author=T.%20V.%20L.%20Van&amp;volume=98&amp;publication_year=2008&amp;pages=1425-1430&amp;pmid=18414470&amp;doi=10.1038/sj.bjc.6604315&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0117">
<span class="label">117.</span><cite>
Varadhachary G. R., Talantov D., Raber M. N., et al., “Molecular Profiling of Carcinoma of Unknown Primary and Correlation With Clinical Evaluation,” Journal of Clinical Oncology
26 (2008): 4442–4448.
</cite> [<a href="https://doi.org/10.1200/JCO.2007.14.4378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18802157/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Molecular%20Profiling%20of%20Carcinoma%20of%20Unknown%20Primary%20and%20Correlation%20With%20Clinical%20Evaluation&amp;author=G.%20R.%20Varadhachary&amp;author=D.%20Talantov&amp;author=M.%20N.%20Raber&amp;volume=26&amp;publication_year=2008&amp;pages=4442-4448&amp;pmid=18802157&amp;doi=10.1200/JCO.2007.14.4378&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0118">
<span class="label">118.</span><cite>
Moran S., Martinez‐Cardus A., Boussios S., and Esteller M., “Precision Medicine Based on Epigenomics: The Paradigm of Carcinoma of Unknown Primary,” Nature Reviews Clinical Oncology
14 (2017): 682–694.</cite> [<a href="https://doi.org/10.1038/nrclinonc.2017.97" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28675165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Reviews%20Clinical%20Oncology&amp;title=Precision%20Medicine%20Based%20on%20Epigenomics:%20The%20Paradigm%20of%20Carcinoma%20of%20Unknown%20Primary&amp;author=S.%20Moran&amp;author=A.%20Martinez%E2%80%90Cardus&amp;author=S.%20Boussios&amp;author=M.%20Esteller&amp;volume=14&amp;publication_year=2017&amp;pages=682-694&amp;pmid=28675165&amp;doi=10.1038/nrclinonc.2017.97&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0119">
<span class="label">119.</span><cite>
Hasegawa H., Ando M., Yatabe Y., et al., “Site‐specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site,” Clinical Oncology (Royal College of Radiologists (Great Britain))
30 (2018): 667–673.
</cite> [<a href="https://doi.org/10.1016/j.clon.2018.06.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30196846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Oncology%20(Royal%20College%20of%20Radiologists%20(Great%20Britain))&amp;title=Site%E2%80%90specific%20Chemotherapy%20Based%20on%20Predicted%20Primary%20Site%20by%20Pathological%20Profile%20for%20Carcinoma%20of%20Unknown%20Primary%20Site&amp;author=H.%20Hasegawa&amp;author=M.%20Ando&amp;author=Y.%20Yatabe&amp;volume=30&amp;publication_year=2018&amp;pages=667-673&amp;pmid=30196846&amp;doi=10.1016/j.clon.2018.06.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0120">
<span class="label">120.</span><cite>
van Laar R. K., Ma X. J., de Jong D., et al., “Implementation of a Novel Microarray‐based Diagnostic Test for Cancer of Unknown Primary,” International Journal of Cancer
125 (2009): 1390–1397.
</cite> [<a href="https://doi.org/10.1002/ijc.24504" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19536816/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Cancer&amp;title=Implementation%20of%20a%20Novel%20Microarray%E2%80%90based%20Diagnostic%20Test%20for%20Cancer%20of%20Unknown%20Primary&amp;author=R.%20K.%20van%20Laar&amp;author=X.%20J.%20Ma&amp;author=D.%20de%20Jong&amp;volume=125&amp;publication_year=2009&amp;pages=1390-1397&amp;pmid=19536816&amp;doi=10.1002/ijc.24504&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0121">
<span class="label">121.</span><cite>
Pillai R., Deeter R., Rigl C. T., et al., “Validation and Reproducibility of a Microarray‐based Gene Expression Test for Tumor Identification in Formalin‐fixed, Paraffin‐embedded Specimens,” The Journal of Molecular Diagnostics
13 (2011): 48–56.
</cite> [<a href="https://doi.org/10.1016/j.jmoldx.2010.11.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3070545/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21227394/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Journal%20of%20Molecular%20Diagnostics&amp;title=Validation%20and%20Reproducibility%20of%20a%20Microarray%E2%80%90based%20Gene%20Expression%20Test%20for%20Tumor%20Identification%20in%20Formalin%E2%80%90fixed,%20Paraffin%E2%80%90embedded%20Specimens&amp;author=R.%20Pillai&amp;author=R.%20Deeter&amp;author=C.%20T.%20Rigl&amp;volume=13&amp;publication_year=2011&amp;pages=48-56&amp;pmid=21227394&amp;doi=10.1016/j.jmoldx.2010.11.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0122">
<span class="label">122.</span><cite>
Monzon F. A., Medeiros F., Lyons‐Weiler M., and Henner W. D., “Identification of Tissue of Origin in Carcinoma of Unknown Primary With a Microarray‐based Gene Expression Test,” Diagnostic Pathology
5 (2010): 3.
</cite> [<a href="https://doi.org/10.1186/1746-1596-5-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2823680/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20205775/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostic%20Pathology&amp;title=Identification%20of%20Tissue%20of%20Origin%20in%20Carcinoma%20of%20Unknown%20Primary%20With%20a%20Microarray%E2%80%90based%20Gene%20Expression%20Test&amp;author=F.%20A.%20Monzon&amp;author=F.%20Medeiros&amp;author=M.%20Lyons%E2%80%90Weiler&amp;author=W.%20D.%20Henner&amp;volume=5&amp;publication_year=2010&amp;pages=3&amp;pmid=20205775&amp;doi=10.1186/1746-1596-5-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0123">
<span class="label">123.</span><cite>
Hainsworth J. D., Schnabel C. A., Erlander M. G., Haines D. W. 3rd, and Greco F. A., “A Retrospective Study of Treatment Outcomes in Patients With Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile,” Clinical Colorectal Cancer
11 (2012): 112–118.
</cite> [<a href="https://doi.org/10.1016/j.clcc.2011.08.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22000811/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Colorectal%20Cancer&amp;title=A%20Retrospective%20Study%20of%20Treatment%20Outcomes%20in%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site%20and%20a%20Colorectal%20Cancer%20Molecular%20Profile&amp;author=J.%20D.%20Hainsworth&amp;author=C.%20A.%20Schnabel&amp;author=M.%20G.%20Erlander&amp;author=D.%20W.%20Haines&amp;author=F.%20A.%20Greco&amp;volume=11&amp;publication_year=2012&amp;pages=112-118&amp;pmid=22000811&amp;doi=10.1016/j.clcc.2011.08.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0124">
<span class="label">124.</span><cite>
Zhang Y., Xia L., Ma D., Wu J., Xu X., and Xu Y., “90‐Gene Expression Profiling for Tissue Origin Diagnosis of Cancer of Unknown Primary,” Frontiers in Oncology
11 (2021): 722808.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.722808" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8529103/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34692498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=90%E2%80%90Gene%20Expression%20Profiling%20for%20Tissue%20Origin%20Diagnosis%20of%20Cancer%20of%20Unknown%20Primary&amp;author=Y.%20Zhang&amp;author=L.%20Xia&amp;author=D.%20Ma&amp;author=J.%20Wu&amp;author=X.%20Xu&amp;volume=11&amp;publication_year=2021&amp;pages=722808&amp;pmid=34692498&amp;doi=10.3389/fonc.2021.722808&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0125">
<span class="label">125.</span><cite>
Qi P., Sun Y., Pang Y., et al., “Diagnostic Utility of a 90‐Gene Expression Assay (Canhelp‐Origin) for Patients With Metastatic Cancer With an Unclear or Unknown Diagnosis,” Molecular Diagnosis &amp; Therapy (2024).</cite> [<a href="https://doi.org/10.1007/s40291-024-00746-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39333459/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Diagnosis%20&amp;%20Therapy&amp;title=Diagnostic%20Utility%20of%20a%2090%E2%80%90Gene%20Expression%20Assay%20(Canhelp%E2%80%90Origin)%20for%20Patients%20With%20Metastatic%20Cancer%20With%20an%20Unclear%20or%20Unknown%20Diagnosis&amp;author=P.%20Qi&amp;author=Y.%20Sun&amp;author=Y.%20Pang&amp;publication_year=2024&amp;pmid=39333459&amp;doi=10.1007/s40291-024-00746-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0126">
<span class="label">126.</span><cite>
Wang Q., Li F., Jiang Q., et al., “Gene Expression Profiling for Differential Diagnosis of Liver Metastases: A Multicenter, Retrospective Cohort Study,” Frontiers in Oncology
11 (2021): 725988.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.725988" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8493028/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34631555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers%20in%20Oncology&amp;title=Gene%20Expression%20Profiling%20for%20Differential%20Diagnosis%20of%20Liver%20Metastases:%20A%20Multicenter,%20Retrospective%20Cohort%20Study&amp;author=Q.%20Wang&amp;author=F.%20Li&amp;author=Q.%20Jiang&amp;volume=11&amp;publication_year=2021&amp;pages=725988&amp;pmid=34631555&amp;doi=10.3389/fonc.2021.725988&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0127">
<span class="label">127.</span><cite>
Ferracin M., Pedriali M., Veronese A., et al., “MicroRNA Profiling for the Identification of Cancers With Unknown Primary Tissue‐of‐origin,” Journal of Pathology
225 (2011): 43–53.
</cite> [<a href="https://doi.org/10.1002/path.2915" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4325368/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21630269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pathology&amp;title=MicroRNA%20Profiling%20for%20the%20Identification%20of%20Cancers%20With%20Unknown%20Primary%20Tissue%E2%80%90of%E2%80%90origin&amp;author=M.%20Ferracin&amp;author=M.%20Pedriali&amp;author=A.%20Veronese&amp;volume=225&amp;publication_year=2011&amp;pages=43-53&amp;pmid=21630269&amp;doi=10.1002/path.2915&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0128">
<span class="label">128.</span><cite>
Varadhachary G. R., Spector Y., Abbruzzese J. L., et al., “Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients With Carcinoma of Unknown Primary,” Clinical Cancer Research
17 (2011): 4063–4070.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-10-2599" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21531815/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Cancer%20Research&amp;title=Prospective%20Gene%20Signature%20Study%20Using%20microRNA%20to%20Identify%20the%20Tissue%20of%20Origin%20in%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary&amp;author=G.%20R.%20Varadhachary&amp;author=Y.%20Spector&amp;author=J.%20L.%20Abbruzzese&amp;volume=17&amp;publication_year=2011&amp;pages=4063-4070&amp;pmid=21531815&amp;doi=10.1158/1078-0432.CCR-10-2599&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0129">
<span class="label">129.</span><cite>
Laprovitera N., Riefolo M., Porcellini E., et al., “MicroRNA Expression Profiling With a Droplet Digital PCR Assay Enables Molecular Diagnosis and Prognosis of Cancers of Unknown Primary,” Molecular Oncology
15 (2021): 2732–2751.
</cite> [<a href="https://doi.org/10.1002/1878-0261.13026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8486570/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34075699/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Oncology&amp;title=MicroRNA%20Expression%20Profiling%20With%20a%20Droplet%20Digital%20PCR%20Assay%20Enables%20Molecular%20Diagnosis%20and%20Prognosis%20of%20Cancers%20of%20Unknown%20Primary&amp;author=N.%20Laprovitera&amp;author=M.%20Riefolo&amp;author=E.%20Porcellini&amp;volume=15&amp;publication_year=2021&amp;pages=2732-2751&amp;pmid=34075699&amp;doi=10.1002/1878-0261.13026&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0130">
<span class="label">130.</span><cite>
Meiri E., Mueller W. C., Rosenwald S., et al., “A Second‐generation microRNA‐based Assay for Diagnosing Tumor Tissue Origin,” The Oncologist
17 (2012): 801–812.
</cite> [<a href="https://doi.org/10.1634/theoncologist.2011-0466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3380879/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22618571/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Oncologist&amp;title=A%20Second%E2%80%90generation%20microRNA%E2%80%90based%20Assay%20for%20Diagnosing%20Tumor%20Tissue%20Origin&amp;author=E.%20Meiri&amp;author=W.%20C.%20Mueller&amp;author=S.%20Rosenwald&amp;volume=17&amp;publication_year=2012&amp;pages=801-812&amp;pmid=22618571&amp;doi=10.1634/theoncologist.2011-0466&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0131">
<span class="label">131.</span><cite>
Sanden M. O., Wassman R., Ashkenazi K., Benjamin H., Spector Y., and Goren E., “Observational Study of Real World Clinical Performance of Microrna Molecular Profiling for Cancer of Unknown Primary (CUP),” Journal of Clinical Oncology (2013): abstr e22173.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Observational%20Study%20of%20Real%20World%20Clinical%20Performance%20of%20Microrna%20Molecular%20Profiling%20for%20Cancer%20of%20Unknown%20Primary%20(CUP)&amp;author=M.%20O.%20Sanden&amp;author=R.%20Wassman&amp;author=K.%20Ashkenazi&amp;author=H.%20Benjamin&amp;author=Y.%20Spector&amp;publication_year=2013&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0132">
<span class="label">132.</span><cite>
Tothill R. W., Kowalczyk A., Rischin D., et al., “An Expression‐based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin,” Cancer Research
65 (2005): 4031–4040.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-04-3617" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15899792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Research&amp;title=An%20Expression%E2%80%90based%20Site%20of%20Origin%20Diagnostic%20Method%20Designed%20for%20Clinical%20Application%20to%20Cancer%20of%20Unknown%20Origin&amp;author=R.%20W.%20Tothill&amp;author=A.%20Kowalczyk&amp;author=D.%20Rischin&amp;volume=65&amp;publication_year=2005&amp;pages=4031-4040&amp;pmid=15899792&amp;doi=10.1158/0008-5472.CAN-04-3617&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0133">
<span class="label">133.</span><cite>
Morawietz L., Floore A., Stork‐Sloots L., et al., “Comparison of Histopathological and Gene Expression‐based Typing of Cancer of Unknown Primary,” Virchows Archiv
456 (2010): 23–29.
</cite> [<a href="https://doi.org/10.1007/s00428-009-0867-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20012089/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Virchows%20Archiv&amp;title=Comparison%20of%20Histopathological%20and%20Gene%20Expression%E2%80%90based%20Typing%20of%20Cancer%20of%20Unknown%20Primary&amp;author=L.%20Morawietz&amp;author=A.%20Floore&amp;author=L.%20Stork%E2%80%90Sloots&amp;volume=456&amp;publication_year=2010&amp;pages=23-29&amp;pmid=20012089&amp;doi=10.1007/s00428-009-0867-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0134">
<span class="label">134.</span><cite>
Dumur C. I., Fuller C. E., Blevins T. L., et al., “Clinical Verification of the Performance of the Pathwork Tissue of Origin Test: Utility and Limitations,” American Journal of Clinical Pathology
136 (2011): 924–933.
</cite> [<a href="https://doi.org/10.1309/AJCPDQPFO73SSNFR" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22095379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Clinical%20Pathology&amp;title=Clinical%20Verification%20of%20the%20Performance%20of%20the%20Pathwork%20Tissue%20of%20Origin%20Test:%20Utility%20and%20Limitations&amp;author=C.%20I.%20Dumur&amp;author=C.%20E.%20Fuller&amp;author=T.%20L.%20Blevins&amp;volume=136&amp;publication_year=2011&amp;pages=924-933&amp;pmid=22095379&amp;doi=10.1309/AJCPDQPFO73SSNFR&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0135">
<span class="label">135.</span><cite>
Fernandez A. F., Assenov Y., Martin‐Subero J. I., et al., “A DNA Methylation Fingerprint of 1628 human Samples,” Genome Research
22 (2012): 407–419.
</cite> [<a href="https://doi.org/10.1101/gr.119867.110" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3266047/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21613409/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genome%20Research&amp;title=A%20DNA%20Methylation%20Fingerprint%20of%201628%20human%20Samples&amp;author=A.%20F.%20Fernandez&amp;author=Y.%20Assenov&amp;author=J.%20I.%20Martin%E2%80%90Subero&amp;volume=22&amp;publication_year=2012&amp;pages=407-419&amp;pmid=21613409&amp;doi=10.1101/gr.119867.110&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0136">
<span class="label">136.</span><cite>
Ades F., de Azambuja E., Daugaard G., et al., “Comparison of a Gene Expression Profiling Strategy to Standard Clinical Work‐up for Determination of Tumour Origin in Cancer of Unknown Primary (CUP),” Journal of Chemotherapy
25 (2013): 239–246.
</cite> [<a href="https://doi.org/10.1179/1973947813Y.0000000085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23906077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Chemotherapy&amp;title=Comparison%20of%20a%20Gene%20Expression%20Profiling%20Strategy%20to%20Standard%20Clinical%20Work%E2%80%90up%20for%20Determination%20of%20Tumour%20Origin%20in%20Cancer%20of%20Unknown%20Primary%20(CUP)&amp;author=F.%20Ades&amp;author=E.%20de%20Azambuja&amp;author=G.%20Daugaard&amp;volume=25&amp;publication_year=2013&amp;pages=239-246&amp;pmid=23906077&amp;doi=10.1179/1973947813Y.0000000085&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0137">
<span class="label">137.</span><cite>
Tothill R. W., Shi F., Paiman L., et al., “Development and Validation of a Gene Expression Tumour Classifier for Cancer of Unknown Primary,” Pathology
47 (2015): 7–12.
</cite> [<a href="https://doi.org/10.1097/PAT.0000000000000194" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25485653/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pathology&amp;title=Development%20and%20Validation%20of%20a%20Gene%20Expression%20Tumour%20Classifier%20for%20Cancer%20of%20Unknown%20Primary&amp;author=R.%20W.%20Tothill&amp;author=F.%20Shi&amp;author=L.%20Paiman&amp;volume=47&amp;publication_year=2015&amp;pages=7-12&amp;pmid=25485653&amp;doi=10.1097/PAT.0000000000000194&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0138">
<span class="label">138.</span><cite>
Posner A., Prall O. W., Sivakumaran T., et al., “A Comparison of DNA Sequencing and Gene Expression Profiling to Assist Tissue of Origin Diagnosis in Cancer of Unknown Primary,” Journal of Pathology
259 (2023): 81–92.
</cite> [<a href="https://doi.org/10.1002/path.6022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10099529/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36287571/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Pathology&amp;title=A%20Comparison%20of%20DNA%20Sequencing%20and%20Gene%20Expression%20Profiling%20to%20Assist%20Tissue%20of%20Origin%20Diagnosis%20in%20Cancer%20of%20Unknown%20Primary&amp;author=A.%20Posner&amp;author=O.%20W.%20Prall&amp;author=T.%20Sivakumaran&amp;volume=259&amp;publication_year=2023&amp;pages=81-92&amp;pmid=36287571&amp;doi=10.1002/path.6022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0139">
<span class="label">139.</span><cite>
Mathew B. G., Aliyuda F., Taiwo D., et al., “From Biology to Diagnosis and Treatment: The Ariadne's Thread in Cancer of Unknown Primary,” International Journal of Molecular Sciences
24 (2023).</cite> [<a href="https://doi.org/10.3390/ijms24065588" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10053301/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36982662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Molecular%20Sciences&amp;title=From%20Biology%20to%20Diagnosis%20and%20Treatment:%20The%20Ariadne's%20Thread%20in%20Cancer%20of%20Unknown%20Primary&amp;author=B.%20G.%20Mathew&amp;author=F.%20Aliyuda&amp;author=D.%20Taiwo&amp;volume=24&amp;publication_year=2023&amp;pmid=36982662&amp;doi=10.3390/ijms24065588&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0140">
<span class="label">140.</span><cite>
De Wilde J., Van Paemel R., De Koker A., et al., “A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling,” Laboratory Investigation
104 (2024): 102091.
</cite> [<a href="https://doi.org/10.1016/j.labinv.2024.102091" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38830578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Laboratory%20Investigation&amp;title=A%20Fast,%20Affordable,%20and%20Minimally%20Invasive%20Diagnostic%20Test%20for%20Cancer%20of%20Unknown%20Primary%20Using%20DNA%20Methylation%20Profiling&amp;author=J.%20De%20Wilde&amp;author=R.%20Van%20Paemel&amp;author=A.%20De%20Koker&amp;volume=104&amp;publication_year=2024&amp;pages=102091&amp;pmid=38830578&amp;doi=10.1016/j.labinv.2024.102091&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0141">
<span class="label">141.</span><cite>
Stark L., Kasajima A., Stogbauer F., et al., “Head and Neck Cancer of Unknown Primary: Unveiling Primary Tumor Sites Through Machine Learning on DNA Methylation Profiles,” Clinical Epigenetics
16 (2024): 47.
</cite> [<a href="https://doi.org/10.1186/s13148-024-01657-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10964705/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38528631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clinical%20Epigenetics&amp;title=Head%20and%20Neck%20Cancer%20of%20Unknown%20Primary:%20Unveiling%20Primary%20Tumor%20Sites%20Through%20Machine%20Learning%20on%20DNA%20Methylation%20Profiles&amp;author=L.%20Stark&amp;author=A.%20Kasajima&amp;author=F.%20Stogbauer&amp;volume=16&amp;publication_year=2024&amp;pages=47&amp;pmid=38528631&amp;doi=10.1186/s13148-024-01657-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0142">
<span class="label">142.</span><cite>
Hwang J., Lee Y., Yoo S. K., and Kim J. I., “Image‐based Deep Learning Model Using DNA Methylation Data Predicts the Origin of Cancer of Unknown Primary,” Neoplasia
55 (2024): 101021.
</cite> [<a href="https://doi.org/10.1016/j.neo.2024.101021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11261876/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38943996/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neoplasia&amp;title=Image%E2%80%90based%20Deep%20Learning%20Model%20Using%20DNA%20Methylation%20Data%20Predicts%20the%20Origin%20of%20Cancer%20of%20Unknown%20Primary&amp;author=J.%20Hwang&amp;author=Y.%20Lee&amp;author=S.%20K.%20Yoo&amp;author=J.%20I.%20Kim&amp;volume=55&amp;publication_year=2024&amp;pages=101021&amp;pmid=38943996&amp;doi=10.1016/j.neo.2024.101021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0143">
<span class="label">143.</span><cite>
Epigenetic Profiling of CUP. Cancer Discovery
2016, 6:1203.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-NB2016-118" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27658716/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Discovery&amp;title=Epigenetic%20Profiling%20of%20CUP&amp;volume=6&amp;publication_year=2016&amp;pages=1203&amp;pmid=27658716&amp;doi=10.1158/2159-8290.CD-NB2016-118&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0144">
<span class="label">144.</span><cite>
Stackpole M. L., Zeng W., Li S., et al., “Cost‐effective Methylome Sequencing of Cell‐free DNA for Accurately Detecting and Locating Cancer,” Nature Communications
13 (2022): 5566.</cite> [<a href="https://doi.org/10.1038/s41467-022-32995-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9522828/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36175411/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Cost%E2%80%90effective%20Methylome%20Sequencing%20of%20Cell%E2%80%90free%20DNA%20for%20Accurately%20Detecting%20and%20Locating%20Cancer&amp;author=M.%20L.%20Stackpole&amp;author=W.%20Zeng&amp;author=S.%20Li&amp;volume=13&amp;publication_year=2022&amp;pages=5566&amp;pmid=36175411&amp;doi=10.1038/s41467-022-32995-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0145">
<span class="label">145.</span><cite>
Swanson K., Wu E., Zhang A., Alizadeh A. A., and Zou J., “From Patterns to Patients: Advances in Clinical Machine Learning for Cancer Diagnosis, Prognosis, and Treatment,” Cell
186 (2023): 1772–1791.
</cite> [<a href="https://doi.org/10.1016/j.cell.2023.01.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36905928/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=From%20Patterns%20to%20Patients:%20Advances%20in%20Clinical%20Machine%20Learning%20for%20Cancer%20Diagnosis,%20Prognosis,%20and%20Treatment&amp;author=K.%20Swanson&amp;author=E.%20Wu&amp;author=A.%20Zhang&amp;author=A.%20A.%20Alizadeh&amp;author=J.%20Zou&amp;volume=186&amp;publication_year=2023&amp;pages=1772-1791&amp;pmid=36905928&amp;doi=10.1016/j.cell.2023.01.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0146">
<span class="label">146.</span><cite>
Wang X., Zhao J., Marostica E., et al., “A Pathology Foundation Model for Cancer Diagnosis and Prognosis Prediction,” Nature
634 (2024): 970–978.
</cite> [<a href="https://doi.org/10.1038/s41586-024-07894-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39232164/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A%20Pathology%20Foundation%20Model%20for%20Cancer%20Diagnosis%20and%20Prognosis%20Prediction&amp;author=X.%20Wang&amp;author=J.%20Zhao&amp;author=E.%20Marostica&amp;volume=634&amp;publication_year=2024&amp;pages=970-978&amp;pmid=39232164&amp;doi=10.1038/s41586-024-07894-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0147">
<span class="label">147.</span><cite>
Gould M. K., Huang B. Z., Tammemagi M. C., Kinar Y., and Shiff R., “Machine Learning for Early Lung Cancer Identification Using Routine Clinical and Laboratory Data,” American Journal of Respiratory and Critical Care Medicine
204 (2021): 445–453.
</cite> [<a href="https://doi.org/10.1164/rccm.202007-2791OC" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33823116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Respiratory%20and%20Critical%20Care%20Medicine&amp;title=Machine%20Learning%20for%20Early%20Lung%20Cancer%20Identification%20Using%20Routine%20Clinical%20and%20Laboratory%20Data&amp;author=M.%20K.%20Gould&amp;author=B.%20Z.%20Huang&amp;author=M.%20C.%20Tammemagi&amp;author=Y.%20Kinar&amp;author=R.%20Shiff&amp;volume=204&amp;publication_year=2021&amp;pages=445-453&amp;pmid=33823116&amp;doi=10.1164/rccm.202007-2791OC&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0148">
<span class="label">148.</span><cite>
Dong D., Fang M. J., Tang L., et al., “Deep Learning Radiomic Nomogram Can Predict the Number of Lymph Node Metastasis in Locally Advanced Gastric Cancer: An International Multicenter Study,” Annals of Oncology
31 (2020): 912–920.
</cite> [<a href="https://doi.org/10.1016/j.annonc.2020.04.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32304748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Deep%20Learning%20Radiomic%20Nomogram%20Can%20Predict%20the%20Number%20of%20Lymph%20Node%20Metastasis%20in%20Locally%20Advanced%20Gastric%20Cancer:%20An%20International%20Multicenter%20Study&amp;author=D.%20Dong&amp;author=M.%20J.%20Fang&amp;author=L.%20Tang&amp;volume=31&amp;publication_year=2020&amp;pages=912-920&amp;pmid=32304748&amp;doi=10.1016/j.annonc.2020.04.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0149">
<span class="label">149.</span><cite>
Liu Y., Jain A., Eng C., et al., “A Deep Learning System for Differential Diagnosis of Skin Diseases,” Nature Medicine
26 (2020): 900–908.</cite> [<a href="https://doi.org/10.1038/s41591-020-0842-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32424212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Medicine&amp;title=A%20Deep%20Learning%20System%20for%20Differential%20Diagnosis%20of%20Skin%20Diseases&amp;author=Y.%20Liu&amp;author=A.%20Jain&amp;author=C.%20Eng&amp;volume=26&amp;publication_year=2020&amp;pages=900-908&amp;pmid=32424212&amp;doi=10.1038/s41591-020-0842-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0150">
<span class="label">150.</span><cite>
Lorkowski S. W., Dermawan J. K., and Rubin B. P., “The Practical Utility of AI‐assisted Molecular Profiling in the Diagnosis and Management of Cancer of Unknown Primary: An Updated Review,” Virchows Archiv
484 (2024): 369–375.
</cite> [<a href="https://doi.org/10.1007/s00428-023-03708-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37999736/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Virchows%20Archiv&amp;title=The%20Practical%20Utility%20of%20AI%E2%80%90assisted%20Molecular%20Profiling%20in%20the%20Diagnosis%20and%20Management%20of%20Cancer%20of%20Unknown%20Primary:%20An%20Updated%20Review&amp;author=S.%20W.%20Lorkowski&amp;author=J.%20K.%20Dermawan&amp;author=B.%20P.%20Rubin&amp;volume=484&amp;publication_year=2024&amp;pages=369-375&amp;pmid=37999736&amp;doi=10.1007/s00428-023-03708-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0151">
<span class="label">151.</span><cite>
Michuda J., Breschi A., Kapilivsky J., et al., “Validation of a Transcriptome‐Based Assay for Classifying Cancers of Unknown Primary Origin,” Molecular Diagnosis &amp; Therapy
27 (2023): 499–511.
</cite> [<a href="https://doi.org/10.1007/s40291-023-00650-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10300170/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37099070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecular%20Diagnosis%20&amp;%20Therapy&amp;title=Validation%20of%20a%20Transcriptome%E2%80%90Based%20Assay%20for%20Classifying%20Cancers%20of%20Unknown%20Primary%20Origin&amp;author=J.%20Michuda&amp;author=A.%20Breschi&amp;author=J.%20Kapilivsky&amp;volume=27&amp;publication_year=2023&amp;pages=499-511&amp;pmid=37099070&amp;doi=10.1007/s40291-023-00650-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0152">
<span class="label">152.</span><cite>
Conway A. M., Pearce S. P., Clipson A., et al., “A cfDNA Methylation‐based Tissue‐of‐origin Classifier for Cancers of Unknown Primary,” Nature Communications
15 (2024): 3292.</cite> [<a href="https://doi.org/10.1038/s41467-024-47195-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11024142/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38632274/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=A%20cfDNA%20Methylation%E2%80%90based%20Tissue%E2%80%90of%E2%80%90origin%20Classifier%20for%20Cancers%20of%20Unknown%20Primary&amp;author=A.%20M.%20Conway&amp;author=S.%20P.%20Pearce&amp;author=A.%20Clipson&amp;volume=15&amp;publication_year=2024&amp;pages=3292&amp;pmid=38632274&amp;doi=10.1038/s41467-024-47195-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0153">
<span class="label">153.</span><cite>
Greco F. A., Erland J. B., Morrissey L. H., et al., “Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel plus Cisplatin or Carboplatin,” Annals of Oncology
11 (2000): 211–215.
</cite> [<a href="https://doi.org/10.1023/a:1008369812295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10761758/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Carcinoma%20of%20Unknown%20Primary%20Site:%20Phase%20II%20Trials%20With%20Docetaxel%20plus%20Cisplatin%20or%20Carboplatin&amp;author=F.%20A.%20Greco&amp;author=J.%20B.%20Erland&amp;author=L.%20H.%20Morrissey&amp;volume=11&amp;publication_year=2000&amp;pages=211-215&amp;pmid=10761758&amp;doi=10.1023/a:1008369812295&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0154">
<span class="label">154.</span><cite>
Greco F. A., Gray J., Burris H. A. 3rd, Erland J. B., Morrissey L. H., and Hainsworth J. D., “Taxane‐based Chemotherapy for Patients With Carcinoma of Unknown Primary Site,” Cancer Journal (Sudbury, Mass.)
7 (2001): 203–212.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/11419028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Journal%20(Sudbury,%20Mass.)&amp;title=Taxane%E2%80%90based%20Chemotherapy%20for%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site&amp;author=F.%20A.%20Greco&amp;author=J.%20Gray&amp;author=H.%20A.%20Burris&amp;author=J.%20B.%20Erland&amp;author=L.%20H.%20Morrissey&amp;volume=7&amp;publication_year=2001&amp;pages=203-212&amp;pmid=11419028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0155">
<span class="label">155.</span><cite>
Briasoulis E., Kalofonos H., Bafaloukos D., et al., “Carboplatin plus Paclitaxel in Unknown Primary Carcinoma: A Phase II Hellenic Cooperative Oncology Group Study,” Journal of Clinical Oncology
18 (2000): 3101–3107.
</cite> [<a href="https://doi.org/10.1200/JCO.2000.18.17.3101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10963638/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Carboplatin%20plus%20Paclitaxel%20in%20Unknown%20Primary%20Carcinoma:%20A%20Phase%20II%20Hellenic%20Cooperative%20Oncology%20Group%20Study&amp;author=E.%20Briasoulis&amp;author=H.%20Kalofonos&amp;author=D.%20Bafaloukos&amp;volume=18&amp;publication_year=2000&amp;pages=3101-3107&amp;pmid=10963638&amp;doi=10.1200/JCO.2000.18.17.3101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0156">
<span class="label">156.</span><cite>
El‐Rayes B. F., Shields A. F., Zalupski M., et al., “A Phase II Study of Carboplatin and Paclitaxel in Adenocarcinoma of Unknown Primary,” American Journal of Clinical Oncology
28 (2005): 152–156.
</cite> [<a href="https://doi.org/10.1097/01.coc.0000142590.70472.e2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15803009/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=American%20Journal%20of%20Clinical%20Oncology&amp;title=A%20Phase%20II%20Study%20of%20Carboplatin%20and%20Paclitaxel%20in%20Adenocarcinoma%20of%20Unknown%20Primary&amp;author=B.%20F.%20El%E2%80%90Rayes&amp;author=A.%20F.%20Shields&amp;author=M.%20Zalupski&amp;volume=28&amp;publication_year=2005&amp;pages=152-156&amp;pmid=15803009&amp;doi=10.1097/01.coc.0000142590.70472.e2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0157">
<span class="label">157.</span><cite>
Briasoulis E., Fountzilas G., Bamias A., et al., “Multicenter Phase‐II Trial of irinotecan plus Oxaliplatin [IROX regimen] in Patients With Poor‐prognosis Cancer of Unknown Primary: A Hellenic cooperative Oncology Group Study,” Cancer Chemotheraphy and Pharmacology
62 (2008): 277–284.</cite> [<a href="https://doi.org/10.1007/s00280-007-0604-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17901952/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemotheraphy%20and%20Pharmacology&amp;title=Multicenter%20Phase%E2%80%90II%20Trial%20of%20irinotecan%20plus%20Oxaliplatin%20%5BIROX%20regimen%5D%20in%20Patients%20With%20Poor%E2%80%90prognosis%20Cancer%20of%20Unknown%20Primary:%20A%20Hellenic%20cooperative%20Oncology%20Group%20Study&amp;author=E.%20Briasoulis&amp;author=G.%20Fountzilas&amp;author=A.%20Bamias&amp;volume=62&amp;publication_year=2008&amp;pages=277-284&amp;pmid=17901952&amp;doi=10.1007/s00280-007-0604-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0158">
<span class="label">158.</span><cite>
Culine S., Lortholary A., Voigt J. J., et al., “Cisplatin in Combination With either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study–trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01),” Journal of Clinical Oncology
21 (2003): 3479–3482.
</cite> [<a href="https://doi.org/10.1200/JCO.2003.12.104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12972523/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Cisplatin%20in%20Combination%20With%20either%20Gemcitabine%20or%20Irinotecan%20in%20Carcinomas%20of%20Unknown%20Primary%20Site:%20Results%20of%20a%20Randomized%20Phase%20II%20Study%E2%80%93trial%20for%20the%20French%20Study%20Group%20on%20Carcinomas%20of%20Unknown%20Primary%20(GEFCAPI%2001)&amp;author=S.%20Culine&amp;author=A.%20Lortholary&amp;author=J.%20J.%20Voigt&amp;volume=21&amp;publication_year=2003&amp;pages=3479-3482&amp;pmid=12972523&amp;doi=10.1200/JCO.2003.12.104&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0159">
<span class="label">159.</span><cite>
Piga A., Nortilli R., Cetto G. L., et al., “Carboplatin, Doxorubicin and Etoposide in the Treatment of Tumours of Unknown Primary Site,” British Journal of Cancer
90 (2004): 1898–1904.
</cite> [<a href="https://doi.org/10.1038/sj.bjc.6601785" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2409455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15138469/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Carboplatin,%20Doxorubicin%20and%20Etoposide%20in%20the%20Treatment%20of%20Tumours%20of%20Unknown%20Primary%20Site&amp;author=A.%20Piga&amp;author=R.%20Nortilli&amp;author=G.%20L.%20Cetto&amp;volume=90&amp;publication_year=2004&amp;pages=1898-1904&amp;pmid=15138469&amp;doi=10.1038/sj.bjc.6601785&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0160">
<span class="label">160.</span><cite>
Pentheroudakis G., Briasoulis E., Kalofonos H. P., et al., “Docetaxel and Carboplatin Combination Chemotherapy as Outpatient Palliative Therapy in Carcinoma of Unknown Primary: A Multicentre Hellenic Cooperative Oncology Group Phase II Study,” Acta Oncologica
47 (2008): 1148–1155.
</cite> [<a href="https://doi.org/10.1080/02841860701843043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18607872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Oncologica&amp;title=Docetaxel%20and%20Carboplatin%20Combination%20Chemotherapy%20as%20Outpatient%20Palliative%20Therapy%20in%20Carcinoma%20of%20Unknown%20Primary:%20A%20Multicentre%20Hellenic%20Cooperative%20Oncology%20Group%20Phase%20II%20Study&amp;author=G.%20Pentheroudakis&amp;author=E.%20Briasoulis&amp;author=H.%20P.%20Kalofonos&amp;volume=47&amp;publication_year=2008&amp;pages=1148-1155&amp;pmid=18607872&amp;doi=10.1080/02841860701843043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0161">
<span class="label">161.</span><cite>
Woods R. L., Fox R. M., Tattersall M. H., Levi J. A., and Brodie G. N., “Metastatic Adenocarcinomas of Unknown Primary Site: A Randomized Study of Two Combination‐chemotherapy Regimens,” New England Journal of Medicine
303 (1980): 87–89.
</cite> [<a href="https://doi.org/10.1056/NEJM198007103030205" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6991941/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=New%20England%20Journal%20of%20Medicine&amp;title=Metastatic%20Adenocarcinomas%20of%20Unknown%20Primary%20Site:%20A%20Randomized%20Study%20of%20Two%20Combination%E2%80%90chemotherapy%20Regimens&amp;author=R.%20L.%20Woods&amp;author=R.%20M.%20Fox&amp;author=M.%20H.%20Tattersall&amp;author=J.%20A.%20Levi&amp;author=G.%20N.%20Brodie&amp;volume=303&amp;publication_year=1980&amp;pages=87-89&amp;pmid=6991941&amp;doi=10.1056/NEJM198007103030205&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0162">
<span class="label">162.</span><cite>
Goldberg R. M., Smith F. P., Ueno W., Ahlgren J. D., and Schein P. S., “5‐fluorouracil, Adriamycin, and Mitomycin in the Treatment of Adenocarcinoma of Unknown Primary,” Journal of Clinical Oncology
4 (1986): 395–399.
</cite> [<a href="https://doi.org/10.1200/JCO.1986.4.3.395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3754004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=5%E2%80%90fluorouracil,%20Adriamycin,%20and%20Mitomycin%20in%20the%20Treatment%20of%20Adenocarcinoma%20of%20Unknown%20Primary&amp;author=R.%20M.%20Goldberg&amp;author=F.%20P.%20Smith&amp;author=W.%20Ueno&amp;author=J.%20D.%20Ahlgren&amp;author=P.%20S.%20Schein&amp;volume=4&amp;publication_year=1986&amp;pages=395-399&amp;pmid=3754004&amp;doi=10.1200/JCO.1986.4.3.395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0163">
<span class="label">163.</span><cite>
Wagener D. J., de Mulder P. H., Burghouts J. T., and Croles J. J., “Phase II Trial of Cisplatin for Adenocarcinoma of Unknown Primary Site. IKZ/IKO Clinical Research Group,” European Journal of Cancer
27 (1991): 755–757.
</cite> [<a href="https://doi.org/10.1016/0277-5379(91)90182-d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1829919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=Phase%20II%20Trial%20of%20Cisplatin%20for%20Adenocarcinoma%20of%20Unknown%20Primary%20Site.%20IKZ/IKO%20Clinical%20Research%20Group&amp;author=D.%20J.%20Wagener&amp;author=P.%20H.%20de%20Mulder&amp;author=J.%20T.%20Burghouts&amp;author=J.%20J.%20Croles&amp;volume=27&amp;publication_year=1991&amp;pages=755-757&amp;pmid=1829919&amp;doi=10.1016/0277-5379(91)90182-d&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0164">
<span class="label">164.</span><cite>
Hainsworth J. D., Erland J. B., Kalman L. A., Schreeder M. T., and Greco F. A., “Carcinoma of Unknown Primary Site: Treatment With 1‐hour Paclitaxel, Carboplatin, and Extended‐schedule Etoposide,” Journal of Clinical Oncology
15 (1997): 2385–2393.
</cite> [<a href="https://doi.org/10.1200/JCO.1997.15.6.2385" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9196154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Carcinoma%20of%20Unknown%20Primary%20Site:%20Treatment%20With%201%E2%80%90hour%20Paclitaxel,%20Carboplatin,%20and%20Extended%E2%80%90schedule%20Etoposide&amp;author=J.%20D.%20Hainsworth&amp;author=J.%20B.%20Erland&amp;author=L.%20A.%20Kalman&amp;author=M.%20T.%20Schreeder&amp;author=F.%20A.%20Greco&amp;volume=15&amp;publication_year=1997&amp;pages=2385-2393&amp;pmid=9196154&amp;doi=10.1200/JCO.1997.15.6.2385&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0165">
<span class="label">165.</span><cite>
Greco F. A. and Hainsworth J. D., “One‐hour Paclitaxel, Carboplatin, and Extended‐schedule Etoposide in the Treatment of Carcinoma of Unknown Primary Site,” Seminars in Oncology
24, no. S19‐S119 (1997): 101–105.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9427278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Seminars%20in%20Oncology&amp;title=One%E2%80%90hour%20Paclitaxel,%20Carboplatin,%20and%20Extended%E2%80%90schedule%20Etoposide%20in%20the%20Treatment%20of%20Carcinoma%20of%20Unknown%20Primary%20Site&amp;author=F.%20A.%20Greco&amp;author=J.%20D.%20Hainsworth&amp;volume=24&amp;issue=S19%E2%80%90S119&amp;publication_year=1997&amp;pages=101-105&amp;pmid=9427278&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0166">
<span class="label">166.</span><cite>
Briasoulis E., Tsavaris N., Fountzilas G., et al., “Combination Regimen With Carboplatin, Epirubicin and Etoposide in Metastatic Carcinomas of Unknown Primary Site: A Hellenic Co‐Operative Oncology Group Phase II Study,” Oncology
55 (1998): 426–430.
</cite> [<a href="https://doi.org/10.1159/000011890" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9732220/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncology&amp;title=Combination%20Regimen%20With%20Carboplatin,%20Epirubicin%20and%20Etoposide%20in%20Metastatic%20Carcinomas%20of%20Unknown%20Primary%20Site:%20A%20Hellenic%20Co%E2%80%90Operative%20Oncology%20Group%20Phase%20II%20Study&amp;author=E.%20Briasoulis&amp;author=N.%20Tsavaris&amp;author=G.%20Fountzilas&amp;volume=55&amp;publication_year=1998&amp;pages=426-430&amp;pmid=9732220&amp;doi=10.1159/000011890&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0167">
<span class="label">167.</span><cite>
Warner E., Goel R., Chang J., et al., “A Multicentre Phase II Study of Carboplatin and Prolonged Oral Etoposide in the Treatment of Cancer of Unknown Primary Site (CUPS),” British Journal of Cancer
77 (1998): 2376–2380.
</cite> [<a href="https://doi.org/10.1038/bjc.1998.395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2150411/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9649162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=A%20Multicentre%20Phase%20II%20Study%20of%20Carboplatin%20and%20Prolonged%20Oral%20Etoposide%20in%20the%20Treatment%20of%20Cancer%20of%20Unknown%20Primary%20Site%20(CUPS)&amp;author=E.%20Warner&amp;author=R.%20Goel&amp;author=J.%20Chang&amp;volume=77&amp;publication_year=1998&amp;pages=2376-2380&amp;pmid=9649162&amp;doi=10.1038/bjc.1998.395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0168">
<span class="label">168.</span><cite>
Falkson C. I. and Cohen G. L., “Mitomycin C, Epirubicin and Cisplatin versus Mitomycin C Alone as Therapy for Carcinoma of Unknown Primary Origin,” Oncology
55 (1998): 116–121.
</cite> [<a href="https://doi.org/10.1159/000011845" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9499185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncology&amp;title=Mitomycin%20C,%20Epirubicin%20and%20Cisplatin%20versus%20Mitomycin%20C%20Alone%20as%20Therapy%20for%20Carcinoma%20of%20Unknown%20Primary%20Origin&amp;author=C.%20I.%20Falkson&amp;author=G.%20L.%20Cohen&amp;volume=55&amp;publication_year=1998&amp;pages=116-121&amp;pmid=9499185&amp;doi=10.1159/000011845&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0169">
<span class="label">169.</span><cite>
Lofts F. J., Gogas H., and Mansi J. L., “Management of Adenocarcinoma of Unknown Primary With a 5‐fluorouracil‐cisplatin Chemotherapy Regimen (CFTam),” Annals of Oncology
10 (1999): 1389–1392.
</cite> [<a href="https://doi.org/10.1023/a:1008309204979" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10631472/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Management%20of%20Adenocarcinoma%20of%20Unknown%20Primary%20With%20a%205%E2%80%90fluorouracil%E2%80%90cisplatin%20Chemotherapy%20Regimen%20(CFTam)&amp;author=F.%20J.%20Lofts&amp;author=H.%20Gogas&amp;author=J.%20L.%20Mansi&amp;volume=10&amp;publication_year=1999&amp;pages=1389-1392&amp;pmid=10631472&amp;doi=10.1023/a:1008309204979&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0170">
<span class="label">170.</span><cite>
Dowell J. E., Garrett A. M., Shyr Y., Johnson D. H., and Hande K. R., “A Randomized Phase II Trial in Patients With Carcinoma of an Unknown Primary Site,” Cancer
91 (2001): 592–597.
</cite> [<a href="https://doi.org/10.1002/1097-0142(20010201)91:3&lt;592::aid-cncr1039&gt;3.0.co;2-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11169943/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=A%20Randomized%20Phase%20II%20Trial%20in%20Patients%20With%20Carcinoma%20of%20an%20Unknown%20Primary%20Site&amp;author=J.%20E.%20Dowell&amp;author=A.%20M.%20Garrett&amp;author=Y.%20Shyr&amp;author=D.%20H.%20Johnson&amp;author=K.%20R.%20Hande&amp;volume=91&amp;publication_year=2001&amp;pages=592-597&amp;pmid=11169943&amp;doi=10.1002/1097-0142(20010201)91:3&lt;592::aid-cncr1039&gt;3.0.co;2-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0171">
<span class="label">171.</span><cite>
Greco F. A., Burris H. A. 3rd, Litchy S., et al., “Gemcitabine, Carboplatin, and Paclitaxel for Patients With Carcinoma of Unknown Primary Site: A Minnie Pearl Cancer Research Network Study,” Journal of Clinical Oncology
20 (2002): 1651–1656.
</cite> [<a href="https://doi.org/10.1200/JCO.2002.20.6.1651" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11896116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Gemcitabine,%20Carboplatin,%20and%20Paclitaxel%20for%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site:%20A%20Minnie%20Pearl%20Cancer%20Research%20Network%20Study&amp;author=F.%20A.%20Greco&amp;author=H.%20A.%20Burris&amp;author=S.%20Litchy&amp;volume=20&amp;publication_year=2002&amp;pages=1651-1656&amp;pmid=11896116&amp;doi=10.1200/JCO.2002.20.6.1651&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0172">
<span class="label">172.</span><cite>
Balana C., Manzano J. L., Moreno I., et al., “A Phase II Study of Cisplatin, Etoposide and Gemcitabine in an Unfavourable Group of Patients With Carcinoma of Unknown Primary Site,” Annals of Oncology
14 (2003): 1425–1429.
</cite> [<a href="https://doi.org/10.1093/annonc/mdg361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12954583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=A%20Phase%20II%20Study%20of%20Cisplatin,%20Etoposide%20and%20Gemcitabine%20in%20an%20Unfavourable%20Group%20of%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site&amp;author=C.%20Balana&amp;author=J.%20L.%20Manzano&amp;author=I.%20Moreno&amp;volume=14&amp;publication_year=2003&amp;pages=1425-1429&amp;pmid=12954583&amp;doi=10.1093/annonc/mdg361&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0173">
<span class="label">173.</span><cite>
Pouessel D., Culine S., Becht C., et al., “Gemcitabine and docetaxel as front‐line Chemotherapy in Patients With Carcinoma of an Unknown Primary Site,” Cancer
100 (2004): 1257–1261.
</cite> [<a href="https://doi.org/10.1002/cncr.20100" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15022294/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Gemcitabine%20and%20docetaxel%20as%20front%E2%80%90line%20Chemotherapy%20in%20Patients%20With%20Carcinoma%20of%20an%20Unknown%20Primary%20Site&amp;author=D.%20Pouessel&amp;author=S.%20Culine&amp;author=C.%20Becht&amp;volume=100&amp;publication_year=2004&amp;pages=1257-1261&amp;pmid=15022294&amp;doi=10.1002/cncr.20100&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0174">
<span class="label">174.</span><cite>
Greco F. A., Rodriguez G. I., Shaffer D. W., et al., “Carcinoma of Unknown Primary Site: Sequential Treatment With Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial,” The Oncologist
9 (2004): 644–652.
</cite> [<a href="https://doi.org/10.1634/theoncologist.9-6-644" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15561808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Oncologist&amp;title=Carcinoma%20of%20Unknown%20Primary%20Site:%20Sequential%20Treatment%20With%20Paclitaxel/Carboplatin/Etoposide%20and%20Gemcitabine/Irinotecan:%20A%20Minnie%20Pearl%20Cancer%20Research%20Network%20Phase%20II%20Trial&amp;author=F.%20A.%20Greco&amp;author=G.%20I.%20Rodriguez&amp;author=D.%20W.%20Shaffer&amp;volume=9&amp;publication_year=2004&amp;pages=644-652&amp;pmid=15561808&amp;doi=10.1634/theoncologist.9-6-644&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0175">
<span class="label">175.</span><cite>
Park Y. H., Ryoo B. Y., Choi S. J., Yang S. H., and Kim H. T., “A Phase II Study of paclitaxel plus Cisplatin Chemotherapy in an Unfavourable Group of Patients With Cancer of Unknown Primary Site,” Japanese Journal of Clinical Oncology
34 (2004): 681–685.
</cite> [<a href="https://doi.org/10.1093/jjco/hyh124" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15613558/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Japanese%20Journal%20of%20Clinical%20Oncology&amp;title=A%20Phase%20II%20Study%20of%20paclitaxel%20plus%20Cisplatin%20Chemotherapy%20in%20an%20Unfavourable%20Group%20of%20Patients%20With%20Cancer%20of%20Unknown%20Primary%20Site&amp;author=Y.%20H.%20Park&amp;author=B.%20Y.%20Ryoo&amp;author=S.%20J.%20Choi&amp;author=S.%20H.%20Yang&amp;author=H.%20T.%20Kim&amp;volume=34&amp;publication_year=2004&amp;pages=681-685&amp;pmid=15613558&amp;doi=10.1093/jjco/hyh124&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0176">
<span class="label">176.</span><cite>
Hainsworth J. D., Spigel D. R., Raefsky E. L., et al., “Combination Chemotherapy With Gemcitabine and Irinotecan in Patients With Previously Treated Carcinoma of an Unknown Primary Site: A Minnie Pearl Cancer Research Network Phase II Trial,” Cancer
104 (2005): 1992–1997.
</cite> [<a href="https://doi.org/10.1002/cncr.21416" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16130138/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Combination%20Chemotherapy%20With%20Gemcitabine%20and%20Irinotecan%20in%20Patients%20With%20Previously%20Treated%20Carcinoma%20of%20an%20Unknown%20Primary%20Site:%20A%20Minnie%20Pearl%20Cancer%20Research%20Network%20Phase%20II%20Trial&amp;author=J.%20D.%20Hainsworth&amp;author=D.%20R.%20Spigel&amp;author=E.%20L.%20Raefsky&amp;volume=104&amp;publication_year=2005&amp;pages=1992-1997&amp;pmid=16130138&amp;doi=10.1002/cncr.21416&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0177">
<span class="label">177.</span><cite>
Carlson H., Lenzi R., Raber M. N., and Varadhachary G. R., “A Phase II Study to Evaluate the Efficacy and Toxicity of Oxaliplatin in Combination With Gemcitabine in Carcinoma of Unknown Primary,” International Journal of Clinical Oncology
18 (2013): 226–231.
</cite> [<a href="https://doi.org/10.1007/s10147-011-0366-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22218909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=International%20Journal%20of%20Clinical%20Oncology&amp;title=A%20Phase%20II%20Study%20to%20Evaluate%20the%20Efficacy%20and%20Toxicity%20of%20Oxaliplatin%20in%20Combination%20With%20Gemcitabine%20in%20Carcinoma%20of%20Unknown%20Primary&amp;author=H.%20Carlson&amp;author=R.%20Lenzi&amp;author=M.%20N.%20Raber&amp;author=G.%20R.%20Varadhachary&amp;volume=18&amp;publication_year=2013&amp;pages=226-231&amp;pmid=22218909&amp;doi=10.1007/s10147-011-0366-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0178">
<span class="label">178.</span><cite>
Palmeri S., Lorusso V., Palmeri L., et al., “Cisplatin and Gemcitabine With either Vinorelbine or Paclitaxel in the Treatment of Carcinomas of Unknown Primary Site: Results of an Italian Multicenter, Randomized, Phase II Study,” Cancer
107 (2006): 2898–2905.
</cite> [<a href="https://doi.org/10.1002/cncr.22379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17109447/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Cisplatin%20and%20Gemcitabine%20With%20either%20Vinorelbine%20or%20Paclitaxel%20in%20the%20Treatment%20of%20Carcinomas%20of%20Unknown%20Primary%20Site:%20Results%20of%20an%20Italian%20Multicenter,%20Randomized,%20Phase%20II%20Study&amp;author=S.%20Palmeri&amp;author=V.%20Lorusso&amp;author=L.%20Palmeri&amp;volume=107&amp;publication_year=2006&amp;pages=2898-2905&amp;pmid=17109447&amp;doi=10.1002/cncr.22379&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0179">
<span class="label">179.</span><cite>
Hainsworth J. D., Spigel D. R., Thompson D. S., et al., “Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First‐line Treatment of Patients With Carcinoma of Unknown Primary Site,” The Oncologist
14 (2009): 1189–1197.
</cite> [<a href="https://doi.org/10.1634/theoncologist.2009-0112" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19965914/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Oncologist&amp;title=Paclitaxel/Carboplatin%20plus%20Bevacizumab/Erlotinib%20in%20the%20First%E2%80%90line%20Treatment%20of%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site&amp;author=J.%20D.%20Hainsworth&amp;author=D.%20R.%20Spigel&amp;author=D.%20S.%20Thompson&amp;volume=14&amp;publication_year=2009&amp;pages=1189-1197&amp;pmid=19965914&amp;doi=10.1634/theoncologist.2009-0112&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0180">
<span class="label">180.</span><cite>
Schuette K., Folprecht G., Kretzschmar A., et al., “Phase II Trial of Capecitabine and Oxaliplatin in Patients With Adeno‐ and Undifferentiated Carcinoma of Unknown Primary,” Onkologie
32 (2009): 162–166.
</cite> [<a href="https://doi.org/10.1159/000201125" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19372710/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Onkologie&amp;title=Phase%20II%20Trial%20of%20Capecitabine%20and%20Oxaliplatin%20in%20Patients%20With%20Adeno%E2%80%90%20and%20Undifferentiated%20Carcinoma%20of%20Unknown%20Primary&amp;author=K.%20Schuette&amp;author=G.%20Folprecht&amp;author=A.%20Kretzschmar&amp;volume=32&amp;publication_year=2009&amp;pages=162-166&amp;pmid=19372710&amp;doi=10.1159/000201125&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0181">
<span class="label">181.</span><cite>
Huebner G., Link H., Kohne C. H., et al., “Paclitaxel and Carboplatin vs Gemcitabine and Vinorelbine in Patients With Adeno‐ or Undifferentiated Carcinoma of Unknown Primary: A Randomised Prospective Phase II Trial,” British Journal of Cancer
100 (2009): 44–49.
</cite> [<a href="https://doi.org/10.1038/sj.bjc.6604818" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2634671/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19066607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=British%20Journal%20of%20Cancer&amp;title=Paclitaxel%20and%20Carboplatin%20vs%20Gemcitabine%20and%20Vinorelbine%20in%20Patients%20With%20Adeno%E2%80%90%20or%20Undifferentiated%20Carcinoma%20of%20Unknown%20Primary:%20A%20Randomised%20Prospective%20Phase%20II%20Trial&amp;author=G.%20Huebner&amp;author=H.%20Link&amp;author=C.%20H.%20Kohne&amp;volume=100&amp;publication_year=2009&amp;pages=44-49&amp;pmid=19066607&amp;doi=10.1038/sj.bjc.6604818&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0182">
<span class="label">182.</span><cite>
Hainsworth J. D. and Spigel D. R., “Oxaliplatin and Capecitabine in the Treatment of Patients With Recurrent or Refractory Carcinoma of Unknown Primary Site: A Phase 2 Trial of the Sarah Cannon Oncology Research Consortium,” Cancer
116 (2010): 2448–2454.
</cite> [<a href="https://doi.org/10.1002/cncr.25029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20209610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Oxaliplatin%20and%20Capecitabine%20in%20the%20Treatment%20of%20Patients%20With%20Recurrent%20or%20Refractory%20Carcinoma%20of%20Unknown%20Primary%20Site:%20A%20Phase%202%20Trial%20of%20the%20Sarah%20Cannon%20Oncology%20Research%20Consortium&amp;author=J.%20D.%20Hainsworth&amp;author=D.%20R.%20Spigel&amp;volume=116&amp;publication_year=2010&amp;pages=2448-2454&amp;pmid=20209610&amp;doi=10.1002/cncr.25029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0183">
<span class="label">183.</span><cite>
Gross‐Goupil M., Fourcade A., Blot E., et al., “Cisplatin Alone or Combined With Gemcitabine in Carcinomas of Unknown Primary: Results of the Randomised GEFCAPI 02 Trial,” European Journal of Cancer
48 (2012): 721–727.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2012.01.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22317952/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Cancer&amp;title=Cisplatin%20Alone%20or%20Combined%20With%20Gemcitabine%20in%20Carcinomas%20of%20Unknown%20Primary:%20Results%20of%20the%20Randomised%20GEFCAPI%2002%20Trial&amp;author=M.%20Gross%E2%80%90Goupil&amp;author=A.%20Fourcade&amp;author=E.%20Blot&amp;volume=48&amp;publication_year=2012&amp;pages=721-727&amp;pmid=22317952&amp;doi=10.1016/j.ejca.2012.01.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0184">
<span class="label">184.</span><cite>
Hainsworth J. D., Daugaard G., Lesimple T., et al., “Paclitaxel/Carboplatin With or Without Belinostat as Empiric First‐line Treatment for Patients With Carcinoma of Unknown Primary Site: A Randomized, Phase 2 Trial,” Cancer
121 (2015): 1654–1661.
</cite> [<a href="https://doi.org/10.1002/cncr.29229" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25611313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Paclitaxel/Carboplatin%20With%20or%20Without%20Belinostat%20as%20Empiric%20First%E2%80%90line%20Treatment%20for%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site:%20A%20Randomized,%20Phase%202%20Trial&amp;author=J.%20D.%20Hainsworth&amp;author=G.%20Daugaard&amp;author=T.%20Lesimple&amp;volume=121&amp;publication_year=2015&amp;pages=1654-1661&amp;pmid=25611313&amp;doi=10.1002/cncr.29229&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0185">
<span class="label">185.</span><cite>
Shin D. Y., Choi Y. H., HR L., et al., “A Phase II Trial of Modified FOLFOX6 as First‐line Therapy for Adenocarcinoma of an Unknown Primary Site,” Cancer Chemotheraphy and Pharmacology
77 (2016): 163–168.</cite> [<a href="https://doi.org/10.1007/s00280-015-2904-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26589790/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemotheraphy%20and%20Pharmacology&amp;title=A%20Phase%20II%20Trial%20of%20Modified%20FOLFOX6%20as%20First%E2%80%90line%20Therapy%20for%20Adenocarcinoma%20of%20an%20Unknown%20Primary%20Site&amp;author=D.%20Y.%20Shin&amp;author=Y.%20H.%20Choi&amp;author=L.%20HR&amp;volume=77&amp;publication_year=2016&amp;pages=163-168&amp;pmid=26589790&amp;doi=10.1007/s00280-015-2904-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0186">
<span class="label">186.</span><cite>
Martin M., Villar A., Sole‐Calvo A., et al., “Doxorubicin in Combination With Fluorouracil and Cyclophosphamide (i.v. FAC regimen, day 1, 21) versus Methotrexate in Combination With Fluorouracil and Cyclophosphamide (i.v. CMF regimen, day 1, 21) as Adjuvant Chemotherapy for Operable Breast Cancer: A Study by the GEICAM Group,” Annals of Oncology
14 (2003): 833–842.
</cite> [<a href="https://doi.org/10.1093/annonc/mdg260" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12796019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Doxorubicin%20in%20Combination%20With%20Fluorouracil%20and%20Cyclophosphamide%20(i.v.%20FAC%20regimen,%20day%201,%2021)%20versus%20Methotrexate%20in%20Combination%20With%20Fluorouracil%20and%20Cyclophosphamide%20(i.v.%20CMF%20regimen,%20day%201,%2021)%20as%20Adjuvant%20Chemotherapy%20for%20Operable%20Breast%20Cancer:%20A%20Study%20by%20the%20GEICAM%20Group&amp;author=M.%20Martin&amp;author=A.%20Villar&amp;author=A.%20Sole%E2%80%90Calvo&amp;volume=14&amp;publication_year=2003&amp;pages=833-842&amp;pmid=12796019&amp;doi=10.1093/annonc/mdg260&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0187">
<span class="label">187.</span><cite>
Reck M., Remon J., and Hellmann M. D., “First‐Line Immunotherapy for Non‐Small‐Cell Lung Cancer,” Journal of Clinical Oncology
40 (2022): 586–597.
</cite> [<a href="https://doi.org/10.1200/JCO.21.01497" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34985920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=First%E2%80%90Line%20Immunotherapy%20for%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer&amp;author=M.%20Reck&amp;author=J.%20Remon&amp;author=M.%20D.%20Hellmann&amp;volume=40&amp;publication_year=2022&amp;pages=586-597&amp;pmid=34985920&amp;doi=10.1200/JCO.21.01497&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0188">
<span class="label">188.</span><cite>
Pinter M., Scheiner B., and Pinato D. J., “Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Emerging Challenges in Clinical Practice,” The Lancet Gastroenterology and Hepatology
8 (2023): 760–770.
</cite> [<a href="https://doi.org/10.1016/S2468-1253(23)00147-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37327807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet%20Gastroenterology%20and%20Hepatology&amp;title=Immune%20Checkpoint%20Inhibitors%20in%20Hepatocellular%20Carcinoma:%20Emerging%20Challenges%20in%20Clinical%20Practice&amp;author=M.%20Pinter&amp;author=B.%20Scheiner&amp;author=D.%20J.%20Pinato&amp;volume=8&amp;publication_year=2023&amp;pages=760-770&amp;pmid=37327807&amp;doi=10.1016/S2468-1253(23)00147-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0189">
<span class="label">189.</span><cite>
Liu X., Zhang X., Jiang S., et al., “Site‐specific Therapy Guided by a 90‐gene Expression Assay versus Empirical Chemotherapy in Patients With Cancer of Unknown Primary (Fudan CUP‐001): A Randomised Controlled Trial,” The Lancet Oncology
25 (2024): 1092–1102.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(24)00313-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39068945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet%20Oncology&amp;title=Site%E2%80%90specific%20Therapy%20Guided%20by%20a%2090%E2%80%90gene%20Expression%20Assay%20versus%20Empirical%20Chemotherapy%20in%20Patients%20With%20Cancer%20of%20Unknown%20Primary%20(Fudan%20CUP%E2%80%90001):%20A%20Randomised%20Controlled%20Trial&amp;author=X.%20Liu&amp;author=X.%20Zhang&amp;author=S.%20Jiang&amp;volume=25&amp;publication_year=2024&amp;pages=1092-1102&amp;pmid=39068945&amp;doi=10.1016/S1470-2045(24)00313-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0190">
<span class="label">190.</span><cite>
Hu X., Jiang S., and Liu X., “Site‐specific or Empirical Chemotherapy for Cancer of Unknown Primary: The Right Answer?—Authors' reply,” The Lancet Oncology
25 (2024): e530.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(24)00569-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39481400/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=The%20Lancet%20Oncology&amp;title=Site%E2%80%90specific%20or%20Empirical%20Chemotherapy%20for%20Cancer%20of%20Unknown%20Primary:%20The%20Right%20Answer?%E2%80%94Authors'%20reply&amp;author=X.%20Hu&amp;author=S.%20Jiang&amp;author=X.%20Liu&amp;volume=25&amp;publication_year=2024&amp;pages=e530&amp;pmid=39481400&amp;doi=10.1016/S1470-2045(24)00569-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0191">
<span class="label">191.</span><cite>
Aggarwal C., Marmarelis M. E., Hwang W. T., et al., “Association between Availability of Molecular Genotyping Results and Overall Survival in Patients with Advanced Nonsquamous Non‐Small‐Cell Lung Cancer,” JCO Precision Oncology
7 (2023): e2300191.
</cite> [<a href="https://doi.org/10.1200/PO.23.00191" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37499192/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Precision%20Oncology&amp;title=Association%20between%20Availability%20of%20Molecular%20Genotyping%20Results%20and%20Overall%20Survival%20in%20Patients%20with%20Advanced%20Nonsquamous%20Non%E2%80%90Small%E2%80%90Cell%20Lung%20Cancer&amp;author=C.%20Aggarwal&amp;author=M.%20E.%20Marmarelis&amp;author=W.%20T.%20Hwang&amp;volume=7&amp;publication_year=2023&amp;pages=e2300191&amp;pmid=37499192&amp;doi=10.1200/PO.23.00191&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0192">
<span class="label">192.</span><cite>
Nierengarten M. B., “Molecularly Guided Therapy Improves Survival Outcomes for Patients With a Cancer of Unknown Primary,” Cancer
130 (2024): 4165.
</cite> [<a href="https://doi.org/10.1002/cncr.35630" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39579358/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer&amp;title=Molecularly%20Guided%20Therapy%20Improves%20Survival%20Outcomes%20for%20Patients%20With%20a%20Cancer%20of%20Unknown%20Primary&amp;author=M.%20B.%20Nierengarten&amp;volume=130&amp;publication_year=2024&amp;pages=4165&amp;pmid=39579358&amp;doi=10.1002/cncr.35630&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0193">
<span class="label">193.</span><cite>
Haratani K., Hayashi H., Takahama T., et al., “Clinical and Immune Profiling for Cancer of Unknown Primary Site,” Journal for ImmunoTherapy of Cancer
7 (2019): 251.
</cite> [<a href="https://doi.org/10.1186/s40425-019-0720-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6743146/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31519206/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20for%20ImmunoTherapy%20of%20Cancer&amp;title=Clinical%20and%20Immune%20Profiling%20for%20Cancer%20of%20Unknown%20Primary%20Site&amp;author=K.%20Haratani&amp;author=H.%20Hayashi&amp;author=T.%20Takahama&amp;volume=7&amp;publication_year=2019&amp;pages=251&amp;pmid=31519206&amp;doi=10.1186/s40425-019-0720-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0194">
<span class="label">194.</span><cite>
Rassy E., Boussios S., and Pavlidis N., “Genomic Correlates of Response and Resistance to Immune Checkpoint Inhibitors in Carcinomas of Unknown Primary,” European Journal of Clinical Investigation
51 (2021): e13583.
</cite> [<a href="https://doi.org/10.1111/eci.13583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33970501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Clinical%20Investigation&amp;title=Genomic%20Correlates%20of%20Response%20and%20Resistance%20to%20Immune%20Checkpoint%20Inhibitors%20in%20Carcinomas%20of%20Unknown%20Primary&amp;author=E.%20Rassy&amp;author=S.%20Boussios&amp;author=N.%20Pavlidis&amp;volume=51&amp;publication_year=2021&amp;pages=e13583&amp;pmid=33970501&amp;doi=10.1111/eci.13583&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0195">
<span class="label">195.</span><cite>
Hainsworth J. D., Burris H. A. 3rd, Calvert S. W., et al., “Gemcitabine in the Second‐line Therapy of Patients With Carcinoma of Unknown Primary Site: A Phase II Trial of the Minnie Pearl Cancer Research Network,” Cancer Investigation
19 (2001): 335–339.
</cite> [<a href="https://doi.org/10.1081/cnv-100103127" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11405172/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Investigation&amp;title=Gemcitabine%20in%20the%20Second%E2%80%90line%20Therapy%20of%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site:%20A%20Phase%20II%20Trial%20of%20the%20Minnie%20Pearl%20Cancer%20Research%20Network&amp;author=J.%20D.%20Hainsworth&amp;author=H.%20A.%20Burris&amp;author=S.%20W.%20Calvert&amp;volume=19&amp;publication_year=2001&amp;pages=335-339&amp;pmid=11405172&amp;doi=10.1081/cnv-100103127&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0196">
<span class="label">196.</span><cite>
Hainsworth J. D., Spigel D. R., Farley C., et al., “Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network,” Journal of Clinical Oncology
25 (2007): 1747–1752.
</cite> [<a href="https://doi.org/10.1200/JCO.2006.09.3047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17470864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Clinical%20Oncology&amp;title=Phase%20II%20Trial%20of%20Bevacizumab%20and%20Erlotinib%20in%20Carcinomas%20of%20Unknown%20Primary%20Site:%20The%20Minnie%20Pearl%20Cancer%20Research%20Network&amp;author=J.%20D.%20Hainsworth&amp;author=D.%20R.%20Spigel&amp;author=C.%20Farley&amp;volume=25&amp;publication_year=2007&amp;pages=1747-1752&amp;pmid=17470864&amp;doi=10.1200/JCO.2006.09.3047&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0197">
<span class="label">197.</span><cite>
Moller A. K., Pedersen K. D., Abildgaard J., Petersen B. L., and Daugaard G., “Capecitabine and Oxaliplatin as Second‐line Treatment in Patients With Carcinoma of Unknown Primary Site,” Acta Oncologica
49 (2010): 431–435.
</cite> [<a href="https://doi.org/10.3109/02841861003649240" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20235750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acta%20Oncologica&amp;title=Capecitabine%20and%20Oxaliplatin%20as%20Second%E2%80%90line%20Treatment%20in%20Patients%20With%20Carcinoma%20of%20Unknown%20Primary%20Site&amp;author=A.%20K.%20Moller&amp;author=K.%20D.%20Pedersen&amp;author=J.%20Abildgaard&amp;author=B.%20L.%20Petersen&amp;author=G.%20Daugaard&amp;volume=49&amp;publication_year=2010&amp;pages=431-435&amp;pmid=20235750&amp;doi=10.3109/02841861003649240&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0198">
<span class="label">198.</span><cite>
Tanizaki J., Yonemori K., Akiyoshi K., et al., “Open‐label Phase II Study of the Efficacy of nivolumab for Cancer of Unknown Primary,” Annals of Oncology
33 (2022): 216–226.
</cite> [<a href="https://doi.org/10.1016/j.annonc.2021.11.009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34843940/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annals%20of%20Oncology&amp;title=Open%E2%80%90label%20Phase%20II%20Study%20of%20the%20Efficacy%20of%20nivolumab%20for%20Cancer%20of%20Unknown%20Primary&amp;author=J.%20Tanizaki&amp;author=K.%20Yonemori&amp;author=K.%20Akiyoshi&amp;volume=33&amp;publication_year=2022&amp;pages=216-226&amp;pmid=34843940&amp;doi=10.1016/j.annonc.2021.11.009&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0199">
<span class="label">199.</span><cite>
Raghav K. P., Stephen B., Karp D. D., et al., “Efficacy of pembrolizumab in Patients With Advanced Cancer of Unknown Primary (CUP): A Phase 2 Non‐randomized Clinical Trial,” Journal for ImmunoTherapy of Cancer
10 (2022).</cite> [<a href="https://doi.org/10.1136/jitc-2022-004822" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9125753/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35618285/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20for%20ImmunoTherapy%20of%20Cancer&amp;title=Efficacy%20of%20pembrolizumab%20in%20Patients%20With%20Advanced%20Cancer%20of%20Unknown%20Primary%20(CUP):%20A%20Phase%202%20Non%E2%80%90randomized%20Clinical%20Trial&amp;author=K.%20P.%20Raghav&amp;author=B.%20Stephen&amp;author=D.%20D.%20Karp&amp;volume=10&amp;publication_year=2022&amp;pmid=35618285&amp;doi=10.1136/jitc-2022-004822&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="mco270161-bib-0200">
<span class="label">200.</span><cite>
Pouyiourou M., Kraft B. N., Wohlfromm T., et al., “Nivolumab and ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: A Phase II Trial,” Nature Communications
14 (2023): 6761.</cite> [<a href="https://doi.org/10.1038/s41467-023-42400-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10598029/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37875494/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nature%20Communications&amp;title=Nivolumab%20and%20ipilimumab%20in%20Recurrent%20or%20Refractory%20Cancer%20of%20Unknown%20Primary:%20A%20Phase%20II%20Trial&amp;author=M.%20Pouyiourou&amp;author=B.%20N.%20Kraft&amp;author=T.%20Wohlfromm&amp;volume=14&amp;publication_year=2023&amp;pages=6761&amp;pmid=37875494&amp;doi=10.1038/s41467-023-42400-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Not applicable.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from MedComm are provided here courtesy of <strong>Wiley</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1002/mco2.70161"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/MCO2-6-e70161.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.9 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12000684/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12000684/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12000684%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12000684/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12000684/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12000684/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40242159/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12000684/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40242159/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12000684/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12000684/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="m38abrGX1W8DBwDnFx42ShktBNC6bLZPQPmBNCoitYp75EJzGrMXm83quNBehkS3">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
    

    </body>
</html>
